WO2006099015A2 - Carotenoids, carotenoid analogs, or carotenoid derivatives for the treatment of proliferative disorders - Google Patents
Carotenoids, carotenoid analogs, or carotenoid derivatives for the treatment of proliferative disorders Download PDFInfo
- Publication number
- WO2006099015A2 WO2006099015A2 PCT/US2006/008363 US2006008363W WO2006099015A2 WO 2006099015 A2 WO2006099015 A2 WO 2006099015A2 US 2006008363 W US2006008363 W US 2006008363W WO 2006099015 A2 WO2006099015 A2 WO 2006099015A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- aryl
- carotenoid
- cancer
- derivatives
- Prior art date
Links
- 235000021466 carotenoid Nutrition 0.000 title claims abstract description 401
- 150000001747 carotenoids Chemical class 0.000 title claims abstract description 381
- 230000002062 proliferating effect Effects 0.000 title claims abstract description 38
- 238000011282 treatment Methods 0.000 title claims description 39
- 238000000034 method Methods 0.000 claims abstract description 141
- 230000002113 chemopreventative effect Effects 0.000 claims abstract description 6
- 238000002512 chemotherapy Methods 0.000 claims abstract 3
- 239000000203 mixture Substances 0.000 claims description 123
- 239000003963 antioxidant agent Substances 0.000 claims description 105
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 88
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical class OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 87
- 125000003118 aryl group Chemical group 0.000 claims description 70
- 125000000217 alkyl group Chemical group 0.000 claims description 69
- 229910052739 hydrogen Inorganic materials 0.000 claims description 66
- 239000001257 hydrogen Substances 0.000 claims description 66
- 206010028980 Neoplasm Diseases 0.000 claims description 63
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 claims description 60
- 235000013793 astaxanthin Nutrition 0.000 claims description 60
- 239000001168 astaxanthin Substances 0.000 claims description 60
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 claims description 60
- 229940022405 astaxanthin Drugs 0.000 claims description 60
- 239000008194 pharmaceutical composition Substances 0.000 claims description 56
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 55
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 48
- 208000035475 disorder Diseases 0.000 claims description 44
- 235000006708 antioxidants Nutrition 0.000 claims description 42
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 39
- 229930003268 Vitamin C Natural products 0.000 claims description 39
- 230000003078 antioxidant effect Effects 0.000 claims description 39
- 229930003935 flavonoid Chemical class 0.000 claims description 39
- 150000002215 flavonoids Chemical class 0.000 claims description 39
- 235000017173 flavonoids Nutrition 0.000 claims description 39
- 235000019154 vitamin C Nutrition 0.000 claims description 39
- 239000011718 vitamin C Substances 0.000 claims description 39
- 201000011510 cancer Diseases 0.000 claims description 37
- 150000003700 vitamin C derivatives Chemical class 0.000 claims description 36
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 34
- 125000001424 substituent group Chemical group 0.000 claims description 33
- 150000003712 vitamin E derivatives Chemical class 0.000 claims description 32
- 239000003795 chemical substances by application Substances 0.000 claims description 30
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 30
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 28
- 150000002431 hydrogen Chemical group 0.000 claims description 28
- 206010060862 Prostate cancer Diseases 0.000 claims description 27
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 26
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 claims description 24
- 229930003427 Vitamin E Chemical class 0.000 claims description 24
- 239000002246 antineoplastic agent Substances 0.000 claims description 24
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Chemical class CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 24
- 239000011709 vitamin E Chemical class 0.000 claims description 24
- 235000019165 vitamin E Nutrition 0.000 claims description 24
- 229940046009 vitamin E Drugs 0.000 claims description 24
- 150000001413 amino acids Chemical class 0.000 claims description 22
- 239000003112 inhibitor Substances 0.000 claims description 21
- 239000002777 nucleoside Substances 0.000 claims description 20
- 150000003833 nucleoside derivatives Chemical class 0.000 claims description 20
- 229910052751 metal Inorganic materials 0.000 claims description 19
- 239000002184 metal Substances 0.000 claims description 19
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 19
- 241000124008 Mammalia Species 0.000 claims description 18
- 150000001720 carbohydrates Chemical class 0.000 claims description 18
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 claims description 16
- 150000002214 flavonoid derivatives Chemical class 0.000 claims description 16
- YKGCBLWILMDSAV-GOSISDBHSA-N Isoxanthohumol Natural products O(C)c1c2C(=O)C[C@H](c3ccc(O)cc3)Oc2c(C/C=C(\C)/C)c(O)c1 YKGCBLWILMDSAV-GOSISDBHSA-N 0.000 claims description 14
- JEVVKJMRZMXFBT-CCHFXWJWSA-N lycophyll Chemical compound OCC(/C)=C/CC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CC\C=C(/C)CO JEVVKJMRZMXFBT-CCHFXWJWSA-N 0.000 claims description 13
- 235000018626 lycophyll Nutrition 0.000 claims description 13
- 230000035992 intercellular communication Effects 0.000 claims description 12
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 10
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 9
- 239000007864 aqueous solution Substances 0.000 claims description 9
- 239000012829 chemotherapy agent Substances 0.000 claims description 9
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 claims description 8
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 claims description 8
- 230000008901 benefit Effects 0.000 claims description 8
- 230000001419 dependent effect Effects 0.000 claims description 8
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims description 8
- 235000005875 quercetin Nutrition 0.000 claims description 8
- 229960001285 quercetin Drugs 0.000 claims description 8
- 230000010076 replication Effects 0.000 claims description 8
- 239000012623 DNA damaging agent Substances 0.000 claims description 7
- 239000003098 androgen Substances 0.000 claims description 7
- 239000000969 carrier Substances 0.000 claims description 7
- FUSADYLVRMROPL-UHFFFAOYSA-N demethylxanthohumol Natural products CC(C)=CCC1=C(O)C=C(O)C(C(=O)C=CC=2C=CC(O)=CC=2)=C1O FUSADYLVRMROPL-UHFFFAOYSA-N 0.000 claims description 7
- 235000006539 genistein Nutrition 0.000 claims description 7
- 229940045109 genistein Drugs 0.000 claims description 7
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 claims description 7
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 claims description 7
- YKGCBLWILMDSAV-SFHVURJKSA-N isoxanthohumol Chemical compound C1([C@H]2OC=3C(CC=C(C)C)=C(O)C=C(C=3C(=O)C2)OC)=CC=C(O)C=C1 YKGCBLWILMDSAV-SFHVURJKSA-N 0.000 claims description 7
- 239000002207 metabolite Substances 0.000 claims description 7
- ORXQGKIUCDPEAJ-YRNVUSSQSA-N xanthohumol Chemical compound COC1=CC(O)=C(CC=C(C)C)C(O)=C1C(=O)\C=C\C1=CC=C(O)C=C1 ORXQGKIUCDPEAJ-YRNVUSSQSA-N 0.000 claims description 7
- 235000008209 xanthohumol Nutrition 0.000 claims description 7
- UVBDKJHYMQEAQV-UHFFFAOYSA-N xanthohumol Natural products OC1=C(CC=C(C)C)C(OC)=CC(OC)=C1C(=O)C=CC1=CC=C(O)C=C1 UVBDKJHYMQEAQV-UHFFFAOYSA-N 0.000 claims description 7
- 208000003170 Bronchiolo-Alveolar Adenocarcinoma Diseases 0.000 claims description 6
- 206010058354 Bronchioloalveolar carcinoma Diseases 0.000 claims description 6
- 239000012625 DNA intercalator Substances 0.000 claims description 6
- 102000004190 Enzymes Human genes 0.000 claims description 6
- 108090000790 Enzymes Proteins 0.000 claims description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 6
- 229940079156 Proteasome inhibitor Drugs 0.000 claims description 6
- 238000003776 cleavage reaction Methods 0.000 claims description 6
- 208000016992 lung adenocarcinoma in situ Diseases 0.000 claims description 6
- 201000005202 lung cancer Diseases 0.000 claims description 6
- 208000020816 lung neoplasm Diseases 0.000 claims description 6
- 208000024191 minimally invasive lung adenocarcinoma Diseases 0.000 claims description 6
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 6
- 239000003207 proteasome inhibitor Substances 0.000 claims description 6
- 230000007017 scission Effects 0.000 claims description 6
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 6
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 claims description 5
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 claims description 5
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims description 5
- WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 claims description 5
- 108010006654 Bleomycin Proteins 0.000 claims description 5
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 claims description 5
- FVLVBPDQNARYJU-XAHDHGMMSA-N C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O Chemical compound C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O FVLVBPDQNARYJU-XAHDHGMMSA-N 0.000 claims description 5
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims description 5
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims description 5
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 5
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims description 5
- 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 claims description 5
- 229940124087 DNA topoisomerase II inhibitor Drugs 0.000 claims description 5
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 5
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 5
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 claims description 5
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 5
- 229930012538 Paclitaxel Natural products 0.000 claims description 5
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 claims description 5
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 claims description 5
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 claims description 5
- 229940100198 alkylating agent Drugs 0.000 claims description 5
- 239000002168 alkylating agent Substances 0.000 claims description 5
- 229960000397 bevacizumab Drugs 0.000 claims description 5
- 229960001561 bleomycin Drugs 0.000 claims description 5
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims description 5
- 229960002092 busulfan Drugs 0.000 claims description 5
- 229940127093 camptothecin Drugs 0.000 claims description 5
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims description 5
- 229960004117 capecitabine Drugs 0.000 claims description 5
- 229960004562 carboplatin Drugs 0.000 claims description 5
- 229960005395 cetuximab Drugs 0.000 claims description 5
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims description 5
- 229960004630 chlorambucil Drugs 0.000 claims description 5
- 229960004316 cisplatin Drugs 0.000 claims description 5
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 5
- 229960004397 cyclophosphamide Drugs 0.000 claims description 5
- 229960000684 cytarabine Drugs 0.000 claims description 5
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims description 5
- 229960003668 docetaxel Drugs 0.000 claims description 5
- 229960004679 doxorubicin Drugs 0.000 claims description 5
- 229960005420 etoposide Drugs 0.000 claims description 5
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 5
- 229960000390 fludarabine Drugs 0.000 claims description 5
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims description 5
- 229960002949 fluorouracil Drugs 0.000 claims description 5
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 5
- 229960005277 gemcitabine Drugs 0.000 claims description 5
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims description 5
- 229960001101 ifosfamide Drugs 0.000 claims description 5
- 229960003685 imatinib mesylate Drugs 0.000 claims description 5
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 claims description 5
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 5
- 229960004768 irinotecan Drugs 0.000 claims description 5
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims description 5
- 229960002247 lomustine Drugs 0.000 claims description 5
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims description 5
- 229960001924 melphalan Drugs 0.000 claims description 5
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 claims description 5
- 229960001428 mercaptopurine Drugs 0.000 claims description 5
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 5
- 229960000485 methotrexate Drugs 0.000 claims description 5
- 229960004857 mitomycin Drugs 0.000 claims description 5
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims description 5
- 229960001756 oxaliplatin Drugs 0.000 claims description 5
- 229960001592 paclitaxel Drugs 0.000 claims description 5
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 claims description 5
- 229960002340 pentostatin Drugs 0.000 claims description 5
- UVSMNLNDYGZFPF-UHFFFAOYSA-N pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 claims description 5
- 229960004641 rituximab Drugs 0.000 claims description 5
- 229960003440 semustine Drugs 0.000 claims description 5
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 claims description 5
- 229960001052 streptozocin Drugs 0.000 claims description 5
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 5
- 229960001278 teniposide Drugs 0.000 claims description 5
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 claims description 5
- 229960003433 thalidomide Drugs 0.000 claims description 5
- 229960001196 thiotepa Drugs 0.000 claims description 5
- 229960003087 tioguanine Drugs 0.000 claims description 5
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims description 5
- 229960000303 topotecan Drugs 0.000 claims description 5
- 229960000575 trastuzumab Drugs 0.000 claims description 5
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims description 5
- JXLYSJRDGCGARV-CFWMRBGOSA-N vinblastine Chemical compound C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-CFWMRBGOSA-N 0.000 claims description 5
- 229960003048 vinblastine Drugs 0.000 claims description 5
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 5
- 229960004528 vincristine Drugs 0.000 claims description 5
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims description 5
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 4
- 206010005003 Bladder cancer Diseases 0.000 claims description 4
- 206010005949 Bone cancer Diseases 0.000 claims description 4
- 208000018084 Bone neoplasm Diseases 0.000 claims description 4
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 201000009030 Carcinoma Diseases 0.000 claims description 4
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 4
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims description 4
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 206010039491 Sarcoma Diseases 0.000 claims description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 4
- 201000010881 cervical cancer Diseases 0.000 claims description 4
- 229960000975 daunorubicin Drugs 0.000 claims description 4
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 4
- 201000004101 esophageal cancer Diseases 0.000 claims description 4
- 206010017758 gastric cancer Diseases 0.000 claims description 4
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims description 4
- 229960002584 gefitinib Drugs 0.000 claims description 4
- 230000006882 induction of apoptosis Effects 0.000 claims description 4
- 208000014018 liver neoplasm Diseases 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- 230000001394 metastastic effect Effects 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- 201000011549 stomach cancer Diseases 0.000 claims description 4
- 238000002560 therapeutic procedure Methods 0.000 claims description 4
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 4
- 206010073128 Anaplastic oligodendroglioma Diseases 0.000 claims description 3
- 206010003571 Astrocytoma Diseases 0.000 claims description 3
- 206010055113 Breast cancer metastatic Diseases 0.000 claims description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 3
- 208000032612 Glial tumor Diseases 0.000 claims description 3
- 206010018338 Glioma Diseases 0.000 claims description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 3
- 206010050513 Metastatic renal cell carcinoma Diseases 0.000 claims description 3
- 201000010133 Oligodendroglioma Diseases 0.000 claims description 3
- 208000026149 Primary peritoneal carcinoma Diseases 0.000 claims description 3
- 206010038389 Renal cancer Diseases 0.000 claims description 3
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims description 3
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims description 3
- 208000030002 adult glioblastoma Diseases 0.000 claims description 3
- 206010002224 anaplastic astrocytoma Diseases 0.000 claims description 3
- 230000001093 anti-cancer Effects 0.000 claims description 3
- 239000006185 dispersion Substances 0.000 claims description 3
- 208000005017 glioblastoma Diseases 0.000 claims description 3
- 201000010536 head and neck cancer Diseases 0.000 claims description 3
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 3
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 3
- 238000010255 intramuscular injection Methods 0.000 claims description 3
- 239000007927 intramuscular injection Substances 0.000 claims description 3
- 201000010982 kidney cancer Diseases 0.000 claims description 3
- 201000005249 lung adenocarcinoma Diseases 0.000 claims description 3
- 201000002120 neuroendocrine carcinoma Diseases 0.000 claims description 3
- 201000011519 neuroendocrine tumor Diseases 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 230000000750 progressive effect Effects 0.000 claims description 3
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 claims 4
- 239000003458 I kappa b kinase inhibitor Substances 0.000 claims 4
- 239000000427 antigen Substances 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 190000008236 carboplatin Chemical compound 0.000 claims 4
- MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 claims 4
- FAWLNURBQMTKEB-URDPEVQOSA-N 213546-53-3 Chemical compound N([C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N1[C@@H](CCC1)C(O)=O)C(C)C)C(C)C)C(=O)[C@@H]1CCCN1C(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)N)C(C)C FAWLNURBQMTKEB-URDPEVQOSA-N 0.000 claims 3
- 230000017128 negative regulation of NF-kappaB transcription factor activity Effects 0.000 claims 3
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 claims 2
- 206010052399 Neuroendocrine tumour Diseases 0.000 claims 2
- 229960005243 carmustine Drugs 0.000 claims 2
- 208000016065 neuroendocrine neoplasm Diseases 0.000 claims 2
- 238000011319 anticancer therapy Methods 0.000 claims 1
- 210000000056 organ Anatomy 0.000 abstract description 26
- 230000006907 apoptotic process Effects 0.000 abstract description 23
- 230000002829 reductive effect Effects 0.000 abstract description 7
- 210000004027 cell Anatomy 0.000 description 201
- 150000001875 compounds Chemical class 0.000 description 107
- -1 analogs Chemical class 0.000 description 65
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 60
- 229960005375 lutein Drugs 0.000 description 49
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 49
- 201000010099 disease Diseases 0.000 description 44
- 239000000243 solution Substances 0.000 description 43
- 108050001175 Connexin Proteins 0.000 description 42
- 102000010970 Connexin Human genes 0.000 description 41
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 41
- 210000003976 gap junction Anatomy 0.000 description 40
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 38
- 210000001519 tissue Anatomy 0.000 description 38
- 235000012680 lutein Nutrition 0.000 description 37
- 239000001656 lutein Substances 0.000 description 35
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 35
- 238000009472 formulation Methods 0.000 description 34
- 230000000694 effects Effects 0.000 description 30
- 102000001381 Arachidonate 5-Lipoxygenase Human genes 0.000 description 29
- 108010093579 Arachidonate 5-lipoxygenase Proteins 0.000 description 29
- 230000001965 increasing effect Effects 0.000 description 29
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 28
- 241001465754 Metazoa Species 0.000 description 28
- 239000003814 drug Substances 0.000 description 28
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
- 230000015572 biosynthetic process Effects 0.000 description 26
- 235000002639 sodium chloride Nutrition 0.000 description 25
- 239000000126 substance Substances 0.000 description 24
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 23
- 239000000543 intermediate Substances 0.000 description 23
- 238000002360 preparation method Methods 0.000 description 22
- 102000001045 Connexin 43 Human genes 0.000 description 21
- 108010069241 Connexin 43 Proteins 0.000 description 21
- 238000006243 chemical reaction Methods 0.000 description 21
- 239000000825 pharmaceutical preparation Substances 0.000 description 21
- 239000007787 solid Substances 0.000 description 21
- 125000004122 cyclic group Chemical group 0.000 description 20
- 230000012010 growth Effects 0.000 description 20
- 229940079593 drug Drugs 0.000 description 19
- 230000014509 gene expression Effects 0.000 description 19
- 150000003839 salts Chemical class 0.000 description 19
- 238000003786 synthesis reaction Methods 0.000 description 19
- 230000006870 function Effects 0.000 description 18
- 239000002775 capsule Substances 0.000 description 17
- 108090000623 proteins and genes Proteins 0.000 description 17
- 239000002904 solvent Substances 0.000 description 16
- 235000008210 xanthophylls Nutrition 0.000 description 16
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 15
- 231100000504 carcinogenesis Toxicity 0.000 description 15
- 235000019441 ethanol Nutrition 0.000 description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 14
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 14
- 229910052783 alkali metal Inorganic materials 0.000 description 14
- 150000001340 alkali metals Chemical class 0.000 description 14
- 230000001413 cellular effect Effects 0.000 description 14
- 230000005764 inhibitory process Effects 0.000 description 14
- 230000000670 limiting effect Effects 0.000 description 14
- 150000004291 polyenes Polymers 0.000 description 14
- 229920001223 polyethylene glycol Polymers 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 14
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 13
- 241000282412 Homo Species 0.000 description 13
- 239000003937 drug carrier Substances 0.000 description 13
- 230000002401 inhibitory effect Effects 0.000 description 13
- 230000001225 therapeutic effect Effects 0.000 description 13
- 239000002202 Polyethylene glycol Substances 0.000 description 12
- 238000000338 in vitro Methods 0.000 description 12
- 210000005170 neoplastic cell Anatomy 0.000 description 12
- 230000010309 neoplastic transformation Effects 0.000 description 12
- 239000003826 tablet Substances 0.000 description 12
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 11
- 229910019142 PO4 Inorganic materials 0.000 description 11
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 11
- 229940114079 arachidonic acid Drugs 0.000 description 11
- 235000021342 arachidonic acid Nutrition 0.000 description 11
- 235000013734 beta-carotene Nutrition 0.000 description 11
- 239000011648 beta-carotene Substances 0.000 description 11
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 11
- 229960002747 betacarotene Drugs 0.000 description 11
- 235000012661 lycopene Nutrition 0.000 description 11
- 239000001751 lycopene Substances 0.000 description 11
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 11
- 229960004999 lycopene Drugs 0.000 description 11
- 230000007246 mechanism Effects 0.000 description 11
- 239000000546 pharmaceutical excipient Substances 0.000 description 11
- 235000021317 phosphate Nutrition 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 11
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 11
- 229920002472 Starch Polymers 0.000 description 10
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 10
- 238000000862 absorption spectrum Methods 0.000 description 10
- 239000002253 acid Substances 0.000 description 10
- 230000002776 aggregation Effects 0.000 description 10
- 238000004220 aggregation Methods 0.000 description 10
- 230000037396 body weight Effects 0.000 description 10
- SILCDLWESNHZKB-UHFFFAOYSA-L disodium 4-hydroxy-4-oxobutanoate Chemical class [Na+].[Na+].OC(=O)CCC([O-])=O.OC(=O)CCC([O-])=O SILCDLWESNHZKB-UHFFFAOYSA-L 0.000 description 10
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 10
- 239000003755 preservative agent Substances 0.000 description 10
- 150000003254 radicals Chemical class 0.000 description 10
- 238000001228 spectrum Methods 0.000 description 10
- 239000000725 suspension Substances 0.000 description 10
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 description 9
- 108020004414 DNA Proteins 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 description 9
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 description 9
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 description 9
- 239000002585 base Substances 0.000 description 9
- 230000033228 biological regulation Effects 0.000 description 9
- 229940127089 cytotoxic agent Drugs 0.000 description 9
- 239000001177 diphosphate Substances 0.000 description 9
- 230000003389 potentiating effect Effects 0.000 description 9
- 235000010930 zeaxanthin Nutrition 0.000 description 9
- 239000001775 zeaxanthin Substances 0.000 description 9
- 229940043269 zeaxanthin Drugs 0.000 description 9
- 229920002307 Dextran Polymers 0.000 description 8
- 229910018830 PO3H Inorganic materials 0.000 description 8
- 239000011230 binding agent Substances 0.000 description 8
- FDSDTBUPSURDBL-LOFNIBRQSA-N canthaxanthin Chemical compound CC=1C(=O)CCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)CCC1(C)C FDSDTBUPSURDBL-LOFNIBRQSA-N 0.000 description 8
- 210000000170 cell membrane Anatomy 0.000 description 8
- 235000013305 food Nutrition 0.000 description 8
- 238000005755 formation reaction Methods 0.000 description 8
- 210000000224 granular leucocyte Anatomy 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 150000002500 ions Chemical class 0.000 description 8
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 8
- 239000002417 nutraceutical Substances 0.000 description 8
- 235000021436 nutraceutical agent Nutrition 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 230000001105 regulatory effect Effects 0.000 description 8
- 235000019698 starch Nutrition 0.000 description 8
- 229940124597 therapeutic agent Drugs 0.000 description 8
- 239000003981 vehicle Substances 0.000 description 8
- 238000004435 EPR spectroscopy Methods 0.000 description 7
- 102100021337 Gap junction alpha-1 protein Human genes 0.000 description 7
- 108091006905 Human Serum Albumin Proteins 0.000 description 7
- 102000008100 Human Serum Albumin Human genes 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 230000004913 activation Effects 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 7
- 239000003183 carcinogenic agent Substances 0.000 description 7
- 230000003247 decreasing effect Effects 0.000 description 7
- 150000002066 eicosanoids Chemical class 0.000 description 7
- 150000002148 esters Chemical class 0.000 description 7
- 125000000524 functional group Chemical group 0.000 description 7
- 230000036541 health Effects 0.000 description 7
- 239000010452 phosphate Substances 0.000 description 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 238000010791 quenching Methods 0.000 description 7
- 230000000171 quenching effect Effects 0.000 description 7
- 238000001959 radiotherapy Methods 0.000 description 7
- 239000003381 stabilizer Substances 0.000 description 7
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 7
- 210000004881 tumor cell Anatomy 0.000 description 7
- KGIJOOYOSFUGPC-MSFIICATSA-N 5-Hydroxyeicosatetraenoic acid Chemical compound CCCCCC=CCC=CCC=C\C=C\[C@@H](O)CCCC(O)=O KGIJOOYOSFUGPC-MSFIICATSA-N 0.000 description 6
- 102100022278 Arachidonate 5-lipoxygenase-activating protein Human genes 0.000 description 6
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 108010010803 Gelatin Proteins 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 230000001594 aberrant effect Effects 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 239000000443 aerosol Substances 0.000 description 6
- 230000004075 alteration Effects 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 150000001514 astaxanthins Chemical class 0.000 description 6
- 230000022131 cell cycle Effects 0.000 description 6
- 238000000576 coating method Methods 0.000 description 6
- 239000008273 gelatin Substances 0.000 description 6
- 229920000159 gelatin Polymers 0.000 description 6
- 229940014259 gelatin Drugs 0.000 description 6
- 235000019322 gelatine Nutrition 0.000 description 6
- 235000011852 gelatine desserts Nutrition 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 238000001990 intravenous administration Methods 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 230000003000 nontoxic effect Effects 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 239000008107 starch Substances 0.000 description 6
- 235000000346 sugar Nutrition 0.000 description 6
- 238000012546 transfer Methods 0.000 description 6
- KGIJOOYOSFUGPC-CABOLEKPSA-N 5-HETE Natural products CCCCC\C=C/C\C=C/C\C=C/C=C/[C@H](O)CCCC(O)=O KGIJOOYOSFUGPC-CABOLEKPSA-N 0.000 description 5
- 101710187011 Arachidonate 5-lipoxygenase-activating protein Proteins 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 150000001298 alcohols Chemical class 0.000 description 5
- 229960005070 ascorbic acid Drugs 0.000 description 5
- 238000000065 atmospheric pressure chemical ionisation Methods 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 231100000357 carcinogen Toxicity 0.000 description 5
- 230000030833 cell death Effects 0.000 description 5
- 230000010261 cell growth Effects 0.000 description 5
- 230000008878 coupling Effects 0.000 description 5
- 238000010168 coupling process Methods 0.000 description 5
- 238000005859 coupling reaction Methods 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 235000005911 diet Nutrition 0.000 description 5
- 235000011180 diphosphates Nutrition 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 239000008298 dragée Substances 0.000 description 5
- 230000032050 esterification Effects 0.000 description 5
- 238000005886 esterification reaction Methods 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 229940088597 hormone Drugs 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 150000002617 leukotrienes Chemical class 0.000 description 5
- 239000000314 lubricant Substances 0.000 description 5
- 235000019359 magnesium stearate Nutrition 0.000 description 5
- 230000003211 malignant effect Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 231100000252 nontoxic Toxicity 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 238000007911 parenteral administration Methods 0.000 description 5
- 230000001575 pathological effect Effects 0.000 description 5
- 230000026731 phosphorylation Effects 0.000 description 5
- 238000006366 phosphorylation reaction Methods 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 230000004224 protection Effects 0.000 description 5
- 230000002685 pulmonary effect Effects 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 4
- OKCDBZSDRSXFIB-UHFFFAOYSA-N 2-diethoxyphosphoryl-2-methyl-1-oxido-3,4-dihydropyrrol-1-ium Chemical compound CCOP(=O)(OCC)C1(C)CCC=[N+]1[O-] OKCDBZSDRSXFIB-UHFFFAOYSA-N 0.000 description 4
- 102000004023 5-Lipoxygenase-Activating Proteins Human genes 0.000 description 4
- 108090000411 5-Lipoxygenase-Activating Proteins Proteins 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 102000003820 Lipoxygenases Human genes 0.000 description 4
- 108090000128 Lipoxygenases Proteins 0.000 description 4
- OOUTWVMJGMVRQF-DOYZGLONSA-N Phoenicoxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)C(=O)C(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)C(=O)CCC2(C)C OOUTWVMJGMVRQF-DOYZGLONSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 230000002292 Radical scavenging effect Effects 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 125000002015 acyclic group Chemical group 0.000 description 4
- 239000011795 alpha-carotene Substances 0.000 description 4
- 230000001640 apoptogenic effect Effects 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- 235000010323 ascorbic acid Nutrition 0.000 description 4
- 239000011668 ascorbic acid Substances 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 235000012682 canthaxanthin Nutrition 0.000 description 4
- 239000001659 canthaxanthin Substances 0.000 description 4
- 229940008033 canthaxanthin Drugs 0.000 description 4
- 210000004413 cardiac myocyte Anatomy 0.000 description 4
- 150000001746 carotenes Chemical class 0.000 description 4
- 235000005473 carotenes Nutrition 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 230000032823 cell division Effects 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 230000021615 conjugation Effects 0.000 description 4
- 210000002808 connective tissue Anatomy 0.000 description 4
- 230000001086 cytosolic effect Effects 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- GYQBBRRVRKFJRG-UHFFFAOYSA-L disodium pyrophosphate Chemical class [Na+].[Na+].OP([O-])(=O)OP(O)([O-])=O GYQBBRRVRKFJRG-UHFFFAOYSA-L 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 229930195733 hydrocarbon Natural products 0.000 description 4
- 150000002430 hydrocarbons Chemical class 0.000 description 4
- 230000001771 impaired effect Effects 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 238000007918 intramuscular administration Methods 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 239000002502 liposome Substances 0.000 description 4
- 238000011068 loading method Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 239000003182 parenteral nutrition solution Substances 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 4
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 4
- 239000000049 pigment Substances 0.000 description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 239000002516 radical scavenger Substances 0.000 description 4
- 239000003642 reactive oxygen metabolite Substances 0.000 description 4
- 230000001850 reproductive effect Effects 0.000 description 4
- 230000019491 signal transduction Effects 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 159000000000 sodium salts Chemical class 0.000 description 4
- 239000000600 sorbitol Substances 0.000 description 4
- 235000010356 sorbitol Nutrition 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 238000013268 sustained release Methods 0.000 description 4
- 239000012730 sustained-release form Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 239000011732 tocopherol Substances 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 235000019155 vitamin A Nutrition 0.000 description 4
- 239000011719 vitamin A Substances 0.000 description 4
- 229940045997 vitamin a Drugs 0.000 description 4
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 3
- 239000003406 5-lipoxygenase-activating protein inhibitor Substances 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- HDLNSTQYXPTXMC-UHFFFAOYSA-N Astaxanthin-diacetat Natural products O=C1C(OC(=O)C)CC(C)(C)C(C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC=2C(CC(C(=O)C=2C)OC(C)=O)(C)C)=C1C HDLNSTQYXPTXMC-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 208000005623 Carcinogenesis Diseases 0.000 description 3
- 229920000858 Cyclodextrin Polymers 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- 239000007990 PIPES buffer Substances 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 102000001253 Protein Kinase Human genes 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 235000010419 agar Nutrition 0.000 description 3
- 150000001336 alkenes Chemical class 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 229940114078 arachidonate Drugs 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- MQZIGYBFDRPAKN-UWFIBFSHSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-UWFIBFSHSA-N 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000008827 biological function Effects 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- 230000036952 cancer formation Effects 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 230000024245 cell differentiation Effects 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000013375 chromatographic separation Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000030944 contact inhibition Effects 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 235000015872 dietary supplement Nutrition 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 3
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 210000000981 epithelium Anatomy 0.000 description 3
- 150000002170 ethers Chemical class 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 230000007407 health benefit Effects 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 239000000017 hydrogel Substances 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 125000005647 linker group Chemical group 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000007937 lozenge Substances 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 150000002665 lycophylls Chemical class 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 229960002900 methylcellulose Drugs 0.000 description 3
- 230000009826 neoplastic cell growth Effects 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 230000001590 oxidative effect Effects 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 230000035790 physiological processes and functions Effects 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000000644 propagated effect Effects 0.000 description 3
- 208000023958 prostate neoplasm Diseases 0.000 description 3
- 108060006633 protein kinase Proteins 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 230000000241 respiratory effect Effects 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 230000003595 spectral effect Effects 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 3
- 238000011285 therapeutic regimen Methods 0.000 description 3
- 229960001295 tocopherol Drugs 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 238000006257 total synthesis reaction Methods 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 3
- 210000003932 urinary bladder Anatomy 0.000 description 3
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- OTXNTMVVOOBZCV-UHFFFAOYSA-N 2R-gamma-tocotrienol Natural products OC1=C(C)C(C)=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 OTXNTMVVOOBZCV-UHFFFAOYSA-N 0.000 description 2
- QXNWZXMBUKUYMD-ITUXNECMSA-N 4-keto-beta-carotene Chemical compound CC=1C(=O)CCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C QXNWZXMBUKUYMD-ITUXNECMSA-N 0.000 description 2
- 229940124125 5 Lipoxygenase inhibitor Drugs 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-M Arachidonate Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC([O-])=O YZXBAPSDXZZRGB-DOFZRALJSA-M 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- 241000972773 Aulopiformes Species 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- OINNEUNVOZHBOX-XBQSVVNOSA-N Geranylgeranyl diphosphate Natural products [P@](=O)(OP(=O)(O)O)(OC/C=C(\CC/C=C(\CC/C=C(\CC/C=C(\C)/C)/C)/C)/C)O OINNEUNVOZHBOX-XBQSVVNOSA-N 0.000 description 2
- 241000168517 Haematococcus lacustris Species 0.000 description 2
- 206010062767 Hypophysitis Diseases 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- 239000000867 Lipoxygenase Inhibitor Substances 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 239000007832 Na2SO4 Substances 0.000 description 2
- 208000022873 Ocular disease Diseases 0.000 description 2
- 102000043276 Oncogene Human genes 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 235000019482 Palm oil Nutrition 0.000 description 2
- 235000019483 Peanut oil Nutrition 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 229920000954 Polyglycolide Polymers 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 235000019774 Rice Bran oil Nutrition 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 241000223109 Trypanosoma cruzi Species 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 2
- 150000001241 acetals Chemical class 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 210000004100 adrenal gland Anatomy 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 125000003158 alcohol group Chemical group 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- RZFHLOLGZPDCHJ-DLQZEEBKSA-N alpha-Tocotrienol Natural products Oc1c(C)c(C)c2O[C@@](CC/C=C(/CC/C=C(\CC/C=C(\C)/C)/C)\C)(C)CCc2c1C RZFHLOLGZPDCHJ-DLQZEEBKSA-N 0.000 description 2
- 230000001668 ameliorated effect Effects 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 208000036878 aneuploidy Diseases 0.000 description 2
- 231100001075 aneuploidy Toxicity 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 235000019445 benzyl alcohol Nutrition 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 238000000451 chemical ionisation Methods 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 239000007891 compressed tablet Substances 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 229940111134 coxibs Drugs 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 229940097362 cyclodextrins Drugs 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 210000000172 cytosol Anatomy 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 235000013367 dietary fats Nutrition 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 2
- XPPKVPWEQAFLFU-UHFFFAOYSA-N diphosphoric acid Chemical class OP(O)(=O)OP(O)(O)=O XPPKVPWEQAFLFU-UHFFFAOYSA-N 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 210000001508 eye Anatomy 0.000 description 2
- 239000010685 fatty oil Substances 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 210000004392 genitalia Anatomy 0.000 description 2
- OINNEUNVOZHBOX-KGODAQDXSA-N geranylgeranyl diphosphate Chemical compound CC(C)=CCC\C(C)=C/CC\C(C)=C\CC\C(C)=C\CO[P@@](O)(=O)OP(O)(O)=O OINNEUNVOZHBOX-KGODAQDXSA-N 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 150000002334 glycols Chemical class 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 201000011066 hemangioma Diseases 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000013632 homeostatic process Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000037041 intracellular level Effects 0.000 description 2
- 230000004068 intracellular signaling Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004561 lacrimal apparatus Anatomy 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- UFPQIRYSPUYQHK-WAQVJNLQSA-N leukotriene A4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@@H]1O[C@H]1CCCC(O)=O UFPQIRYSPUYQHK-WAQVJNLQSA-N 0.000 description 2
- 230000003859 lipid peroxidation Effects 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 150000002658 luteins Chemical class 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 208000010658 metastatic prostate carcinoma Diseases 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 2
- 210000000944 nerve tissue Anatomy 0.000 description 2
- 239000012038 nucleophile Substances 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 239000010502 orange oil Substances 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N p-hydroxybenzoic acid methyl ester Natural products COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 239000002540 palm oil Substances 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000000312 peanut oil Substances 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 150000003904 phospholipids Chemical group 0.000 description 2
- 150000003014 phosphoric acid esters Chemical class 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 210000003635 pituitary gland Anatomy 0.000 description 2
- 229920000747 poly(lactic acid) Polymers 0.000 description 2
- 239000004633 polyglycolic acid Substances 0.000 description 2
- 239000004626 polylactic acid Substances 0.000 description 2
- 229920000656 polylysine Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 2
- 150000003138 primary alcohols Chemical class 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 208000016691 refractory malignant neoplasm Diseases 0.000 description 2
- 230000030198 regulation of embryonic development Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 239000008165 rice bran oil Substances 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- 210000003079 salivary gland Anatomy 0.000 description 2
- 230000002000 scavenging effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 238000007614 solvation Methods 0.000 description 2
- 235000014347 soups Nutrition 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 238000004611 spectroscopical analysis Methods 0.000 description 2
- 238000013319 spin trapping Methods 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 229940014800 succinic anhydride Drugs 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 2
- 239000002511 suppository base Substances 0.000 description 2
- 239000011885 synergistic combination Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- 238000011287 therapeutic dose Methods 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- KKFOMYPMTJLQGA-UHFFFAOYSA-N tribenzyl phosphite Chemical compound C=1C=CC=CC=1COP(OCC=1C=CC=CC=1)OCC1=CC=CC=C1 KKFOMYPMTJLQGA-UHFFFAOYSA-N 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 239000000717 tumor promoter Substances 0.000 description 2
- 239000002691 unilamellar liposome Substances 0.000 description 2
- 210000000626 ureter Anatomy 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 230000036642 wellbeing Effects 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 150000003735 xanthophylls Chemical class 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- FGYKUFVNYVMTAM-UHFFFAOYSA-N (R)-2,5,8-trimethyl-2-(4,8,12-trimethyl-trideca-3t,7t,11-trienyl)-chroman-6-ol Natural products OC1=CC(C)=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1C FGYKUFVNYVMTAM-UHFFFAOYSA-N 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- GJJVAFUKOBZPCB-ZGRPYONQSA-N (r)-3,4-dihydro-2-methyl-2-(4,8,12-trimethyl-3,7,11-tridecatrienyl)-2h-1-benzopyran-6-ol Chemical class OC1=CC=C2OC(CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-ZGRPYONQSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 description 1
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- VOXBZHOHGGBLCQ-UHFFFAOYSA-N 2-amino-3,7-dihydropurine-6-thione;hydrate Chemical compound O.N1C(N)=NC(=S)C2=C1N=CN2.N1C(N)=NC(=S)C2=C1N=CN2 VOXBZHOHGGBLCQ-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 229940013085 2-diethylaminoethanol Drugs 0.000 description 1
- HZLCGUXUOFWCCN-UHFFFAOYSA-N 2-hydroxynonadecane-1,2,3-tricarboxylic acid Chemical compound CCCCCCCCCCCCCCCCC(C(O)=O)C(O)(C(O)=O)CC(O)=O HZLCGUXUOFWCCN-UHFFFAOYSA-N 0.000 description 1
- ZNBGBHISQKMEPA-UHFFFAOYSA-N 2-oxoacetyl chloride Chemical compound ClC(=O)C=O ZNBGBHISQKMEPA-UHFFFAOYSA-N 0.000 description 1
- ODADKLYLWWCHNB-UHFFFAOYSA-N 2R-delta-tocotrienol Natural products OC1=CC(C)=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 ODADKLYLWWCHNB-UHFFFAOYSA-N 0.000 description 1
- HVCNXQOWACZAFN-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound CCN1CCOCC1 HVCNXQOWACZAFN-UHFFFAOYSA-N 0.000 description 1
- 101710118202 43 kDa protein Proteins 0.000 description 1
- 150000000556 5-HETE derivatives Chemical class 0.000 description 1
- JNUUNUQHXIOFDA-XTDASVJISA-N 5-HPETE Chemical compound CCCCC\C=C/C\C=C/C\C=C/C=C/C(OO)CCCC(O)=O JNUUNUQHXIOFDA-XTDASVJISA-N 0.000 description 1
- KGIJOOYOSFUGPC-XRXZHELTSA-N 5-hydroxyeicosatetraenoic acid Natural products CCCCCC=CCC=CCC=C\C=C\C(O)CCCC(O)=O KGIJOOYOSFUGPC-XRXZHELTSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 208000029483 Acquired immunodeficiency Diseases 0.000 description 1
- 208000004804 Adenomatous Polyps Diseases 0.000 description 1
- OSDWBNJEKMUWAV-UHFFFAOYSA-N Allyl chloride Chemical class ClCC=C OSDWBNJEKMUWAV-UHFFFAOYSA-N 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-M Aminoacetate Chemical compound NCC([O-])=O DHMQDGOQFOQNFH-UHFFFAOYSA-M 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 208000005440 Basal Cell Neoplasms Diseases 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 206010060999 Benign neoplasm Diseases 0.000 description 1
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 108010051479 Bombesin Proteins 0.000 description 1
- 102000013585 Bombesin Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- 102100030497 Cytochrome c Human genes 0.000 description 1
- 108010075031 Cytochromes c Proteins 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 206010012422 Derealisation Diseases 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 101710102044 Envelope protein F13 homolog Proteins 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 241000239366 Euphausiacea Species 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 239000001116 FEMA 4028 Substances 0.000 description 1
- 201000006107 Familial adenomatous polyposis Diseases 0.000 description 1
- 206010053172 Fatal outcomes Diseases 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010019668 Hepatic fibrosis Diseases 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 101000755875 Homo sapiens Arachidonate 5-lipoxygenase-activating protein Proteins 0.000 description 1
- 206010062904 Hormone-refractory prostate cancer Diseases 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- 208000001718 Immediate Hypersensitivity Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- KIENGQUGHPTFGC-JLAZNSOCSA-N L-ascorbic acid 6-phosphate Chemical compound OP(=O)(O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O KIENGQUGHPTFGC-JLAZNSOCSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 229910013596 LiOH—H2O Inorganic materials 0.000 description 1
- 206010061523 Lip and/or oral cavity cancer Diseases 0.000 description 1
- 206010062038 Lip neoplasm Diseases 0.000 description 1
- IFTRFNLCKUZSNG-ZZAFTVETSA-N Lycoxanthin Natural products OC/C(=C\CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(\C)/C)\C)/C)\C)/C)\C)/C)/C IFTRFNLCKUZSNG-ZZAFTVETSA-N 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 238000006751 Mitsunobu reaction Methods 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 241000282339 Mustela Species 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 108091093105 Nuclear DNA Proteins 0.000 description 1
- 108010047956 Nucleosomes Proteins 0.000 description 1
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 208000037062 Polyps Diseases 0.000 description 1
- 241000097929 Porphyria Species 0.000 description 1
- 208000010642 Porphyrias Diseases 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010001267 Protein Subunits Proteins 0.000 description 1
- 102000002067 Protein Subunits Human genes 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- 201000010829 Spina bifida Diseases 0.000 description 1
- 208000006097 Spinal Dysraphism Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- SHGAZHPCJJPHSC-NWVFGJFESA-N Tretinoin Chemical compound OC(=O)/C=C(\C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NWVFGJFESA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 206010045240 Type I hypersensitivity Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- MMWCIQZXVOZEGG-HOZKJCLWSA-N [(1S,2R,3S,4S,5R,6S)-2,3,5-trihydroxy-4,6-diphosphonooxycyclohexyl] dihydrogen phosphate Chemical compound O[C@H]1[C@@H](O)[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](O)[C@H]1OP(O)(O)=O MMWCIQZXVOZEGG-HOZKJCLWSA-N 0.000 description 1
- SMEGJBVQLJJKKX-HOTMZDKISA-N [(2R,3S,4S,5R,6R)-5-acetyloxy-3,4,6-trihydroxyoxan-2-yl]methyl acetate Chemical compound CC(=O)OC[C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)O)OC(=O)C)O)O SMEGJBVQLJJKKX-HOTMZDKISA-N 0.000 description 1
- UWWGQJSXOZIDFJ-UHFFFAOYSA-N [iodo(phenylmethoxy)phosphoryl]oxymethylbenzene Chemical compound C=1C=CC=CC=1COP(=O)(I)OCC1=CC=CC=C1 UWWGQJSXOZIDFJ-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229940081735 acetylcellulose Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000036982 action potential Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 229940040563 agaric acid Drugs 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 229940064063 alpha tocotrienol Drugs 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229940124326 anaesthetic agent Drugs 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000006851 antioxidant defense Effects 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000010425 asbestos Substances 0.000 description 1
- 125000003999 astaxanthin group Chemical group 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 208000010216 atopic IgE responsiveness Diseases 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 238000010533 azeotropic distillation Methods 0.000 description 1
- 238000011021 bench scale process Methods 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- FGYKUFVNYVMTAM-YMCDKREISA-N beta-Tocotrienol Natural products Oc1c(C)c2c(c(C)c1)O[C@@](CC/C=C(\CC/C=C(\CC/C=C(\C)/C)/C)/C)(C)CC2 FGYKUFVNYVMTAM-YMCDKREISA-N 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- PSQYTAPXSHCGMF-BQYQJAHWSA-N beta-ionone group Chemical group CC1=C(C(CCC1)(C)C)/C=C/C(C)=O PSQYTAPXSHCGMF-BQYQJAHWSA-N 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 238000013378 biophysical characterization Methods 0.000 description 1
- 208000002352 blister Diseases 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- DNDCVAGJPBKION-DOPDSADYSA-N bombesin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1NC2=CC=CC=C2C=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CN=CN1 DNDCVAGJPBKION-DOPDSADYSA-N 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- IYYIVELXUANFED-UHFFFAOYSA-N bromo(trimethyl)silane Chemical compound C[Si](C)(C)Br IYYIVELXUANFED-UHFFFAOYSA-N 0.000 description 1
- 210000003123 bronchiole Anatomy 0.000 description 1
- 125000003865 brosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Br)S(*)(=O)=O 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 125000001369 canonical nucleoside group Chemical group 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000003293 cardioprotective effect Effects 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000009134 cell regulation Effects 0.000 description 1
- 230000010001 cellular homeostasis Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 208000029664 classic familial adenomatous polyposis Diseases 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000008094 contradictory effect Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 150000004292 cyclic ethers Chemical class 0.000 description 1
- 230000001120 cytoprotective effect Effects 0.000 description 1
- 230000000254 damaging effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- BTNBMQIHCRIGOU-UHFFFAOYSA-N delta-tocotrienol Natural products CC(=CCCC(=CCCC(=CCCOC1(C)CCc2cc(O)cc(C)c2O1)C)C)C BTNBMQIHCRIGOU-UHFFFAOYSA-N 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- WDEABJKSGGRCQA-UHFFFAOYSA-N docebenone Chemical compound CC1=C(C)C(=O)C(CCCCC#CCCCC#CCO)=C(C)C1=O WDEABJKSGGRCQA-UHFFFAOYSA-N 0.000 description 1
- 229950003667 docebenone Drugs 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000010410 dusting Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 235000006932 echinenone Nutrition 0.000 description 1
- YXPMCBGFLULSGQ-YHEDCBSUSA-N echinenone Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(=O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CCCC2(C)C YXPMCBGFLULSGQ-YHEDCBSUSA-N 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 210000004242 electrical synapse Anatomy 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 210000002308 embryonic cell Anatomy 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 208000037828 epithelial carcinoma Diseases 0.000 description 1
- FGYKUFVNYVMTAM-MUUNZHRXSA-N epsilon-Tocopherol Natural products OC1=CC(C)=C2O[C@@](CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1C FGYKUFVNYVMTAM-MUUNZHRXSA-N 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000006266 etherification reaction Methods 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 102000018823 fas Receptor Human genes 0.000 description 1
- 108010052621 fas Receptor Proteins 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000011832 ferret model Methods 0.000 description 1
- 230000001842 fibrogenetic effect Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000009093 first-line therapy Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- OTXNTMVVOOBZCV-YMCDKREISA-N gamma-Tocotrienol Natural products Oc1c(C)c(C)c2O[C@@](CC/C=C(\CC/C=C(\CC/C=C(\C)/C)/C)/C)(C)CCc2c1 OTXNTMVVOOBZCV-YMCDKREISA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 231100000024 genotoxic Toxicity 0.000 description 1
- 230000001738 genotoxic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 235000003969 glutathione Nutrition 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1
- 229960003132 halothane Drugs 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 1
- 210000004024 hepatic stellate cell Anatomy 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 235000006486 human diet Nutrition 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N hydrochloric acid Substances Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-N hydroperoxyl Chemical group O[O] OUUQCZGPVNCOIJ-UHFFFAOYSA-N 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 230000006951 hyperphosphorylation Effects 0.000 description 1
- 201000006122 hypervitaminosis A Diseases 0.000 description 1
- 230000037451 immune surveillance Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000266 injurious effect Effects 0.000 description 1
- 229910001410 inorganic ion Inorganic materials 0.000 description 1
- 229910052816 inorganic phosphate Inorganic materials 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 230000008776 intercellular pathway Effects 0.000 description 1
- 230000035990 intercellular signaling Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 238000005040 ion trap Methods 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000001865 kupffer cell Anatomy 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 238000010667 large scale reaction Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 201000006721 lip cancer Diseases 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium;hydroxide;hydrate Chemical compound [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 241000238565 lobster Species 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 125000002635 lutein group Chemical group 0.000 description 1
- 125000002726 lycophyll group Chemical group 0.000 description 1
- 235000008699 lycoxanthin Nutrition 0.000 description 1
- IFTRFNLCKUZSNG-UHFFFAOYSA-N lycoxanthin Chemical compound CC(C)=CCCC(C)=CC=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC=C(C)CCC=C(C)CO IFTRFNLCKUZSNG-UHFFFAOYSA-N 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000009973 maize Nutrition 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000000936 membranestabilizing effect Effects 0.000 description 1
- 230000006609 metabolic stress Effects 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 238000005232 molecular self-assembly Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 231100000707 mutagenic chemical Toxicity 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 230000008298 non-genomic mechanism Effects 0.000 description 1
- 231100000804 nongenotoxic Toxicity 0.000 description 1
- 210000000633 nuclear envelope Anatomy 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 210000001623 nucleosome Anatomy 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 230000006548 oncogenic transformation Effects 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 125000000962 organic group Chemical group 0.000 description 1
- 239000003791 organic solvent mixture Substances 0.000 description 1
- 229940127084 other anti-cancer agent Drugs 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000004963 pathophysiological condition Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 229940097156 peroxyl Drugs 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002644 phorbol ester Substances 0.000 description 1
- 150000008105 phosphatidylcholines Chemical class 0.000 description 1
- FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 description 1
- 230000003711 photoprotective effect Effects 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920006324 polyoxymethylene Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 150000004032 porphyrins Chemical class 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940116317 potato starch Drugs 0.000 description 1
- 238000004237 preparative chromatography Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 238000011165 process development Methods 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 230000002633 protecting effect Effects 0.000 description 1
- 244000000040 protozoan parasite Species 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 230000025915 regulation of apoptotic process Effects 0.000 description 1
- 230000031539 regulation of cell division Effects 0.000 description 1
- 230000026267 regulation of growth Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 150000004492 retinoid derivatives Chemical class 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 229910052895 riebeckite Inorganic materials 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 238000005464 sample preparation method Methods 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 238000001338 self-assembly Methods 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- YPURUCMVRRNPHJ-UHFFFAOYSA-M sodium;3-[3-tert-butylsulfanyl-1-[(4-chlorophenyl)methyl]-5-(quinolin-2-ylmethoxy)indol-2-yl]-2,2-dimethylpropanoate Chemical compound [Na+].C12=CC=C(OCC=3N=C4C=CC=CC4=CC=3)C=C2C(SC(C)(C)C)=C(CC(C)(C)C([O-])=O)N1CC1=CC=C(Cl)C=C1 YPURUCMVRRNPHJ-UHFFFAOYSA-M 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 150000003900 succinic acid esters Chemical class 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000003390 teratogenic effect Effects 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 229960004559 theobromine Drugs 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 230000030968 tissue homeostasis Effects 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 125000002640 tocopherol group Chemical class 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 229930003802 tocotrienol Natural products 0.000 description 1
- 239000011731 tocotrienol Substances 0.000 description 1
- 235000019148 tocotrienols Nutrition 0.000 description 1
- 229940068778 tocotrienols Drugs 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 239000000225 tumor suppressor protein Substances 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- MWLSOWXNZPKENC-SSDOTTSWSA-N zileuton Chemical compound C1=CC=C2SC([C@H](N(O)C(N)=O)C)=CC2=C1 MWLSOWXNZPKENC-SSDOTTSWSA-N 0.000 description 1
- 229960005332 zileuton Drugs 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- RZFHLOLGZPDCHJ-XZXLULOTSA-N α-Tocotrienol Chemical compound OC1=C(C)C(C)=C2O[C@@](CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1C RZFHLOLGZPDCHJ-XZXLULOTSA-N 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000019145 α-tocotrienol Nutrition 0.000 description 1
- 239000011730 α-tocotrienol Substances 0.000 description 1
- 229930195724 β-lactose Natural products 0.000 description 1
- 235000019151 β-tocotrienol Nutrition 0.000 description 1
- 239000011723 β-tocotrienol Substances 0.000 description 1
- FGYKUFVNYVMTAM-WAZJVIJMSA-N β-tocotrienol Chemical compound OC1=CC(C)=C2O[C@@](CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1C FGYKUFVNYVMTAM-WAZJVIJMSA-N 0.000 description 1
- 235000019150 γ-tocotrienol Nutrition 0.000 description 1
- 239000011722 γ-tocotrienol Substances 0.000 description 1
- OTXNTMVVOOBZCV-WAZJVIJMSA-N γ-tocotrienol Chemical compound OC1=C(C)C(C)=C2O[C@@](CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 OTXNTMVVOOBZCV-WAZJVIJMSA-N 0.000 description 1
- 235000019144 δ-tocotrienol Nutrition 0.000 description 1
- 239000011729 δ-tocotrienol Substances 0.000 description 1
- ODADKLYLWWCHNB-LDYBVBFYSA-N δ-tocotrienol Chemical compound OC1=CC(C)=C2O[C@@](CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 ODADKLYLWWCHNB-LDYBVBFYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
- A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7024—Esters of saccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- Gap junctions are specialized regions of the cell membrane with clusters of hundreds to thousands of densely packed gap junction channels that directly connect the cytoplasmic compartment of two neighboring cells.
- the gap junction channels are composed of two hemichannels (connexons) provided by each of two neighboring cells.
- Each connexon consists of six proteins called connexins (Cx).
- the connexins are a large family of proteins all sharing the basic structure of four transmembrane domains, two extracellular loops, and a cytoplasmic loop. There is a high degree of conservation of the extracellular loops and transmembrane domains among species and connexin isoforms.
- the length of the C-terminus varies considerably giving rise to the classification of the connexins on the basis of the molecular weight.
- the gap junction channel can switch between an open and a closed state by a twisting motion. In the open state ions and small molecules can pass through the pore. The conduction of the electrical impulse and intercellular diffusion of signaling molecules take place through the gap junctions and normally functioning gap junctions are therefore a prerequisite for normal intercellular communication. Normal intercellular communication is essential for for cellular homeostasis, proliferation and differentiation.
- GJIC regulation or junctional gating has been widely studied for gap junctions especially gap junctions composed of Cx43.
- Some factors exert their inhibitory effects on GJIC indirectly, for example, by altering the lipid environment and cell membrane fluidity, whereas other GJIC inhibitors include oncogenes, growth factors, and tumor promoters, which induce various modifications of the Cx43. Disruption of junctional permeability may be necessary for mediating the specific biological functions of the latter group. These agents initiate complex signaling pathways consisting of the activation of kinases, phosphatases, and interacting proteins.
- Second messengers such as cyclic nucleotides, calcium, and inositol phosphates are small enough to pass from hormonally activated cells to quiescent cells through junctional channels and activate the latter. Such an effect may increase the tissue response to an agonist.
- Regulation of embryonic development Gap junctions may serve as intercellular pathways for chemical and/or electrical developmental signals in embryos and for defining the boundaries of developmental compartments. GJIC occurs in specific patterns in embryonic cells and the impairment of GJIC has been related to developmental anomalies and the teratogenic effects of many chemicals.
- astaxanthin is a powerful lipid-phase antioxidant, and has been reported to suppress production of inflammatory cytokines (Lee at al, 2003). Based on this evidence, astaxanthin has significant cancer chemopreventive potential.
- carotenoids share common chemical features, such as a polyisoprenoid structure, a long polyene chain forming the chromophore, and near symmetry around the central double bond.
- Tail-to-tail linkage of two C 20 geranyl-geranyl diphosphate molecules produces the parent C 40 carbon skeleton.
- Carotenoids without oxygenated functional groups are called "carotenes", reflecting their hydrocarbon nature; oxygenated carotenes are known as “xanthophylls.” Cyclization at one or both ends of the molecule yields 7 identified end groups (illustrative structures shown in FIG. 1). Examples of uses of carotenoid derivatives and analogs are illustrated in U.S. Patent Application Serial No. 10/793,671 filed on March 4, 2004, entitled
- Metastatic prostate cancer responds initially to androgen withdrawal therapy, but hormone resistance frequently (and some reports state universally) develops. Chemotherapeutic agents currently available have little or no impact on the survival of the patients with hormone-refractory prostate cancer. For this reason, metastatic prostate cancer almost always has a fatal outcome. Although the incidence of the localized, latent form of prostate cancer is the same globally regardless of ethnic origin, there is significant variation in the occurrence of metastatic disease between Western countries and Eastern countries, suggesting involvement of environmental factors in metastatic progression. The underlying molecular mechanism involved in the progression phase of the disease is an active area of current research.
- Synthetic astaxanthin produced by large manufacturers such as Hoffmann-LaRoche AG, Buckton Scott (USA), or BASF AG, are provided as defined geometric isomer mixtures of a 1:2:1 stereoisomer mixture [3S, 3'S; 3R, 3'S, 3'R,3S (meso); 3R, 3'R] of non-esterified, free astaxanthin.
- Natural source astaxanthin from salmon fish is predominantly a single stereoisomer (3S,3'S), but does contain a mixture of geometric isomers. Astaxanthin from the natural source Haematococcus pluvialis may contain nearly 50% Z isomers.
- the presently disclosed treatment methods relate to preventing or treating proliferative disorders caused, at least in part, by impaired gap junction function by facilitating (maintaining and/or restoring) the intercellular communication in the diseased cells and tissues occurring through gap junctions, preferably by administering a therapeutically effective amount of at least one carotenoid analog or derivative which facilitates CX43 expression and gap junction intercellular communication to a patient suffering from said disease.
- Proliferative disorders that may be influenced by administration of analogs or derivatives of carotenoids according to some embodiments may include those disorders that are characterized by aberrant or otherwise dysregulated cell growth, such as, for example, benign or malignant neoplasms or any other disorder characterized by the proliferation of anaplastic cells, and/or invasion of such cells into surrounding tissues or distal sites.
- Water-soluble carotenoid analogs or derivatives may include those compounds and synthetic derivatives which form molecular self-assemblies, and may be more properly termed "water dispersible” carotenoid analogs or derivatives. Water-soluble and/or “water- dispersible” carotenoid analogs or derivatives may be preferred in some embodiments.
- a method of inhibiting or reducing at least some of the side effects associated with therapeutic administration of COX-2 selective inhibitors may include administering to the subject an effective amount of a pharmaceutically acceptable formulation including a synthetic analog or derivative of a carotenoid.
- the synthetic analog or derivative of the carotenoid may have the structure
- FIG. 16 shows a series of flow cytometric profiles indicating the DNA content and approximate cell cycle profile of LNCaP human prostate cancer cells treated with various carotenoids or MK886 for 24 hours in the presence of fetal calf serum. Apoptotic cells are indicated as the population of cells having sub Gl DNA content;
- Secondary cells are those cells that are explanted directly from a donor organism or tissue and that are maintained and propagated in culture for a protracted period of time, typically exceeding that of primary cells. Often times, secondary cells may be propagated in vitro for up to as many as 100 generations or more. Secondary cells are typically not immortalized however, and eventually undergo senescence. The number of cell divisions that secondary cells may undergo is related to their degree of differentiation. More terminally differentiated cells undergo fewer cell divisions and senesce early. Less well-differentiated cells, such as embryonic fibroblasts and cells that have begun to undergo neoplastic transformation, typically have a higher generation potential and can undergo a greater number of divisions.
- Immortalized cells may typically be maintained and propagated in vitro indefinitely as long as the correct culture conditions are maintained. Immortalized cell lines are commonly referred to in the art as “transformed cells.” The growth properties of such cells are altered. Typically, such cells have undergone one or more genotypic changes, such as, for example point mutations, aneuploidy or other chromosomal alterations. Immortalized cells may or may not be cancerous or malignant. Non-malignant transformed cells typically exhibit one or more of several properties when grown in vitro. Non-limiting examples of the phenotypic properties exhibited by non-malignant transformed cells include anchorage-dependent growth, growth factor dependence, and growth-arrest under conditions of nutritional deficiency.
- Apoptosis of a cell can be characterized at least by the rapid condensation of the cell with collapse of the nucleus but preservation of membranes; or, cleavage of nuclear DNA at the linker regions between nucleosomes to produce fragments which can be easily visualized by agarose gel electrophoresis as a characteristic ladder pattern.
- Cells undergoing apoptosis exhibit a characteristic series of morphological changes including mitochondrial membrane swelling and rupture, leakage of cytosolic contents into the surrounding area, and inflammation in tissues.
- the pattern of events occurring during apoptosis is orderly and includes; cell shrinkage; appearance of bubble-like blebs on their surface; degradation of chromatin (DNA and protein) in their nucleus; mitochondrial rupture and release of cytochrome c into the cytosol; breakage of the cell into small, membrane-wrapped, fragments (commonly referred to as "apoptotic bodies” or “corpses”); exposure of phosphatidylserine on the outer leaflet of the cell membrane; and recruitment of phagocytic cells like macrophages and dendritic cells which then engulf the cell fragments.
- Various pathologies occur due to a defective or aberrant regulation of apoptosis in the affected cells of an organism. For example, defects that result in a decreased level of apoptosis in a tissue as compared to the normal level required to maintain the steady-state of the tissue can promote an abnormal increase of the amount of cells in a tissue. This has been observed in various cancers, where the formation of tumors occurs because the cells are not dying at their normal rate.
- administration when used in the context of providing a pharmaceutical or nutraceutical composition to a subject generally refers to providing to the subject one or more pharmaceutical, “over-the-counter” (OTC) or nutraceutical compositions in combination with an appropriate delivery vehicle by any means such that the administered compound achieves one or more of the intended biological effects for which the compound was administered.
- OTC over-the-counter
- a composition may be administered parenteral, subcutaneous, intravenous, intracoronary, rectal, intramuscular, intraperitoneal, transdermal, or buccal routes of delivery.
- administration may be by the oral route.
- the dosage administered will be dependent upon the age, health, weight, and/or disease state of the recipient, kind of concurrent treatment, if any, frequency of treatment, and/or the nature of the effect desired.
- the dosage of pharmacologically active compound that is administered will be dependent upon multiple factors, such as the age, health, weight, and/or disease state of the recipient, concurrent treatments, if any, the frequency of treatment, and/or the nature and magnitude of the biological effect that is desired.
- pharmaceutical preparation generally refer to formulations that are adapted to deliver a prescribed dosage of one or more pharmacologically active compounds to a cell, a group of cells, an organ or tissue, an animal or a human. Methods of incorporating pharmacologically active compounds into pharmaceutical preparations are widely known in the art. The determination of an appropriate prescribed dosage of a pharmacologically active compound to include in a pharmaceutical composition in order to achieve a desired biological outcome is within the skill level of an ordinary practitioner of the art.
- a pharmaceutical composition may be provided as sustained-release or timed-release formulations.
- Such formulations may release a bolus of a compound from the formulation at a desired time, or may ensure a relatively constant amount of the compound present in the dosage is released over a given period of time.
- Terms such as “sustained release” or “timed release” and the like are widely used in the pharmaceutical arts and are readily understood by a practitioner of ordinary skill in the art.
- Pharmaceutical preparations may be prepared as solids, semi-solids, gels, hydrogels, liquids, solutions, suspensions, emulsions, aerosols, powders, or combinations thereof.
- salts includes salts prepared from by reacting pharmaceutically acceptable non-toxic bases or acids, including inorganic or organic bases, with inorganic or organic acids.
- Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins, such as argmine, betaine, caffeine, choline, N,N'-dibenzylethylenediamine, diethylamine, 2- dibenzylethylenediamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N- ethyl-morpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, etc.
- prophylactically effective amount is meant an amount of a pharmaceutical composition that will substantially prevent, delay or reduce the risk of occurrence of the biological or physiological event in a cell, a tissue, a system, animal or human that is being sought by a researcher, veterinarian, physician or other caregiver.
- co-antioxidant may be generally defined as an antioxidant that is used and that acts in combination with another antioxidant (e.g., two antioxidants that are chemically and/or functionally coupled, or two antioxidants that are combined and function with each another in a pharmaceutical preparation).
- the effects of co-antioxidants may be additive (i.e., the anti-oxidative potential of one or more anti-oxidants acting additively is approximately the sum of the oxidative potential of each component anti-oxidant) or synergistic (i.e., the anti- oxidative potential of one or more anti-oxidants acting synergistically may be greater than the sum of the oxidative potential of each component anti-oxidant).
- the carotenoid analog or derivative is an analog or derivative of astaxanthin. In other embodiments, the carotenoid analog or derivative is an analog or derivative of astaxanthin.
- astaxanthin analogs or derivatives that maybe suited to at least some of the therapeutic applications comtemplated herein may include an analog or derivative of an astaxanthin diphosphate. In certain embodiments, the carotenoid analog or derivative is a salt of an analog or derivative of astaxanthin.
- the restoration or maintenance of growth inhibitory mechanisms may result, at least in part, from a restoration of physiologically normal amounts of one or more connexin proteins, such as, for example, connexin 43.
- physiologically normal amounts of a reference protein when used in the context of a transformed cell, generally refers to the level of the reference protein that is typically expressed in a non-transformed, or normal, cell of the same lineage as the transformed cell.
- Restoration of growth inhibitory mechanisms in neoplastic cells may further result from the reestablishment of GJIC between adjacent or substantially adjacent cells.
- the direct superoxide anion scavenging ability of the carotenoid analogs and derivatives described herein may provide further advantageous health benefits.
- proliferative disorders include chronic inflammatory proliferative disorders, e.g., psoriasis and rheumatoid arthritis; proliferative ocular disorders, e.g., diabetic retinopathy; benign proliferative disorders, e.g., hemangiomas; and cancer.
- LNCaP human prostate cancer cells were contacted with an effective amount of various carotenoids and xanthophyll carotenoids (over a 2 log concentration range). Induction of apoptosis was measured by flow cytometric and cell cycle analysis of DNA content in propidium iodide-stains cells. Apoptotic cells were identified as those having sub-Gl amounts of DNA (corresponding to apoptotic bodies). The results of these studies are disclosed below and presented in FIGs 15-20.
- compositions containing carotenoid analogs or derivatives Treatment of proliferative disorders with compositions containing carotenoid analogs or derivatives
- carotenoid analogs or derivatives and methods for the treatment of cancer maybe particularly advantageous and may enhance the effectiveness of the anticancer agent when combined with radiation therapy or chemotherapeutic agents that act by causing damage to the genetic material of cells (collectively referred to herein as "DNA damaging agents”); when combined with agents which are otherwise cytotoxic to cancer cells during cell division; when combined with agents which are proteasome inhibitors; when combined with agents which inhibit NF- ⁇ B (e.g., HCK inhibitors) (Bottero et al., Cancer Res., 61:7785 (2001)); or used with combinations of cancer drags with which are not cytotoxic when administered alone, yet in combination produce a toxic effect.
- Anti-cancer agents having having the properties described above are collectively referred to herein as "chemotherapy agents.”
- carotenoid analogs or derivatives may be combined with one or more DNA damaging agent and treatment methods.
- the disclosed carotenoid analogs or derivatives and treatment methods are also effective when used in combination with chemotherapy agents and/or radiation therapy to treat subjects with multi-drug resistant cancers.
- a cancer is resistant to a drug when it resumes a normal rate of tumor growth while undergoing treatment with the drug after the tumor had initially responded to the drug.
- a tumor "responds to a drag” when it exhibits a decrease in tumor mass or a decrease in the rate of tumor growth.
- multi-drag resistant cancer refers to cancer that is resistant to two or more drags, often as many as five or more.
- an "effective amount" of the a carotenoid analog or derivative suitable for the treatment methods described herein is the quantity which increases Cx43 expression and/or induced apoptosis of neoplastic cells when administered to a subject or which, when administered to a subject with cancer, slows rumor growth, ameliorates the symptoms of the disease and/or increases longevity.
- an effective amount of the carotenoid analog or derivative is the quantity at which a greater response is achieved when the carotenoid analog or derivative is co-administered with the chemotherapy agents and/or radiation therapy than is achieved when the chemotherapy agent and/or radiation therapy is administered alone.
- an "effective amount" of the chemotherapy agents is administered to the subject, which is a quantity that normally produces an anti-cancer effect.
- a disclosed carotenoid analog or derivative may be co-administered with another therapeutic chemotheraeutic agent (e.g., DNA-damaging agent, agent that disrupts cell replication, proteasome inhibitor, NF-IdB inhibitor, or other anticancer agent) as part of the same pharmaceutical composition or, alternatively, as separate pharmaceutical compositions.
- another therapeutic chemotheraeutic agent e.g., DNA-damaging agent, agent that disrupts cell replication, proteasome inhibitor, NF-IdB inhibitor, or other anticancer agent
- carotenoid analog or derivative may be administered prior to, at the same time as, or following administration of the other agent, provided that the enhancing effect on Cx43 expression of the carotenoid analog or derivative is retained.
- Some specific embodiments may include phosphate derivatives, succinate derivatives, co-antioxidant derivatives (e.g., Vitamin C, Vitamin C analogs, Vitamin C derivatives, Vitamin E, Vitamin E analogs, Vitamin E derivatives, flavonoids, flavonoid analogs, or flavonoid derivatives), or combinations thereof derivatives or analogs of carotenoids.
- Flavonoids may include, for example, quercetin, xanthohumol, isoxanthohumol, or genistein.
- Derivatives or analogs may be derived from any known carotenoid (naturally or synthetically derived).
- Specific examples of naturally occurring carotenoids which compounds described herein may be derived from include for example zeaxanthin, lutein, lycophyll, astaxanthin, and lycopene.
- the carotenoid derivatives may include compounds having a structure including a polyene chain (i.e., backbone of the molecule).
- the polyene chain may include between about 5 and about 15 unsaturated bonds.
- the polyene chain may include between about 7 and about 12 unsaturated bonds.
- a carotenoid derivative may include 7 or more conjugated double bonds to achieve acceptable antioxidant properties.
- a chemical compound including a carotenoid derivative or analog may have the general structure (126):
- the carotenoid derivatives may include compounds having the structure (128):
- Each R 11 may be independently hydrogen, methyl, alkyl, alkenyl, or aromatic substituents.
- R 9 and R 10 may be independently H, an acyclic alkene with at least one substituent, or a cyclic ring with at least one substituent having general structure (130):
- each cyclic ring may be independently two or more rings fused together to form a fused ring system (e.g., a bi-cyclic system).
- a fused ring system e.g., a bi-cyclic system.
- Each ring of the fused ring system may independently contain one or more degrees of unsaturation.
- Each ring of the fused ring system may be independently aromatic. Two or more of the rings forming the fused ring system may form an aromatic system.
- a chemical composition may include a carotenoid derivative having the structure
- R 3 may be independently hydrogen or methyl.
- R 1 and R 2 may be a cyclic ring including at least one substituent.
- Each cyclic ring may be independently:
- At least one substituent W may independently include OO co-antioxidant.
- Each R' may be CH 2 .
- n may range from 1 to 9.
- Each R may be independently H, alkyl, aryl, benzyl, alkali metal, or a co- antioxidant.
- Each co-antioxidant may be independently Vitamin C, Vitamin C analogs, Vitamin C derivatives, Vitamin E, Vitamin E analogs, Vitamin E derivatives, flavonoids, fiavonoid analogs, or flavonoid derivatives.
- Flavonoids may include, for example, quercetin, xanthohumol, isoxanthohumol, or genistein.
- Each R ⁇ may be independently hydrogen or methyl.
- Each R 14 may be independently O or H 2 .
- Each R may be independently OR 12 or R 12 .
- Each R 12 may be independently -alkyl-NR I3 3 + , -aromatic-N R 13 3 + , -alkyl-CO 2 ⁇ , - aromatic-CO 2 " , -amino acid-NH 3 + , -phosphorylated amino acid-NH 3 + , polyethylene glycol, dextran, H, alkyl, co- antioxidant (e.g. Vitamin C, Vitamin C analogs, Vitamin C derivatives, Vitamin E, Vitamin E analogs, Vitamin E derivatives, flavonoids, flavonoid analogs, or flavonoid derivatives), or aryl.
- co- antioxidant e.g. Vitamin C, Vitamin C analogs, Vitamin C derivatives, Vitamin E, Vitamin E analogs, Vitamin E derivatives, flavonoids, flavonoid analogs, or flavonoid derivatives
- a chemical compound including a carotenoid derivative may have the general structure (134):
- Each R 12 is independently -alkyl-N R 1 V, -aromatic-N R 1 V, -alkyl-CO 2 " , -aromatic-CO 2 " , -amino acid-NH 3 + , -phosphorylated amino acid-NH 3 + , polyethylene glycol, dextran, H, alkyl, aryl, benzyl, alkali metal, co-antioxidant (e.g. Vitamin C, Vitamin C analogs, Vitamin C derivatives, Vitamin E, Vitamin E analogs, Vitamin E derivatives, flavonoids, flavonoid analogs, or flavonoid derivatives), or alkali salt.
- Each R 13 may be independently H, alkyl, or aryl. z may range from 5 to 12.
- carotenoid derivatives including five- and/or six-membered rings may be more easily synthesized due to, for example, the availability of naturally-occurring carotenoids including five- and/or six-membered rings.
- five-membered rings may decrease steric hindrance associated with rotation of the cyclic ring around the molecular bond connecting the cyclic ring to the polyene chain. Reducing steric hindrance may allow greater overlap of any ⁇ oribitals within a cyclic ring with the polyene chain, thereby increasing the degree of conjugation and effective chromophore length of the molecule. This may have the salutatory effect of increasing antioxidant capacity of the carotenoid derivatives.
- a substituent (W) may be at least partially hydrophilic.
- a hydrophilic substituent may assist in increasing the water solubility of a carotenoid derivative.
- a carotenoid derivative may be at least partially water-soluble.
- the cyclic ring may include at least one chiral center.
- the acyclic alkene may include at least one chiral center.
- the cyclic ring may include at least one degree of unsaturation.
- the cyclic ring may be aromatic. One or more degrees of unsaturation within the ring may assist in extending the conjugation of the carotenoid derivative.
- substituents may include any combination of (d) through (uu).
- negatively charged substituents may include alkali metals, one metal or a combination of different alkali metals in an embodiment with more than one negatively charged substituent, as counter ions.
- Alkali metals may include, but are not limited to, sodium, potassium, and/or lithium.
- Water-soluble carotenoid analogs or derivatives may have a water solubility of greater than about 1 mg/mL in some embodiments. In certain embodiments, water-soluble carotenoid analogs or derivatives may have a water solubility of greater than about 5 mg/mL. In certain embodiments, water-soluble carotenoid analogs or derivatives may have a water solubility of greater than about 10 mg/mL. In some embodiments, water-soluble carotenoid analogs or derivatives may have a water solubility of greater than about 50 mg/mL.
- highly water-dispersible C40 carotenoid derivatives may 'include natural source RRR-hxteia ( ⁇ , ⁇ -carotene-3,3'-diol) derivatives.
- Derivatives may be synthesized by esterification with inorganic phosphate and succinic acid, respectively, and subsequently converted to the sodium salts. Deep orange, evenly- colored aqueous suspensions were obtained after addition of these derivatives to USP-purified water.
- Aqueous dispersibility of the disuccinate sodium salt of natural lutein was 2.85 mg/mL; the dipshosphate salt demonstrated a > 10-fold increase in dispersibility at 29.27 mg/mL.
- Cellular membranes may be particularly co-evolved with molecules of a length of approximately 30 nm.
- carotenoid derivatives may be greater than or less than about 30 nm in size.
- carotenoid derivatives may be able to change conformation and/or otherwise assume an appropriate shape which effectively enables the carotenoid derivative to efficiently interact with a cellular membrane.
- alkenes in the E configuration this should not be seen as limiting.
- Compounds discussed herein may include embodiments where alkenes are in the Z configuration or include alkenes in a combination of Z and E configurations within the same molecule.
- the compounds depicted herein may naturally convert between the Z and E configuration and/or exist in equilibrium between the two configurations.
- Each R 14 may be independently O or H 2 .
- Each R may be independently OR 12 or R 12 .
- Each R 12 may be independently -alkyl-NR 13 3 + , -aromatic-NR 13 3 + , -alkyl-CO 2 ⁇ , -aromatic-CO 2 " , -amino acid-NH 3 + , -phosphorylated amino acid-NH 3 + , polyethylene glycol, dextran, H, alkyl, peptides, poly-lysine, co-antioxidant (e.g. Vitamin C, Vitamin C analogs, Vitamin C derivatives, Vitamin E, Vitamin E analogs, Vitamin E derivatives, flavonoids, flavonoid analogs, or flavonoid derivatives), or aryl.
- each R 13 may be independently H, alkyl, or aryl.
- the carotenoid derivative may include at least one chiral center.
- the carotenoid derivative may have the structure (138)
- a chemical compound may include a carotenoid derivative having the structure (142)
- Each R 14 may be independently O or H 2 .
- Each R may be independently H, alkyl, benzyl, alkali metal, co- antioxidant, or aryl.
- the carotenoid derivative may include at least one chiral center.
- R 14 may be H 2 , the carotenoid derivative having the structure (144)
- Each R may be independently -alkyl-NR 12 3 + , -aromatic-NR I2 3 + , -alkyl-CO 2 ⁇ - aromatic-CO 2 " , -amino acid-NH 3 + , -phosphorylated amino acid-NH 3 + , polyethylene glycol, dextran, H, alkyl, alkali metal, benzyl, co-antioxidant (e.g.
- Vitamin C Vitamin C analogs, Vitamin C derivatives, Vitamin E, Vitamin E analogs, Vitamin E derivatives, flavonoids, flavonoid analogs, or flavonoid derivatives
- Each R 12 may be independently H, alkyl, or aryl.
- the carotenoid derivative may include at least one chiral center.
- Each R may be independently -alkyl-N R 12 3 + , -aromatic-N R 12 3 + > -alkyl-CO 2 ⁇ , - aromatic-CO 2 " , -amino acid-NH 3 + , -phosphorylated amino acid-NH 3 + , polyethylene glycol, dextran, H, alkyl, alkali metal, co-antioxidant (e.g.
- the carotenoid derivative may have the structure (152)
- a chemical compound may include a disodium salt disuccinic acid ester carotenoid derivative having the structure (162)
- Some embodiments may include solutions or pharmaceutical preparations of carotenoids and/or carotenoid derivatives combined with co-antioxidants, in particular vitamin C and/or vitamin C analogs or derivatives.
- Pharmaceutical preparations may include about a 2:1 ratio of vitamin C to carotenoid respectively.
- co-antioxidants may increase solubility of the chemical compound.
- co-antioxidants e.g., vitamin C
- co-antioxidants may decrease toxicity associated with at least some carotenoid analogs or derivatives.
- co-antioxidants e.g., vitamin C
- co-antioxidants may increase the potency of the chemical compound synergistically.
- Co-antioxidants may be coupled (e.g., a covalent bond) to the carotenoid derivative.
- Co-antioxidants may be included as a part of a pharmaceutically acceptable formulation.
- vitamin C may be selectively esterified.
- Vitamin C may be selectively esterified at the C-3 position (e.g., EQN. 2).
- a carotenoid may be coupled to vitamin C.
- Vitamin C may be coupled to the carotenoid at the C-6, C-5 diol position as depicted in EQNS. 3 and 4 forming an acetal.
- a carotenoid may be coupled to a water-soluble moiety (e.g., vitamin C) with a glyoxylate linker as depicted in EQN. 7.
- a water-soluble moiety e.g., vitamin C
- a glyoxylate linker as depicted in EQN. 7.
- a carotenoid may be coupled to a water-soluble moiety (e.g., vitamin C) with a phosphate linker as depicted in EQN. 8.
- a water-soluble moiety e.g., vitamin C
- a phosphate linker as depicted in EQN. 8.
- a carotenoid may be coupled to a water-soluble moiety (e.g., vitamin C) with a phosphate linker as depicted in EQN. 10.
- a water-soluble moiety e.g., vitamin C
- a phosphate linker as depicted in EQN. 10.
- a carotenoid may be coupled to a water-soluble moiety (e.g., vitamin C) with a phosphate linker as depicted in EQN. 11.
- Vitamin C may be coupled to the carotenoid using selective esterification at C-3 of unprotected ascorbic acid with primary alcohols.
- a carotenoid may be coupled to a water-soluble moiety (e.g., vitamin C) with a phosphate linker as in 242.
- Structure 242 may include one or more counterions (e.g., alkali metals).
- a carotenoid analog or derivative may include:
- a chemical compound may include a disodium salt disuccinic acid ester carotenoid derivative having the structure (162)
- the carotenoid derivatives may be synthesized from naturally-occurring carotenoids.
- the carotenoids may include structures 2A-2E depicted in FIG. 1.
- the carotenoid derivatives may be synthesized from any naturally-occurring carotenoid including one or more alcohol substituents.
- the carotenoid derivatives may be synthesized from a derivative of a naturally-occurring carotenoid including one or more alcohol substituents.
- the synthesis may result in a single stereoisomer.
- the synthesis may result in a single geometric isomer of the carotenoid derivative.
- the synthesis/synthetic sequence may include any prior purification or isolation steps carried out on the parent carotenoid.
- the deprotonated alcohol may act as a nucleophile reacting with the substituent precursor, displacing the leaving group.
- Leaving goups may include, but are not limited to, I, Cl, Br, tosyl, brosyl, mesyl, or trifyl. These are only a few examples of leaving groups that may be used, many more are known and would be apparent to one skilled in the art. In some embodiments, it may not even be necessary to deprotonate the alcohol, depending on the leaving group employed. In other examples the leaving group may be internal and may subsequently be included in the final structure of the carotenoid derivative, a non-limiting example may include anhydrides or strained cyclic ethers.
- the total synthesis of naturally-occurring as well as synthetic carotenoids as starting scaffolds for carotenoid analogs or derivatives may be a method of generation of said carotenoid analogs or derivatives.
- one or more of the conversions and/or reactions discussed herein may be carried out ⁇ within one reaction vessel increasing the overall efficiency of the synthesis of the final product.
- a product of one reaction during a total synthesis may not be fully worked up before continuing on with the following reaction. In general fully working up a reaction implies completely isolating and purify the product from a reaction. A reaction may instead only partially be worked up.
- solid impurities which fall out of solution during the course of a reaction may be filtered off and the filtrate washed with solvent to ensure all of the resulting product is washed through and collected.
- the resulting collected product still in solution may not be isolated, but may then be combined with another reagent and further transformed.
- multiple transformations may be carried out in a single reaction flask simply by adding reagents one at a time without working up intermediate products.
- carotenoid derivatives or analogs such as disodium disuccinate astaxanthin 162 at multigram scale (e.g., 200 g to 1 kg) is necessary if one wishes to produce these molecules commercially.
- Synthetic modifications of carotenoids with the goal of increasing aqueous solubility and/or dispersibility, have been sparingly reported in the literature.
- surveys of the peer-reviewed and patent literature indicated that neither a synthetic sequence nor an efficient process for the synthesis of 160 or 162 had been reported. Therefore, the bench-scale synthetic sequence and later the scale-up to multigram scale were optimized to improve both the yield and purity of the desired compound.
- the disodium disuccinate derivatives of synthetic astaxanthin were successfully synthesized in gram amounts and at high purity (>90%) area under the curve (AUC) by HPLC.
- the compound in "racemic” form demonstrated water "dispersibility" of 8.64 mg/mL, a significant improvement over the parent compound astaxanthin, which is insoluble in water.
- Initial biophysical characterization demonstrated that CardaxTM derivatives (as both the statistical mixture of stereoisomers and as individual stereoisomers) were potent direct scavengers of superoxide anion in the aqueous phase, the first such description in this model system for a C40 carotenoid.
- chromatographic separation techniques may be used to separate stereoisomers of a racemic mixture.
- pure optically active stereoisomers may be reacted with a mixture of stereoisomers of a chemical compound to form a mixture of diastereomers.
- Diastereomers may have different physical properties as opposed to stereoisomers, thus making it easier to separate diastereomers.
- astaxanthin may be coupled to an optically active compound (e.g., dicamphanic acid). Coupling astaxanthin to optically active compounds produces diastereomers with different physical properties. The diastereomers produced may be separated using chromatographic separation techniques as described herein.
- optically active compound e.g., dicamphanic acid
- Typical analogs or derivatives include molecules which demonstrate equivalent or improved biologically useful and relevant function, but which differ structurally from the parent compounds.
- Parent carotenoids are selected from the more than 700 naturally- occurring carotenoids described in the literature, and their stereo- and geometric isomers.
- Such analogs or derivatives may include, but are not limited to, esters, ethers, carbonates, amides, carbamates, phosphate esters and ethers, sulfates, glycoside ethers, with or without spacers (linkers).
- the carotenoid derivatives may have increased bioavailability, relative to the parent carotenoid, upon administration to a subject.
- the parent carotenoid may be naturally occurring.
- Another embodiments may include the administration of a composition comprised of the synergistic combination of more than one structural analog or derivative or synthetic intermediate of carotenoids to a subject such that the occurrence of a proliferative disorder is thereby reduced.
- the composition may be a "racemic" (i.e. mixture of the potential stereoisomeric forms) mixture of carotenoid derivatives.
- a pharmaceutically acceptable carrier may be serum albumin.
- structural analogs or derivatives or synthetic intermediates of carotenoids may be complexed with human serum albumin (i.e., HSA) in a solvent.
- HSA may act as a pharmaceutically acceptable carrier.
- a single stereoisomer of a structural analog or derivative or synthetic intermediate of carotenoids may be administered to a human subject in order to ameliorate a pathological condition.
- Administering a single stereoisomer of a particular compound (e.g., as part of a pharmaceutical composition) to a human subject may be advantageous (e.g., increasing the potency of the pharmaceutical composition).
- Administering a single stereoisomer may be advantageous due to the fact that only one isomer of potentially many may be biologically active enough to have the desired effect.
- the xanthophyll carotenoid, carotenoid derivative or analog may be administered at a dosage level up to conventional dosage levels for xanthophyll carotenoids, carotenoid derivatives or analogs, but will typically be less than about 2 gm per day. Suitable dosage levels may depend upon the overall systemic effect of the chosen xanthophyll carotenoids, carotenoid derivatives or analogs, but typically suitable levels will be about 0.001 to 50 mg/kg body weight of the patient per day, from about 0.005 to 30 mg/kg per day, or from about 0.05 to 10 mg/kg per day.
- the compound may be administered on a regimen of up to 6 times per day, between about 1 to 4 times per day, or once per day.
- a suitable dosage range is, e.g. from about 0.01 mg to about 100 mg of a xanthophyll carotenoid, carotenoid derivative or analog per kg of body weight per day, preferably from about 0.1 mg to about 10 mg per kg and for cytoprotective use from 0.1 mg to about 100 mg of a xanthophyll carotenoid, carotenoid derivative or analog per kg of body weight per day.
- the dosage of the therapeutic agents will vary with the nature and the severity of the condition to be treated, and with the particular therapeutic agents chosen. The dosage will also vary according to the age, weight, physical condition and response of the individual patient.
- a structural carotenoid analog or derivative or synthetic intermediate may be administered to mammals, in particular humans, parenterally at a dose of between 5 to 1000 mg per day referenced to the body weight of the mammal or human being treated for a particular disease. In other embodiments, about 100 mg of a structural carotenoid analog or derivative or synthetic intermediate is either orally or parenterally administered to treat or prevent disease.
- preparations particularly those preparations which may be administered orally and which may be used for the preferred type of administration, such as tablets, softgels, lozenges, dragees, and capsules, and also preparations which may be administered rectally, such as suppositories, as well as suitable solutions for administration by injection or orally or by inhalation of aerosolized preparations, may be prepared in dose ranges that provide similar bioavailability as described above, together with the excipient. While individual needs may vary, determination of the optimal ranges of effectrve amounts of each component is within the skill of, the art.
- any suitable route of administration may be employed for providing a patient with an effective dosage of drugs of the present invention.
- oral, rectal, topical, parenteral, ocular, pulmonary, nasal, and the like may be employed.
- Dosage forms include tablets, troches, dispersions, suspensions, solutions, capsules, creams, ointments, aerosols, and the like.
- compositions may include those compositions suitable for oral, rectal, topical, parenteral (including subcutaneous, intramuscular, and intravenous), ocular (ophthalmic), pulmonary (aerosol inhalation), or nasal administration, although the most suitable route in any given case will depend on the nature and severity of the conditions being treated and on the nature of the active ingredient. They may be conveniently presented in unit dosage form and prepared by any of the methods well-known in the art of pharmacy.
- the drags used in the present invention are conveniently delivered in the form of an aerosol spray presentation from pressurized packs or nebulisers.
- the compounds may also be delivered as powders which may be formulated and the powder composition may be inhaled with the aid of an insufflation powder inhaler device.
- Suitable topical formulations for use in the present embodiments may include transdermal devices, aerosols, creams, ointments, lotions, dusting powders, and the like.
- drugs used can be combined as the active ingredient in intimate admixture with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques.
- the carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g., oral or parenteral (including intravenous).
- the pharmaceutical preparations may be manufactured in a manner which is itself known to one skilled in the art, for example, by means of conventional mixing, granulating, dragee-making, softgel encapsulation, dissolving, extracting, or lyophilizing processes.
- pharmaceutical preparations for oral use may be obtained by combining the active compounds with solid and semi-solid excipients and suitable preservatives, and/or co- antioxidants.
- the resulting mixture may be ground and processed.
- the resulting mixture of granules may be used, after adding suitable auxiliaries, if desired or necessary, to obtain tablets, softgels, lozenges, capsules, or dragee cores.
- Suitable excipients may be fillers such as saccharides (e.g., lactose, sucrose, or mannose), sugar alcohols (e.g., mannitol or sorbitol), cellulose preparations and/or calcium phosphates (e.g., tricalcium phosphate or calcium hydrogen phosphate).
- binders may be used such as starch paste (e.g., maize or corn starch, wheat starch, rice starch, potato starch, gelatin, tragacanth, methyl cellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose, and/or polyvinyl pyrrolidone).
- Disintegrating agents may be added (e.g., the above- mentioned starches) as well as carboxymethyl-starch, cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof (e.g., sodium alginate).
- Auxiliaries are, above all, flow-regulating agents and lubricants (e.g., silica, talc, stearic acid or salts thereof, such as magnesium stearate or calcium stearate, and/or polyethylene glycol, or PEG).
- Dragee cores are provided with suitable coatings, which, if desired, are resistant to gastric juices.
- Softgelatin capsules are provided with suitable coatings, which, typically, contain gelatin and/or suitable edible dye(s).
- Animal component-free and kosher gelatin capsules may be particularly suitable for the embodiments described herein for wide availability of usage and consumption.
- concentrated saccharide solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, polyethylene glycol (PEG) and/or titanium dioxide, lacquer solutions and suitable organic solvents or solvent mixtures, including dimethylsulfoxide (DMSO), tetrahydrofuran (TE-F), acetone, ethanol, or other suitable solvents and co-solvents.
- DMSO dimethylsulfoxide
- TE-F tetrahydrofuran
- acetone ethanol
- ethanol or other suitable solvents and co-solvents.
- pulmonary administration of a pharmaceutical preparation may be desirable.
- Pulmonary administration may include, for example, inhalation of aerosolized or nebulized liquid or solid particles of the pharmaceutically active component dispersed in and surrounded by a gas.
- Possible pharmaceutical preparations which may be used rectally, include, for example, suppositories, which consist of a combination of the active compounds with a suppository base.
- Suitable suppository bases are, for example, natural or synthetic triglycerides, or paraffin hydrocarbons.
- gelatin rectal capsules that consist of a combination of the active compounds with a base.
- Possible base materials include, for example, liquid triglycerides, polyethylene glycols, or paraffin hydrocarbons.
- Suitable formulations for parenteral administration include, but are not limited to, aqueous solutions of the active compounds in water-soluble and/or water dispersible form, for example, water-soluble salts, esters, carbonates, phosphate esters or ethers, sulfates, glycoside ethers, together with spacers and/or linkers.
- Suspensions of the active compounds as appropriate oily injection suspensions may be administered, particularly suitable for intramuscular injection.
- Suitable lipophilic solvents, co-solvents (such as DMSO or ethanol), and/or vehicles including fatty oils, for example, rice bran oil or peanut oil and/or palm oil, or synthetic fatty acid esters, for example, ethyl oleate or triglycerides, may be used.
- Aqueous injection suspensions may contain substances that increase the viscosity of the suspension including, for example, sodium carboxymethyl cellulose, sorbitol, dextran, and/or cyclodextrins. Cyclodextrins (e.g., ⁇ -cyclodextrin) may be used specifically to increase the water solubility for parenteral injection of the structural carotenoid analog.
- Liposomal formulations in which mixtures of the structural carotenoid analog or derivative with, for example, egg yolk phosphotidylcholine (E-PC), may be made for injection.
- the suspension may contain stabilizers, for example, antioxidants such as BHT, and/or preservatives, such as benzyl alcohol.
- the compounds of this invention can be administered in such oral dosage forms as tablets, capsules (each of which includes sustained release or timed release formulations), pills, powders, granules, elixirs, tinctures, suspensions, syrups, and emulsions.
- the dosage regimen for the compounds of the present invention will, of course, vary depending upon known factors, such as the pharmacodynamic characteristics of the particular agent and its mode and route of administration; the species, age, sex, health, medical condition, and weight of the recipient; the nature and extent of the symptoms; the kind of concurrent treatment; the frequency of treatment; the route of administration, the renal and hepatic function of the patient, and the effect desired.
- the daily oral dosage of each active ingredient when used for the indicated effects, will range between about 0.001 to 1000 mg/kg of body weight, between about 0.01 to 100 mg/kg of body weight per day, or between about 1.0 to 20 mg/kg/day.
- Intravenously administered doses may range from about 1 to about 10 mg/kg/minute during a constant rate infusion.
- Compounds of this invention maybe administered in a single daily dose, or the total daily dosage maybe administered in divided doses of two, three, or four or more times daily.
- compositions described herein may further be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal routes, using transdermal skin patches.
- suitable intranasal vehicles or via transdermal routes, using transdermal skin patches.
- the dosage administration will, of course, be continuous rather than intermittent throughout the dosage regimen.
- the compounds are typically administered in admixture with suitable pharmaceutical diluents, excipients, or carriers (collectively referred to herein as "pharmacologically inert carriers”) suitably selected with respect to the intended form of administration, that is, oral tablets, capsules, elixirs, syrups and the like, and consistent with conventional pharmaceutical practices.
- the pharmacologically active component may be combined with an oral, non-toxic, pharmaceutically acceptable, inert carrier such as lactose, starch, sucrose, glucose, methyl cellulose, magnesium stearate, dicalcium phosphate, calcium sulfate, mannitol, sorbitol and the like;
- an oral, non-toxic, pharmaceutically acceptable, inert carrier such as lactose, starch, sucrose, glucose, methyl cellulose, magnesium stearate, dicalcium phosphate, calcium sulfate, mannitol, sorbitol and the like
- the oral drug components can be combined with any oral, non-toxic, pharmaceutically acceptable inert carrier such as ethanol, glycerol, water, and the like.
- suitable binders, lubricants, disintegrating agents, and coloring agents can also be incorporated into the mixture.
- Suitable binders include starch, gelatin, natural sugars such as glucose or beta- lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth, or sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes, and the like.
- Lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride, and the like.
- Disintegrators include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan gum, and the like.
- the compounds of the present invention may also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles, and multilamellar vesicles.
- Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine, or phosphatidylcholines.
- Compounds of the present invention may also be coupled with soluble polymers as targetable drug carriers.
- soluble polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxypropylmethacrylamide- phenol, polyhydroxyethylaspartamidephenol, or polyethyleneoxide-polylysine substituted with pahnitoyl residues.
- Gelatin capsules may contain the active ingredient and powdered carriers, such as lactose, starch, cellulose derivatives, magnesium stearate, stearic acid, and the like. Similar diluents can be used to make compressed tablets. Both tablets and capsules can be manufactured as sustained release products to provide for continuous release of medication over a period of hours. Compressed tablets can be sugar coated or film coated to mask any unpleasant taste and protect the tablet from the atmosphere, or enteric coated for selective disintegration in the gastrointestinal tract.
- powdered carriers such as lactose, starch, cellulose derivatives, magnesium stearate, stearic acid, and the like. Similar diluents can be used to make compressed tablets. Both tablets and capsules can be manufactured as sustained release products to provide for continuous release of medication over a period of hours. Compressed tablets can be sugar coated or film coated to mask any unpleasant taste and protect the tablet from the atmosphere, or enteric coated for selective disintegration in the gastrointestinal tract.
- Liquid dosage forms for oral administration can contain coloring and flavoring to increase patient acceptance.
- water, a suitable oil, saline, aqueous dextrose (glucose), and related sugar solutions and glycols such as propylene glycol or polyethylene glycols are suitable carriers for parenteral solutions.
- Solutions for parenteral administration preferably contain a water soluble salt of the active ingredient, suitable stabilizing agents, and if necessary, buffer substances.
- Antioxidizing agents such as sodium bisulfite, sodium sulfite, or ascorbic acid, either alone or combined, are suitable stabilizing agents.
- citric acid and its salts and sodium EDTA are also used.
- parenteral solutions can contain preservatives, such as benzalkonium chloride, methyl- or propyl-paraben, and chlorobutanol.
- Suitable pharmaceutical carriers are described in Remington's Pharmaceutical Sciences, Mack Publishing Company, a standard reference text in this field.
- the unit intracoronary dose may include from about 25 mg to 1.0 gram, or between 25 mg and 100 mg, of a structural carotenoid analog.
- the unit doses may be administered one or more times daily, on alternate days, in loading dose or bolus form, or titrated in a parenteral solution to commonly accepted or novel biochemical surrogate marker(s) or clinical endpoints as is with the skill of the art.
- the compounds may be administered as part of a pharmaceutical preparation containing suitable pharmaceutically acceptable carriers, preservatives, excipients and auxiliaries which facilitate processing of the structural carotenoid analog or derivative or synthetic intermediates which may be used pharmaceutically.
- Natural source lutein ( ⁇ , ⁇ -carotene-3,3'-diol), 1.
- Tribenzyl phosphite 4. To a well-stirred solution of phosphorus trichloride (1.7 mL, 19.4 mmol) in Et 2 O (430 mL) at 0 0 C was added dropwise a solution of triethylamine (8.4 mL, 60.3 mmol) in Et 2 O (20 mL), followed by a solution of benzyl alcohol (8.1 mL, 77.8 mmol) in Et 2 O (20 mL). The mixture was stirred at 0 0 C for 30 min and then at RT overnight. The mixture was filtered and the filtrate concentrated to give a colorless oil.
- Dibenzyl phosphoroiodidate 5.
- PMNs Human polymorphonuclear leukocytes
- S.F.L. Human polymorphonuclear leukocytes
- Percoll density gradient centrifugation as described previously. Briefly, each 10 mL of whole blood was mixed with 0.8 mL of 0.1 M EDTA and 25 mL of saline. The diluted blood was then layered over 9 mL of Percoll at a specific density of 1.080 g/mL. After centrifugation at 400 x g for 20 min at 20 °C, the plasma, mononuclear cell, and Percoll layers were removed.
- FIG. 2 depicts a time series of the UV/Vis absorption spectra of the disodium disuccinate derivative of natural source lutein in water.
- Existence of head-to-tail (J-type) aggregation in solution cannot be ruled out.
- DMSO more polarizable solvent
- FIG. 5 depicts a time series of the UV/Vis absorption spectra of the disodium diphosphate derivative of natural source lutein in water. Loss of vibrational fine structure (spectral distribution beginning to approach unimodality) and the blue-shifted lambda max relative to the lutein chromophore in EtOH suggested that card-pack aggregation was present immediately upon solvation.
- the ⁇ max (428 nm) obtained at time zero did not appreciably blue-shift over the course of 24 hours, and the spectra became slightly more hypochromic over time (i.e. decreased in absorbance intensity), indicating additional time-dependent supramolecular assembly (aggregation) of the card-pack type during this time period. This spectrum was essentially maintained over the course of 24 hours (compare with FIG. 2, disuccinate lutein sodium salt).
- a red-shift was observed ( ⁇ 3x to 446 nm), as was observed with the disuccinate derivate.
- Wetting of the diphosphate lutein derivative with a small amount of water was required to obtain appreciable solubility in organic solvent (e.g. EtOH and DMSO).
- Spectra were obtained at time zero.
- the expected bathochromic shift (in this case to 459 nm) of the spectrum in the more polarizable solvent (95% DMSO) is seen. Increased vibrational fine structure and red-shifting of the spectra were observed in the organic solvents.
- racemic tetrasodium diphosphate derivative of astaxanthin (pAST; > 97% purity by HPLC) was synthesized from commercial astaxanthin and its structure verified (see below for synthetic methodology).
- the chemical structures of the three stereoisomers, (3R,3'R)-, (3S,3'S)-, and (3R,3'S; meso)-tetrasodium diphosphate astaxanthin are shown in FIG.10.
- the racemic pAST used in this study is comprised of the statistical mixture of the above stereoisomers in a 1 : 1 :2 ratio.
- Non-esterified, ⁇ l-E synthetic astaxanthin utilized for biological tests
- High performance liquid chromatography (HPLC) analysis for in-process control (IPC) was performed on a Varian Prostar Series 210 liquid chromatograph with a PDA detector using methods A and B.
- the intermediate ;- ⁇ c-3,3'-dihydroxy- ⁇ , ⁇ -carotene-4,4'-dione diphosphoric acid bis-(2-cyano-ethyl) ester was synthesized as follows: a 100 ml round bottom flask wrapped with aluminum foil was equipped with a stir bar under nitrogen at room temperature. Racemic astaxanthin (Buckton Scott, India) (0.440 g, 0.74 mmol) was dissolved in methylene chloride (13.2 ml) then reacted with bis (2-cyanoethyl)-N,N-diisopropyl phosphoramidite (0.80 g, 2.95 mmol), and tetrazole (0.21 g, 2.95 mmol).
- the reaction was complete by HPLC after 4d and the reaction mixture was concentrated to dryness.
- the red solid was re-dissolved in 50 ml of water and then eluted through a sodium ion exchange resin (50 g, Amberlite IR-120 Na+). The solution was concentrated using acetonitrile to form an azeotrope with water.
- the red solid was then re-dissolved in a minimum amount of water ( ⁇ 20 ml) and precipitated with the addition of ethanol (20 ml). The precipitate was filtered through a 2 ⁇ m filter and dried under vacuum to afford 66 mg of red solid.
- the solid was again re-dissolved in 2 ml of water and lyophilized to afford 42 mg of red solid (28% yield).
- Mouse embryonic fibroblast 10T1/2 cells were cultured in Eagle's basal medium with Earle's salts supplemented with 4% fetal calf serum (Atlanta Biologicals, Norcross, GA), 25 ⁇ g/ml gentamicin sulfate (Sigma, St. Louis, MO), and passaged by trypsin/EDTA (Gibco Invitrogen, Carlsbad, CA) and maintained at 37 °C in a 5% CO 2 atmosphere. The cells were allowed to grow until a monolayer was formed. The confluent cells were treated 7 days after seeding, unless otherwise indicated.
- dAST was prepared in a formulation of 20% EtOH and sterile water (0.2% final EtOH ) to minimize supramolecular aggregation, and the final concentration of EtOH in culture medium was 0.2%.
- CTX was dissolved in THF and added to media.
- TTNPB was dissolved in acetone (Sigma, St. Louis, MO) and cultures received a final acetone concentration of 0.1%.
- Treatments/Compounds. _TTNPB Biomol, Plymouth Meeting, PA
- Homochiral 35,3 'S- astaxanthin (95% pure, Hawaii Biotech, Inc., Aiea, HI); stocks 10 "2 M and lO "3 M in THF (Sigma, St. Louis, MO) diluted 1:1000 and stirred into culture media immediately before treatment (final 10 "5 M and 10 "6 M in 0.1% THF).
- SDS-PAGE Electrophoresis, Transfer and Immunodetection Cell were trypsinized and pelleted briefly.
- Pellets were lysed in phosphate buffered saline (PBS) containing protease inhibitor cocktail (Roche, Nutley, NJ; 1 tablet/lOmL), 10 mM sodium fluoride, 0.5 mM sodium vanadate, 4 niM para-methyl-sulfonyl fluoride and 0.5% sodium dodecylsulfate. Lysates were sonicated and protein concentrations quantified using the BCA protein determination assay (Pierce, Rockford, IL).
- Equal amounts of total protein were boiled in sample buffer (Fisher, Fairlawn, NJ) containing 10% ⁇ -mercaptoethanol, loaded onto 10% Tris-Glycine gels (Cambrex, East Rutherford, NJ) and run at 115 V for 1.5 hours using Tris (25 mM)/Glycine (192 mM)/SDS (0.1%) running buffer. Protein standards were utilized to confirm molecular weight of detected protein (SeeBlue, Invitrogen, Carlsbad, CA). Protein was transferred from SDS-PAGE gels to PVDF membranes (Invitrogen, Carlsbad, CA) using Tris (19 mM)/Glycine (144 mM)/10% Methanol/0.1% SDS buffer at 33 volts for 2 hours.
- Cx43 protein was detected according to the manufacturer's instructions using the WesternBreeze Immunodetection Kit (Invitrogen, Carlsbad, CA) and a rabbit primary antibody reactive against the cytoplasmic tail of Cx43 (1 :2000, Sigma, St. Louis, MO). Quantification of Relative Western Blot Cx43 Protein Levels. Digital scans of immunodetected membranes were analyzed for relative intensity of Cx43 protein bands using the public domain densitometry program NIH Image J and presented as relative fold inductions standardized to THF only control levels.
- CX43 protein expression Analysis of CX43 protein expression. Expression of CX43 protein in 10T1/2 cells was assessed by Western blotting. 10T1/2 cell monolayers were treated with the indicated carotenoid derivatives or with retinoids (as a positive control for the modulation of CX43 expression) 7 days after seeding in 100 mm dishes (Fisher Scientific, Pittsburgh, PA). Fours days after the drug was added to the cells, the cells were harvested, total cellular protein was isolated and the total protein concentration thereof was determined using a commercially available Protein Assay Reagent kit (Pierce Chemical Co., Rockford, IL).
- CX43 and GAPDH immunoreactive bands were visualized by chemiluminescence using an anti- rabbit HRP-conjugated secondary antibody (Pierce Chemical Co., Rockford, IL). Images were obtained by exposure to X-ray film as previously described [26] and scanned for digital analysis on the Fluoro-S Imager (Bio- Rad, Richmond, CA).
- racemic pAST increased the level of detectable CX43 protein in cells in comparison with solvent-treated controls at concentrations of 10 "6 and 10 '7 M, and was equipotent to CTX at these concentrations (about 5- and 2-fold induction, respectively).
- CTX included as a positive carotenoid control, was active at 10 "5 M as had been previously observed ( ⁇ 7-fold induction).
- No change in CX43 protein levels were detectable in cells treated with identical concentrations of AST.
- no change in protein levels was observed in cells treated with 10 "5 M of either compound, suggesting potential toxicity of the compounds at high concentrations.
- CX43 protein by indirect immunofluorescence. Expression and assembly of CX43 into plaques was assessed by immunofluorescence staining essentially as described in Rogers et al, 1990, which is incorporated herein by reference. Briefly, confluent cultures of 10T1/2 cells were grown on Permanox plastic 4-chamber slides (Nalge Nunc International, Naperville, IL) and treated for 4 days as described above. Cells were fixed with ⁇ 20 0 C methanol overnight, washed in buffer, blocked in 1% bovine serum albumin (Sigma, St. Louis, MO) in PBS, incubated with the rabbit anti-CX43 antibody, and visualized with Alexa568 conjugated anti-rabbit secondary antibody (Molecular Probes, Eugene, OR). Images were acquired with a Zeiss Axioplan microscope and a Roper Scientific cooled CCD camera.
- junctional permeability was assayed by the scrape-loading dye transfer assay essentially as described in El-Fouly et al., 1987, which is incorporated herein by reference. Briefly, confluent cultures of 10T1/2 cells grown in 60 mm dishes were treated with the indicated compounds for 7 days. The treated cells were washed with Ca +2 -free phosphate-buffered saline (PBS). 1.5 ml of Lucifer Yellow CH (Sigma, St.
- the frozen cell pellets subjected to HPLC analysis to determine the cytosolic concentration of the compound. Astaxanthin was extracted from the samples as essentially as described in Showalter et al., 2004, with slight modifications. Methanol (1.0 ml) and water (1.0 ml) were added to each sample weighed in advance, and then mixed with an Ultraturax ® mixer for 20 seconds. Chloroform (3 ml) was added to the samples, and the samples were mixed for 20 seconds. Finally, a saturated sodium chloride (NaCl) solution (1 ml) was added to each sample, after which the samples were mixed for an additional 20 seconds. The samples were allowed to sit for 5 min to allow particulate matter to settle to the bottom of the tube.
- the flow was 1 ml/min and the detection wavelength was set at 470 nm.
- the employed extinction coefficients (Ei cmj i % ) at 472 nm in hexane containing 4% chloroform were 2100 for a ⁇ -E- astaxantbin, and 1350 and 1750 for 13Z- and 9Z-astaxanthin, respectively.
- Connexin43 (Cx43) (Bertram 1999).
- Treatment of the same mouse fibroblast cell line with 10 "5 M, 10 '6 M and 10 '7 M lycophyll for seven days also resulted in increased Cx43 protein levels.
- Lycophyll at 10 "5 M appeared to induce Cx43 protein increases equivalently to 10 "5 M homochiral (3S,3'S) astaxanthin and 10 "5 M, 10 "6 M lycopene.
- Lycophyll from total synthesis in this case was tested as a mixture of geometric isomers (cis and trans), and the utility here for upregulation of Cx43 supports the previous demonstration of activity for all-trans lycophyll prepared by semi- preparative chromatrography (Jackson et al. 2005).
- Immortalized mouse fibroblast cells (C3H10T1/2) were cultured in Dulbecco's Modification of Eagle's Medium (DMEM) containing 5% calf serum (Mediatech Inc.) and Penicillin (200 i.u.)/Streptomycin (200 ⁇ g/ml, Mediatech, Inc.) and incubated at 37 degrees C ( 0 C) in 5% CO 2 /air atmosphere. Cell dissociation was performed utilizing trypsin:EDTA (0.25%: 2.21 mM, Mediatech Inc.).
- Cx43 protein was detected according to the manufacturer's instructions using the WesternBreeze Immunodetection Kit (Invitrogen, Carlsbad, CA) and a rabbit primary antibody reactive against the cytoplasmic tail of Cx43 (1:2000, Sigma, St. Louis, MO).
- results The results presented in FIGs 14A-14C demonstrate once again that lycophyll (in this case a mixture of geometric isomers) is capable of upregulating Cx43 expression in mouse embryonic fibroblast cells.
- the relative inductions (in duplicate) are consistent with induction by the comparable carotenoids lycopene (positive control) and homochiral (3S,3'S) astaxanthin.
- the synthetic retinoid TTNPB demonstrates characteristic strong induction of Cx43 in this system.
- Cx43 is a tumor suppressor gene that has utility in cancer chemoprevention, and its modulation by the naturally-occurring lycophyll compound is novel and suggests potential clinical utility in the setting of cancer chemoprevention and treatment. Results are also summarized in Table 4.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
A method and system used for treating proliferative disorders using carotenoids, carotenoid analogs, and/or carotenoid derivatives. The method and system may be used for chemoprevention and/or chemotherapy. The method and system may induce apoptosis in target cells, tissues, and/or organs. The analog, derivative, or intermediate may be administered to a cell, a group of cells, a tissue, an organ or a subject, such that at least a portion of the undesirable consequences of the proliferative disorder are thereby reduced.
Description
CAROTENOIDS, CAROTENOID ANALOGS, OR CAROTENOm DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISORDERS
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention generally relates to the fields of medicinal and synthetic chemistry. Specifically, the invention relates to the synthesis and use of water-soluble and water dispersible carotenoids, including analogs, derivatives, and intermediates thereof, for the treatment and inhibition of aberrant cell growth.
2. Description of the Relevant Art
Gap junctions are specialized regions of the cell membrane with clusters of hundreds to thousands of densely packed gap junction channels that directly connect the cytoplasmic compartment of two neighboring cells. The gap junction channels are composed of two hemichannels (connexons) provided by each of two neighboring cells. Each connexon consists of six proteins called connexins (Cx). The connexins are a large family of proteins all sharing the basic structure of four transmembrane domains, two extracellular loops, and a cytoplasmic loop. There is a high degree of conservation of the extracellular loops and transmembrane domains among species and connexin isoforms. The length of the C-terminus, however, varies considerably giving rise to the classification of the connexins on the basis of the molecular weight. The gap junction channel can switch between an open and a closed state by a twisting motion. In the open state ions and small molecules can pass through the pore. The conduction of the electrical impulse and intercellular diffusion of signaling molecules take place through the gap junctions and normally functioning gap junctions are therefore a prerequisite for normal intercellular communication. Normal intercellular communication is essential for for cellular homeostasis, proliferation and differentiation.
The link between abnormalities in connexins and disease has been established in humans as will appear in the sections below. One example is Chagas" disease caused by the protozoan parasite Trypanosoma cruzi. This disease is a major cause of cardiac dysfunction in Latin America. An altered Cx43 distribution has been observed in cells infected by Trypanosoma cruzi and this alteration may be involved in the genesis of the conduction disturbances characterizing the disease.
In a multicellular organism, co-ordination between cells is of paramount importance. Among the various means of cellular cross talk, gap junctions provide the most direct pathway. Gap junctions are one type of junctional complex formed between adjacent cells and consist of aggregated channels that directly link the interiors (cytoplasm) of neighbouring cells. In the adult mammal, gap junctions are found in most cell types with one known exception being circulating blood elements.
The pore diameter of the gap junction channel formed has been reported to be in the range of 0.8-1.4 nm. Gap junctions are relatively non-selective and allow the passage of molecules up to about 1000 Daltons (Da). Such substances are, i.a., ions, water, sugars, nucleotides, amino acids, fatty acids, small peptides, drugs, and carcinogens. Channel passage does not require ATP and appears to result from passive diffusion. This flux of materials between cells via gap junction channels is known as gap junctional intercellular communication (GJIC), which plays an important role in the regulation of cell metabolism, proliferation, and cell-to-cell signaling. One of the most significant physiological implications for GJIC is that gap junction coupled cells within a tissue are not individual, discrete entities, but are highly integrated with their neighbors, a "functional syncytium". This property
facilitates homeostasis and also permits the rapid, direct transfer of second messengers between cells to coordinate cellular responses within the tissue.
The process of GJIC is regulated by a variety of mechanisms that can be broadly divided into major categories. In one type of regulation the cellular quantity of gap junctions is controlled by influencing the expression, degradation, and cellular trafficking of connexins to the plasma membrane, or assembly of connexins into functional gap junctions. Impaired GJIC caused by the down-regulation of connexin expression, e.g. in tumor cells, is an example of this mode of regulation. Another type of regulation does not generally involve any gross alteration of the cellular levels of gap junctions or connexins, but induces opening or closure (gating) of existing gap junctions. Extracellular soluble factors, such as mitogens (e.g. DDT), hormones (e.g. catecholamines), anaesthetics (e.g. halothane), intracellular biomolecules (e.g. cAMP), and cell stress (e.g. mechanical or metabolic stress) can result in this type of regulation. Additionally, GJIC is regulated during the cell cycle and during cellular migration.
The mode of GJIC regulation or junctional gating has been widely studied for gap junctions especially gap junctions composed of Cx43. Some factors exert their inhibitory effects on GJIC indirectly, for example, by altering the lipid environment and cell membrane fluidity, whereas other GJIC inhibitors include oncogenes, growth factors, and tumor promoters, which induce various modifications of the Cx43. Disruption of junctional permeability may be necessary for mediating the specific biological functions of the latter group. These agents initiate complex signaling pathways consisting of the activation of kinases, phosphatases, and interacting proteins. Understanding the mechanisms of action of these GJIC modulators will not only define their respective signaling pathways responsible for junctional regulation, but will also provide experimental tools for characterising the biological functions of GJIC and connexins. Changes in the phosphorylation of specific sites of the cytoplasmic carboxy terminal domain of Cx43 appear to be pivotal to the opening and closing of the gap junctional channel. Phosphorylation of the carboxy terminal domain may also be important to the process of bringing Cx43 gap junctional hemicomplex to the cell membrane, its internalisation and degradation. Connexins have half-lives (hours) that are much shorter than most plasma membrane proteins (days), e.g. the half-life of Cx43 in rat heart is less than 11/2 hours. Thus, regulation of the turnover rate would be an important factor in regulating GJIC.
The carboxy terminal domain contains putative phosphorylation sites for multiple protein kinases (PKA, PKC, PKG, MAPK, CaMkII and tyrosine kinase). Phosphorylation of these sites of the carboxy terminal domain results in closure of gap junctional channels and various inhibitors of Cx43 gap junctional channels use different signalling pathways to induce phosphorylation of the carboxy terminal domain. The cell type and the particular inhibitor determine which signalling pathways to be used and the type of the involved protein kinase points to the intracellular messenger system utilised. Thus activation of PKA requires involvement of the cAMP second messenger system while PKC requires involvement of the phosphoinositol intracellular signalling system.
Other mechanisms regulating channel gating include intracellular levels of hydrogen and calcium ions, transjunctional voltage, and free radicals. Decreased pH or pCa induce channel closure in a cell- and connexin- specific manner.
Many physiological roles besides growth control have been proposed for GJIC. Homeostasis: GJIC permits the rapid equilibration of nutrients, ions, and fluids between cells. This might be the most ancient, widespread, and important function for these channels. Electrical coupling: Gap junctions serve as electrical synapses in electrically excitable cells such as cardiac myocytes, smooth muscle cells, and neurons. In these tissues, electrical coupling permits more rapid cell-to-cell transmission of action potentials than chemical synapses. In
cardiomyocytes and smooth muscle cells, this enables their synchronous contraction. Tissue response to hormones: GJIC may enhance the responsiveness of tissues to external stimuli. Second messengers such as cyclic nucleotides, calcium, and inositol phosphates are small enough to pass from hormonally activated cells to quiescent cells through junctional channels and activate the latter. Such an effect may increase the tissue response to an agonist. Regulation of embryonic development: Gap junctions may serve as intercellular pathways for chemical and/or electrical developmental signals in embryos and for defining the boundaries of developmental compartments. GJIC occurs in specific patterns in embryonic cells and the impairment of GJIC has been related to developmental anomalies and the teratogenic effects of many chemicals.
The intercellular communication ensures that the activities of the individual cells happen in a coordinated fashion and integrates these activities into the dynamics of a working tissue serving the organism in which it is set. It is therefore not very surprising that a wide variety of pathological conditions have been associated with decreased GJIC. The link between abnormalities in connexins and a range of disease states has been established both in vitro and in vivo. One example is regulation of gap junctional communication by a pro-inflammatory cytokine in airway epithelium, where Chanson et al. (Am J Pathol 2001 May;158(5):1775-84) found that decreased intercellular communication induced by TNF-α progressively led to inflammation.
In summary, mounting evidence linking malfunction, such as gating or closure or even absence, of gap junctions to an increased risk of disease has recently been collected. Few currently available drugs for the treatment of such diseases act as a facilitators of intercellular communication by facilitating or increasing gap junction function. Development of drugs that modulate Cx activity and/or functional GJIC would therefore improve methods of therapy and treatment of human disease. GJIC in cancer
Aberrant expression and function of several connexin proteins frequently occurs in cells exposed to tumor- promoting agents and during oncogenesis, both in cell culture systems and in tissues and tumors explanted from test animals and patients. Restoration of normal or near-normal levels of functional connexin proteins in neoplastic cells by transfecting the cells with connexin-encoding cDNAs exerts negative growth controls on neoplastic cells, suggesting that connexin proteins share important properties with known tumor-suppressor proteins. This hypothesis is supported by data establishing that GJIC is inhibited in cells or tumors exposed to tumor-promoting carcinogens or other oncogenic agents.
It is speculated that intact GJIC is a necessary, if not sufficient, biological function of metazoan cells for the regulation of growth control, differentiation and apoptosis of normal progenitor cells. Normal, contact-inhibited fibroblasts and epithelial cells have functional GJIC, while most, if not all, tumor cells have dysfunctional homologous or heterologous GJIC. Hallmark features of tumor cells include aberrant growth inhibitory mechanisms, prolonged or immortalized life-span, their lack of ability to reach a fully differentiated state, and then- loss of ability to undergo apoptosis under normal conditions. Chemical tumor promoters, growth factors and hormones have been shown to inhibit GJIC. Moreover, activation of certain cellular oncogenes, or the reduction in cellular levels of connexin proteins using anti-sense technology have been shown to reduce GJIC. Therefore, it is of therapeutic interest to identify compounds (antitumor and chemopreventive compounds) that restore, and/or prevent the loss of GJIC normally seen during neoplastic transformation. Among the leading candidates for cancer chemoprevention are dietary carotenoids — pigments that in plants play a crucial role in protection from oxidative damage (Bertram et al., 1987). There is abundant
epidemiological and laboratory evidence that carotenoids possess potent cancer chemopreventive properties in humans, independent of their antioxidant activity or their potential for conversion to retinoids. Unfortunately three major clinical trials of high-dose supplemental β-carotene, the carotenoid most frequently identified as protective against lung cancer, failed to demonstrate protection. In contrast, in two of these studies conducted in high-risk smokers and/or asbestos exposed workers, lung cancer incidence actually increased (Omenn et al, 1995; Albanes et al., 1996). The third study in largely non-smoking US physicians did not demonstrate protection or risk (Hennekens et al., 1996). In studies conducted in ferrets, one of the few laboratory models which absorb β-carotene to a comparable level as do humans, β-carotene was found to induce lung pathology and molecular changes consistent with retinoic acid deficiency as a consequence of enhanced catabolism of this important regulator of cell differentiation (Wang et al., 2003). These data suggest that use of carotenoids without potential for conversion to vitamin A may provide protection and avoid this toxicity. Recent studies using lycopene, a non-pro-vitamin A carotenoid, in the ferret model showed protection against tobacco-induced pathology, without toxicity (Liu et al., 2003).
Astaxanthin (AST), another non-pro-vitamin A carotenoid, is found predominantly as a dietary source in shrimp, lobster and salmon, and as such is not a major circulating carotenoid as are lycopene and β-carotene. In experimental animal studies astaxanthin has been shown to be capable of inhibiting chemically-induced oral and bladder carcinogenesis (Tanaka et al., 1994; Tanaka et al., 1995). Astaxanthin has also been shown to be effective at stimulating the immune system (Jyonuchi et al., 1995; Jyonuchi et al, 1996; Chew et al., 1999). Similar to other carotenoids, astaxanthin is a powerful lipid-phase antioxidant, and has been reported to suppress production of inflammatory cytokines (Lee at al, 2003). Based on this evidence, astaxanthin has significant cancer chemopreventive potential.
Delivery of highly lipophilic carotenoids such as astaxanthin to biological systems has met with formidable challenges. The most commonly employed method of delivery is in "beadlet" form, a micro-disbursed solution of carotenoids in vegetable oil in a water-soluble matrix. Unfortunately, only β-carotene, canthaxanthin and lycopene have been so formulated, and studies using beadlets in most laboratory animals has been confounded by poor absorption. Delivery of astaxanthin and other carotenoids in cell culture was made possible by using the solvent tetrahydrofuran (THF), although this solvent is unsuitable for animal and clinical use (Cooney et al, 1993).
The need for a water-soluble and/or water-dispersible delivery system for carotenoids has led to the development of a highly bioavailable, water-dispersible, disodium salt disuccinate ester of astaxanthin (dAST), disclosed in United States Patent Application No.: 2004-0162329, published on August 19, 2004, which is incorporated by reference as though fully set forth herein. This compound formed a pseudo-solution in water at concentrations of up to 8 mg/ml (approximately 10 mM), and bioavailability of dAST in vitro was enhanced by the addition of ethanol as a co-solvent to maintain the compound in monomeric form. Oral administration of dAST to mice resulted in rapid absorption of the compound, its cleavage to free astaxanthin, and accumulation in certain target tissues. dAST was shown to be an effective scavenger of free radicals in the aqueous phase using an in vitro human polymorphonuclear leukocyte assay with complete inhibition of the induced superoxide anion at mM concentrations. This compound has also been shown to significantly protect against cardiac ischemia-reperfusion (I/R) injury, generally considered to result from oxidative stress, at doses up to 75 mg/kg in a rat model of experimental infarction, and at 50 mg/kg in canines. Administration of an aqueous ethanolic dAST formulation to carcinogen-promoted 10T1/2 cells, an in vitro model of carcinogenesis, resulted in increased expression of the connexin protein CX43 and GJIC.
Carotenoids are a group of natural pigments produced principally by plants, yeast, and microalgae. The family of related compounds now numbers greater than 700 described members, exclusive of Z and E isomers. Fifty (50) have been found in human sera or tissues. Humans and other animals cannot synthesize carotenoids de novo and must obtain them from their diet. All carotenoids share common chemical features, such as a polyisoprenoid structure, a long polyene chain forming the chromophore, and near symmetry around the central double bond. Tail-to-tail linkage of two C20 geranyl-geranyl diphosphate molecules produces the parent C40 carbon skeleton. Carotenoids without oxygenated functional groups are called "carotenes", reflecting their hydrocarbon nature; oxygenated carotenes are known as "xanthophylls." Cyclization at one or both ends of the molecule yields 7 identified end groups (illustrative structures shown in FIG. 1). Examples of uses of carotenoid derivatives and analogs are illustrated in U.S. Patent Application Serial No. 10/793,671 filed on March 4, 2004, entitled
"CAROTENOID ETHER ANALOGS OR DERIVATIVES FOR THE INHIBITION AND AMELIORATION OF DISEASE" by Lockwood et al. published on January 13, 2005, as Publication No. US-2005-0009758 and PCT International Application Number PCT/US2003/023706 filed on July 29, 2003, entitled "STRUCTURAL CAROTENOID ANALOGS FOR THE INHIBITION AND AMELIORATION OF DISEASE" by Lockwood et al. (International Publication Number WO 2004/011423 A2, published on February 5, 2004) both of which are incorporated by reference as though fully set forth herein. 5-Lipoxygenase in cancer
Cancer of the prostate is the most commonly diagnosed malignancy among men in the United States and Europe, killing thousands "every year. Metastatic prostate cancer responds initially to androgen withdrawal therapy, but hormone resistance frequently (and some reports state universally) develops. Chemotherapeutic agents currently available have little or no impact on the survival of the patients with hormone-refractory prostate cancer. For this reason, metastatic prostate cancer almost always has a fatal outcome. Although the incidence of the localized, latent form of prostate cancer is the same globally regardless of ethnic origin, there is significant variation in the occurrence of metastatic disease between Western countries and Eastern countries, suggesting involvement of environmental factors in metastatic progression. The underlying molecular mechanism involved in the progression phase of the disease is an active area of current research.
Epidemiological evidence suggests a link between the incidence of prostate cancer and dietary fat intake. It has been documented that arachidonic acid can directly stimulate in vitro growth of both hormone-responsive and - nonresponsive human prostate cancer cells, which suggests a causal link between dietary fat and prostate cancer progression.
Arachidonic acid can be metabolized to produce a host of proinflammatory substances, called eicosanoids, that act as potent autocrine and paracrine regulators of cell biology. These substances are known to modulate diverse physiologic and pathologic responses, including growth and invasiveness of tumor cells as well as suppression of immune surveillance. Release of arachidonic acid and formation of eicosanoids have also been implicated in the action of a number of cytokines, including epidermal growth factor, platelet derived growth factor, and bombesin. The specific eicosanoid responsible for mitogenesis varies with the cytokine and the cell lineage involved, and has included prostaglandin E2 (PGE2) as well as several lipoxygenase products. In addition to their role in regulating mitogenesis, various eicosanoids can either trigger or block apoptosis. As with mitogenesis, the specific eicosanoid involved in triggering or blocking apoptosis is cell lineage-dependent. For example, synthesis of PGE2 plays a central role in the apoptosis required for egg release during ovulation. In contrast, PGE2 blocks activation-induced apoptosis in CD4+/CD8+ T lymphocytes. In addition, both FAS and TNF receptor activation are
associated with arachidonic acid release and eicosanoid formation in certain cell lineages. Recent evidence indicates that arachidonic acid suppresses ceramide-induced cell death in prostate cancer cells and that this suppression depends on formation of lipoxygenase products. It has previously been shown that arachidonic acid stimulates mitogenesis of human prostate cancer cells in vitro. This mitogenesis is blocked if further metabolism of arachidonic acid through 5-lipoxygenase is interrupted. Moreover, MK886, a specific inhibitor of 5-lipoxygenase, not only blocked the growth stimulation by arachidonic acid but, at a concentration of 10 mM, killed more than 90% of the cells in culture.
Ghosh et al. (Proc. Natl. Acad. ScL USA, Vol. 95, pp. 13182-13187, October 1998) have reported that that cultured human prostate cancer cell lines constitutively produce 5-HETE (5-hydroxyeicosatetraenoic acid), a product of arachidonate 5-lipoxygenase activity, with no external stimulus, and that addition of exogenous arachidonic acid to the cells dramatically increases 5-HETE production. It was found that inhibiting the activity of the 5-lipoxygenase enzyme in these cells blocks production of 5-HETE and induces apoptosis in both hormone- responsive and hormone-nonresponsive human prostate cancer cells. The induction of apoptosis in these cells could be prevented by the simultaneous addition of the 5-HETE series of arachidonic acid metabolites, indicating a critical role of these metabolites in the survival of human prostate cancer cells. 5-HETE and its closely related, more potent inflammatory eicosanoid 5-oxo-EET can be considered "survival factors" for human prostate cancer cells. Antioxidant Properties of Carotenoids
Free radicals are highly reactive molecules having one or more unpaired electrons in their outer orbital. Free radicals are involved in normal metabolism, and are always present in the human body, but normally at very low concentrations. There is considerable interest in understanding free radical biochemistry, since changes in the bioavailability of these molecules are believed to be involved in the early stages and progression of several diseases, such as cancer, inflammatory disease and cardiovascular, among others.
Carotenoids are a group of natural pigments produced principally by plants, yeast, and microalgae. The family of related compounds now numbers greater than 750 described members, exclusive of Z and E isomers. Humans and other animals cannot synthesize carotenoids de novo and must obtain them from their diet. All carotenoids share common chemical features, such as a polyisoprenoid structure, a long polyene chain forming the chromophore, and near symmetry around the central double bond. Tail-to-tail linkage of two C2o geranyl-geranyl diphosphate molecules produces the parent C40 carbon skeleton. Carotenoids without oxygenated functional groups are called "carotenes", reflecting their hydrocarbon nature; oxygenated carotenes are known as "xanthophylls." "Parent" carotenoids may generally refer to those natural compounds utilized as starting scaffold for structural carotenoid analog synthesis. Carotenoid derivatives may be derived from a naturally occurring carotenoid. Naturally occurring carotenoids may include lycopene, lycophyll, lycoxanthin, astaxanthin, beta-carotene, lutein, zeaxanthin, and/or canthaxanthin to name a few. Cyclization at one or both ends of the molecule yields 7 identified end groups (illustrative structures shown in FIG. 1). Examples of uses of carotenoid derivatives and analogs are illustrated in U.S. Patent Application Serial No. 10/793,671 filed on March 4, 2004, entitled "CAROTENOID ETHER ANALOGS OR DERIVATIVES FOR THE INHIBITION AND AMELIORATION OF DISEASE" by Lockwood et al. published on January 13, 2005, as Publication No. US-2005-0009758 and PCT International Application Number PCT/US2003/023706 filed on July 29, 2003 , entitled "STRUCTURAL CAROTENOID ANALOGS FOR THE INHIBITION AND AMELIORATION
OF DISEASE" by Lockwood et al. (International Publication Number WO 2004/011423 A2, published on February 5, 2004) both of which are incorporated by reference as though fully set forth herein.
Documented carotenoid functions in nature include light-harvesting, photoprotection, and protective and sex-related coloration in microscopic organisms, mammals, and birds, respectively. A relatively recent observation has been the protective role of carotenoids against age-related diseases in humans as part of a complex antioxidant network within cells. This role is dictated by the close relationship between the physicochemical properties of individual carotenoids and their in vivo functions in organisms. The long system of alternating double and single bonds in the central part of the molecule (delocalizing the π-orbital electrons over the entire length of the polyene chain) confers the distinctive molecular shape, chemical reactivity, and light-absorbing properties of carotenoids. Additionally, isomerism around C=C double bonds yields distinctly different molecular structures that may be isolated as separate compounds (known as Z ("cis") and E ("trans"), or geometric, isomers). Of the more than 750 described carotenoids, an even greater number of the theoretically possible mono-Z and poly-Z isomers are sometimes encountered in nature. The presence of a Z double bond creates greater steric hindrance between nearby hydrogen atoms and/or methyl groups, so that Z isomers are generally less stable thermodynamically, and more chemically reactive, than the corresponding all-is form. The all-E configuration is an extended, linear, and rigid molecule. Z-isomers are, by contrast, not simple, linear molecules (the so-called "bent-chain" isomers). The presence of any Z in the polyene chain creates a bent-chain molecule. The tendency of Z-isomers to crystallize or aggregate is much less than the all-i? isomers. Additionally, Z isomers are more readily solubilized, absorbed, and transported in vivo than then" all-is1 counterparts. This has important implications for enteral (e.g., oral) and parenteral (e.g., intravenous, intra-arterial, intramuscular, and subcutaneous) dosing in mammals.
Carotenoids with chiral centers may exist either as the R (rectus) or S (sinister) configurations. As an example, astaxanthin (with 2 chiral centers at the 3 and 3' carbons) may exist as 4 possible stereoisomers: 3S, 3'S; 3R, 3'S and 3S, 3'R (identical meso forms); or 3R, 3'R. The relative proportions of each of the stereoisomers may vary by natural source. For example, Haematococcus pluvialis microalgal meal is 99% 3S, 3'S astaxanthin, and is likely the predominant human evolutionary source of astaxanthin. Krill (3R,3 'R) and yeast sources yield different stereoisomer compositions than the microalgal source. Synthetic astaxanthin, produced by large manufacturers such as Hoffmann-LaRoche AG, Buckton Scott (USA), or BASF AG, are provided as defined geometric isomer mixtures of a 1:2:1 stereoisomer mixture [3S, 3'S; 3R, 3'S, 3'R,3S (meso); 3R, 3'R] of non-esterified, free astaxanthin. Natural source astaxanthin from salmon fish is predominantly a single stereoisomer (3S,3'S), but does contain a mixture of geometric isomers. Astaxanthin from the natural source Haematococcus pluvialis may contain nearly 50% Z isomers. As stated above, the Z conformational change may lead to a higher steric interference between the two parts of the carotenoid molecule, rendering it less stable, more reactive, and more susceptible to reactivity at low oxygen tensions. In such a situation, hi relation to the all-i? form, the Z forms: (1) may be degraded first; (2) may better suppress the attack of cells by reactive oxygen species such as superoxide anion; and (3) may preferentially slow the formation of radicals. Overall, the Z forms may initially be thermodynamically favored to protect the lipophilic portions of the cell and the cell membrane from destruction. It is important to note, however, that the all-is1 form of astaxanthin, unlike β-carotene, retains significant oral bioavailability as well as antioxidant capacity in the form of its dihydroxy- and diketo-substitutions on the β-ionone rings, and has been demonstrated to have increased efficacy over β-carotene in most studies. The all-£ form of astaxanthin has also been postulated to have the most membrane-stabilizing effect on cells in vivo. Therefore, it is likely that the all-i?
form of astaxanthin in natural and synthetic mixtures of stereoisomers is also extremely important in antioxidant mechanisms, and may be the form most suitable for particular pharmaceutical preparations.
The antioxidant mechanism(s) of carotenoids, and in particular astaxanthin, includes singlet oxygen quenching, direct radical scavenging, and lipid peroxidation chain-breaking. The polyene chain of the carotenoid absorbs the excited energy of singlet oxygen, effectively stabilizing the energy transfer by derealization along the chain, and dissipates the energy to the local environment as heat. Transfer of energy from triplet-state chlorophyll (in plants) or other porphyrins and proto-porphyrins (in mammals) to carotenoids occurs much more readily than the alternative energy transfer to oxygen to form the highly reactive and destructive singlet oxygen (1O2). Carotenoids may also accept the excitation energy from singlet oxygen if any should be formed in situ, and again dissipate the energy as heat to the local environment. This singlet oxygen quenching ability has significant implications in cardiac ischemia, macular degeneration, porphyria, and other disease states in which production of singlet oxygen has damaging effects. In the physical quenching mechanism, the carotenoid molecule may be regenerated (most frequently), or be lost. Carotenoids are also excellent chain-breaking antioxidants, a mechanism important in inhibiting the peroxidation of lipids. Astaxanthin can donate a hydrogen (H) to the unstable polyunsaturated fatty acid (PUFA) radical, stopping the chain reaction. Peroxyl radicals may also, by addition to the polyene chain of carotenoids, be the proximate cause for lipid peroxide chain termination. The appropriate dose of astaxanthin has been shown to completely suppress the peroxyl radical chain reaction in liposome systems. Astaxanthin shares with vitamin E this dual antioxidant defense system of singlet oxygen quenching and direct radical scavenging, and in most instances (and particularly at low oxygen tension in vivo) is superior to vitamin E as a radical scavenger and physical quencher of singlet oxygen.
Carotenoids, and in particular astaxanthin, are potent direct radical scavengers and singlet oxygen quenchers and possess all the desirable qualities of such therapeutic agents for inhibition or amelioration of ischemia-reperfusion (I/R) injury. Synthesis of novel carotenoid derivatives with "soft-drug" properties (i.e. activity in the derivatized form), with physiologically relevant, cleavable linkages to pro-moieties, can generate significant levels of free carotenoids in both plasma and solid organs. This is critically important, for in mammals, diesters of carotenoids generate the non-esterified or "free" parent carotenoid, and may be viewed as elegant synthetic and novel delivery vehicles with improved properties for delivery of free carotenoid to the systemic circulation and ultimately to target tissue. In the case of non-esterified, free astaxanthin, this is a particularly useful embodiment (characteristics specific to non-esterified, free astaxanthin below): • Lipid soluble in natural form; may be modified to become more water soluble;
• Molecular weight of 597 Daltons [size < 600 Daltons (Da) readily crosses the blood brain barrier, or BBB];
• Long polyene chain characteristic of carotenoids effective in singlet oxygen quenching and lipid peroxidation chain breaking; • No pro-vitamin A activity in mammals (eliminating concerns of hypervitaminosis A and retinoid toxicity in humans).
The administration of antioxidants, which are potent singlet oxygen quenchers and direct radical scavengers, particularly of superoxide anion, should limit hepatic fibrosis and the progression to cirrhosis by affecting the activation of hepatic stellate cells early in the fibrogenetic pathway. Reduction in the level of ROS by the administration of a potent antioxidant can therefore be crucial in the prevention of the activation of both HSC and Kupffer cells. This protective antioxidant effect appears to be spread across the range of potential therapeutic
antioxidants, including water-soluble (e.g., vitamin C, glutathione, resveratrol) and lipophilic (e.g., vitamin E, β- carotene, astaxanthin) agents. Therefore, a co-antioxidant derivative strategy in which water-soluble and lipophilic agents are combined synthetically is a particularly useful embodiment.
Vitamin E is generally considered the reference antioxidant. When compared with vitamin E, carotenoids are more efficient in quenching singlet oxygen in homogeneous organic solvents and in liposome systems. They are better chain-breaking antioxidants as well in liposomal systems. They have demonstrated increased efficacy and potency in vivo. They are particularly effective at low oxygen tension, and in low concentration, making them extremely effective agents in disease conditions in which ischemia is an important part of the tissue injury and pathology. These carotenoids also have a natural tropism for the liver after oral administration. Therefore, therapeutic administration of carotenoids should provide a greater benefit in limiting fibrosis than vitamin E.
Problems related to the use of some carotenoids and structural carotenoid analogs include: (1) the complex isomeric mixtures, including non-carotenoid contaminants, provided in natural and synthetic sources leading to costly increases in safety and efficacy tests required by such agencies as the FDA; (2) limited bioavailability upon administration to a subject; and (3) the differential induction of cytochrome P450 enzymes (this family of enzymes exhibits species-specific differences which must be taken into account when extrapolating animal work to human studies).
New methods, systems and compounds capable of modulating intracellular levels of connexin proteins, gap junctions and GJIC in cells that have undergone, or that are at risk of undergoing, neoplastic transformation would be useful therapeutic agents. Carotenoid analogs or derivatives displaying properties of increased water- dispersibility and bioavailability would be beneficial for such applications.
SUMMARY
Methods for preventing or treating diseases resulting from impaired intercellular communication or impaired gap junction function are provided for herein. Illustrative diseases include those effecting the respiratory, circulatory or nervous systems, vision and hearing, dental tissues, smooth musculature, and transplantation of cells and tissues. Such methods can be used alone as the sole therapeutic regimen or in combination with one or more other established protocols for addressing a particular disease or condition. Carotenoid analogs or derivatives useful in the treatment methods contemplated herein are characterised in functioning as facilitators of GJIC.
More specifically the presently disclosed treatment methods relate to preventing or treating proliferative disorders caused, at least in part, by impaired gap junction function by facilitating (maintaining and/or restoring) the intercellular communication in the diseased cells and tissues occurring through gap junctions, preferably by administering a therapeutically effective amount of at least one carotenoid analog or derivative which facilitates CX43 expression and gap junction intercellular communication to a patient suffering from said disease.
In some embodiments, methods of reducing neoplastic transformation of a cell, a group of cells or in a subject may include administering to the cell, group of cells or subject an effective amount of a pharmaceutically acceptable formulation including a synthetic analog or derivative of a carotenoid.
In some embodiments, methods of modulating the amount of connexin 43 protein in a cell or in a group of cells may include administering to the cell, group of cells or to a subject, an effective amount of a pharmaceutically acceptable foπnulation including a synthetic analog or derivative of a carotenoid.
In some embodiments, methods of modulating the number of gap junctional complexes at or near the cell membrane of a cell or a group of cells may include administering to the cell, group of cells or to a subject, an
effective amount of a pharmaceutically acceptable formulation including a synthetic analog or derivative of a carotenoid.
In some embodiments, methods of modulating GJIC between adjacent or substantially adjacent cells may include administering to the cell, group of cells or to a subject, an effective amount of a pharmaceutically acceptable formulation including a synthetic analog or derivative of a carotenoid.
In a further set of embodiments, methods for the treatment or prevention of proliferative diseases, in particular cancers that are dependent on the presence of one or more metabolites of the fatty acid arachidonate such as products of the enzyme 5-Lipoxygenase (5-LO), are provided for herein.
In an embodiment, contacting a neoplastic cell, such as a prostate cancer cell, with a pharmaceutically acceptable formulation containing an effective amount of synthetic analog or derivative of a carotenoid may inhibit or reduce the activity of 5-Lipoxygenase in the neoplastic cell. Inhibition or reduction of 5-Lipoxygenase in the neoplastic cell may, in certain embodiments, result in that cell undergoing apoptosis.
In an embodiment, prostate cancer cells may be induced to undergo apoptosis by contacting the cells with a pharmaceutically acceptable formulation containing an effective amount of a synthetic analog or derivative of a carotenoid. In an embodiment, the prostate cancer cells may be part of a solid prostate tumor present in a human subject.
The presently embodied treatment methods, including the administration of pharmaceutically acceptable formulations containing synthetic carotenoid analogs or derivatives, may be provided alone as a primary therapy, or may be provided in conjunction with one more more additional therapeutic agents (e.g. androgen withdrawal therapy) and/or radiation therapy as part of a therapeutic regimen. Such determination may be made by an appropriate healthcare provider and practitioner of ordinary skill in the art.
Administration of analogs or derivatives of carotenoids according to the preceding embodiments may at least partially inhibit and/or influence the occurrence or the progression of proliferative disorders. Proliferative disorders that may be influenced by administration of analogs or derivatives of carotenoids according to some embodiments may include those disorders that are characterized by aberrant or otherwise dysregulated cell growth, such as, for example, benign or malignant neoplasms or any other disorder characterized by the proliferation of anaplastic cells, and/or invasion of such cells into surrounding tissues or distal sites. Non-limiting examples of proliferative disorders that may be influenced according to some embodiments include neoplasia, such as, for example, brain cancer, bone cancer, epithelial cell-derived neoplasia (epithelial carcinoma), such as, for example, basal cell carcinoma, adenocarcinoma, gastrointestinal cancer, such as, for example, lip cancer, mouth cancer, esophageal cancer, small bowel cancer and stomach cancer, colon cancer, liver cancer, bladder cancer, pancreas cancer, ovary cancer, cervical cancer, lung cancer, breast cancer and skin cancer, such as squamus cell and basal cell cancers, prostate cancer, renal cell carcinoma, and other known cancers that effect epithelial cells throughout the body, benign and cancerous tumors, growths, polyps, adenomatous polyps, including, but not limited to, familial adenomatous polyposis.
In some embodiments, the administration of structural analogs or derivatives of carotenoids by one skilled in the art - including consideration of the pharmacokinetics and pharmacodynamics of therapeutic drug delivery - is expected to inhibit and/or ameliorate disease conditions associated with abnormal cell division. In some of the foregoing embodiments, analogs or derivatives of carotenoids administered to cells maybe at least partially water- soluble.
"Water-soluble" structural carotenoid analogs or derivatives are those analogs or derivatives that may be formulated in aqueous solution, either alone or with one or more excipients. Water-soluble carotenoid analogs or derivatives may include those compounds and synthetic derivatives which form molecular self-assemblies, and may be more properly termed "water dispersible" carotenoid analogs or derivatives. Water-soluble and/or "water- dispersible" carotenoid analogs or derivatives may be preferred in some embodiments.
Water-soluble carotenoid analogs or derivatives may have a water solubility of greater than about 1 mg/mL in some embodiments. In certain embodiments, water-soluble carotenoid analogs or derivatives may have a water solubility of greater than about 10 mg/mL. In certain embodiments, water-soluble carotenoid analogs or derivatives may have a water solubility of greater than about 20 mg/mL. In certain embodiments, water-soluble carotenoid analogs or derivatives may have a water solubility of greater than about 25 mg/mL. In some embodiments, water- soluble carotenoid analogs or derivatives may have a water solubility of greater than about 50 mg/mL.
In some embodiments, water-soluble analogs or derivatives of carotenoids may be administered to a cell, a group of cells or to a subject alone or in combination with additional carotenoid analogs or derivatives.
In some embodiments, a method of treating a proliferative disorder may include administering to the subject an effective amount of a pharmaceutically acceptable formulation including a synthetic analog or derivative of a carotenoid. The synthetic analog or derivative of the carotenoid may have the structure
where R4 is hydrogen, methyl, or -CH2OH; and where each R5is independently hydrogen or -OH.
In some embodiments, a method of inhibiting or reducing at least some of the side effects associated with therapeutic administration of COX-2 selective inhibitors may include administering to the subject an effective amount of a pharmaceutically acceptable formulation including a synthetic analog or derivative of a carotenoid. The synthetic analog or derivative of the carotenoid may have the structure
where each R3 is independently hydrogen or methyl, and where each R1 and R2 are independently:
where R4 is hydrogen or methyl; where each R5 is independently hydrogen, -OH, or -OR6 wherein at least one R5 group is -OR6; wherein each R6 is independently: alkyl; aryl; -alkyl-N(R7)2; -aryl-N(R7)2; -alkyl-CO2H; -aryl-CO2H; -O-C(O)-R8;-P(O)(ORS)2; -S(O)(OR8)2; an amino acid; a peptide, a carbohydrate; -C(O)-(CH2)n-CO2R9; -C(O)-OR9; a nucleoside residue, or a co-antioxidant; where R7 is hydrogen, alkyl, or aryl; wherein R8 is hydrogen, alkyl, aryl, benzyl, or a co-antioxidant; and where R9 is hydrogen; alkyl; aryl; -P(O)(OR8)2; -S(O)(OR8)2; an amino acid; a peptide, a carbohydrate; a nucleoside, or a co-antioxidant; and where n is 1 to 9. Pharmaceutically acceptable salts of any of the above listed carotenoid derivatives may also be used to ameliorate at least some of the side effects associated with therapeutic administration of COX-2 selective inhibitors
Each co-antioxidant may be independently Vitamin C, Vitamin C analogs, Vitamin C derivatives, Vitamin E, Vitamin E analogs, Vitamin E derivatives, flavonoids, flavonoid derivatives, or flavonoid analogs. Flavonoids
include, but are not limited to, quercetin, xanthohumol, isoxanthohumol, or genistein. Selection of the co- antioxidant should not be seen as limiting for the therapeutic application of the current invention.
In some embodiments, a pharmaceutical composition is provided that may include one or more synthetic carotenoids ("a co-formulation" strategy), or synthetic derivatives or analogs thereof, in combination with one or more selective 5-LO inhibitor drags, chemotherapeutic agents and/or in conjunction with radiation tharapy. Certain embodiments may further directed to pharmaceutical compositions that include combinations of two or more carotenoids or synthetic analogs or derivatives thereof. In an embodiment, a pharmaceutical composition may include chiral astaxanthin in combination with a 5-LO inhibitor drug or chemotherapeutic agent. In an embodiment, a pharmaceutical composition may include a synthetic derivative of lycophyll in combination with a 5-LO inhibitor drag or chemotherapeutic agent. The pharmaceutical compositions may be adapted to be administered orally, or by one or more parenteral routes of administration. In an embodiment, the pharmaceutical composition may be adapted such that at least a portion of the dosage of carotenoid or synthetic derivative or analog thereof is delivered prior to, during, or after at least a portion of the 5-LO inhibitor drags, chemotherapeutic agents and/or radiation therapy is delivered. In some embodiments, separate pharmaceutical compositions are provided, such that the 5-LO inhibitor drags or additional chemotherapeutic agents are delivered separately from carotenoid, or synthetic derivatives or analogs thereof (sometimes referred to in the art as a "co-administration" strategy). The pharmaceutical compositions may be adapted to be administered orally, or by one or more parenteral routes of administration. In an embodiment, the pharmaceutical composition may be adapted such that at least a portion of the dosage of the carotenoid or synthetic derivative or analog thereof is delivered prior to, during, or after at least a portion of the 5- LO inhibitor drugs or additional chemotherapeutic agents are administered to the subject. The carotenoid, carotenoid analogs and/or derivatives may also be administered alone.
Embodiments directed to pharmaceutical compositions may further include appropriate vehicles for delivery of said pharmaceutical composition to a desired site of action (Le., the site a subject's body where the biological effect of the pharmaceutical composition is most desired). Pharmaceutical compositions including xanthophyll carotenoids or analogs or derivatives of astaxanthin, lutein or zeaxanthin that may be administered orally or intravenously may be particularly advantageous for and suited to embodiments described herein. In yet a further embodiment, an injectable astaxanthin formulation or a structural analog or derivative may be administered with a astaxanthin, zeaxanthin or lutein structural analog or derivative and/or other carotenoid structural analogs or derivatives, or in formulation with antioxidants and/or excipients that further the intended purpose. In some embodiments, one or more of the xanthophyll carotenoids or synthetic analogs or derivatives thereof may be at least partially water-soluble.
Certain embodiments may further directed to pharmaceutical compositions including combinations two or more structural carotenoid analogs or derivatives. Pharmaceutical compositions including injectable structural carotenoid analogs or derivatives of lutein may be particularly advantageous for the methods described herein. In yet a further embodiment, an injectable lutein structural analog or derivative may be administered with a zeaxanthin structural analog or derivative and/or other carotenoid structural analogs or derivatives, or in formulation with antioxidants and/or excipients that further the intended purpose. In some embodiments, one or more of the lutein structural analogs or derivatives are water-soluble.
BRIEF DESCRIPTION OF THE DRAWINGS
The above brief description as well as further objects, features and advantages of the methods and apparatus of the present invention will be more fully appreciated by reference to the following detailed description of presently preferred but nonetheless illustrative embodiments in accordance with the present invention when taken in conjunction with the accompanying drawings.
FIG. 1 depicts a graphic representation of several examples of the structures of several xanthophyll carotenoids and synthetic derivatives or analogs that may be used according to some embodiments. (A) astaxanthin; (B) lutein; (C) zeaxanthin; (D) disuccinic acid astaxanthin ester; (E) disodium disuccinic acid ester astaxanthin salt (Cardax™); and (F) divitamin C disuccinate astaxanthin ester; (G) tetrasodium diphosphate astaxanthin ester;
FIG. 2 depicts a time series of the UV/Vis absorption spectra of the disodium disuccinate derivative of natural source lutein in water;
FIG. 3 depicts a UVTVis absorption spectra of the disodium disuccinate derivative of natural source lutein in water (λmax = 443 nm), ethanol (λmax = 446 run), and DMSO (λmax = 461 nm);
FIG. 4 depicts a UV/Vis absorption spectra of the disodium disuccinate derivative of natural source lutein in water (λmax = 442 nm) with increasing concentrations of ethanol;
FIG. 5 depicts a time series of the UV/Vis absorption spectra of the disodium diphosphate derivative of natural source lutein in water; FIG. 6 depicts a UV/Vis absorption spectra of the disodium diphosphate derivative of natural source lutein in 95% ethanol (λmax = 446 nm), 95% DMSO (λmax = 459 nm), and water (λmax = 428 nm);
FIG. 7 depicts a UV/Vis absorption spectra of the disodium diphosphate derivative of natural source lutein in water (λmax = 428 nm) with increasing concentrations of ethanol;
FIG. 8 depicts a mean percent inhibition (± SEM) of superoxide anion signal as detected by DEPMPO spin-trap by the disodium disuccinate derivative of natural source lutein (tested in water);
FIG. 9 depicts a mean percent inhibition (± SEM) of superoxide anion signal as detected by DEPMPO spin-trap by the disodium diphosphate derivative of natural source lutein (tested in water);
FIG. 10 depicts the chemical structures of three stereoisomers of synthetic water-soluble carotenoid analogs or derivatives according to certain non-limiting embodiments. (A) (3i?,3'i?)-tetrasodium diphosphate astaxanthin; (B) (35,3 'S)- tetrasodium diphosphate astaxanthin; (C) (3R,3'S; mesό)- tetrasodium diphosphate astaxanthin; (D) lycophyll diphosphate
FIG. 1 IA is a Western blot depicting the levels of CX43 protein in 10T1/2 cells treated with AST versus pAST for four days. FIG. 1 IB depicts the relative induction levels of CX43 expression versus untreated control; FIG. 12 depicts various immunofluorescence images of intercellular plaques that are reactive with anti-CX43 antibodies at regions of cell-cell contact. Cells were treated for 4 days as in FIG. 11, then fixed and immuno- stained with CX43 antibody. (A), medium control; (B), pAST 10"6M; (C), AST 10"6 M; (D), CTX lO"5 M; E, TTNPB, 10"8 M. Arrows indicate plaque location;
FIG. 13 depicts the comparative induction of GJIC by pAST and AST. Confluent cultures of 10T1/2 cells were treated with the indicated concentrations for 7 days. Communication was assessed by scrape-loading assays as described. ■-■, AST; •-•, pAST. In these cultures a dye-transfer value of 60 is equal to transfer of dye 1 mm from the region of scrape-load.
FIG. 14A is a bar graph and the corresponding Western Blots showing CX43 induction in 10T1/2 cells after treatment according to the following: Lanes: 1: untreated; 2: THF only; 3: TTNPB 10'8M; 4: lycopene 10"5M; 5: lycopene 10"6M; 6: lycophyll 10"5M; 7: lycophyll 10"6M; 8: 3S,3'S astaxanthin 10"5 M; 9: 35,3'ιS astaxanthin 10"6 M; FIG. 14B is a bar graph showing relative CX43 protein inductions presented as averages of duplicate samples with standard deviation error bars. Bottom Panel (SDS-P AGE/Western Immunodetection). Lanes: 1 : THF only; 2: TTNPB 10"8M; 3: lycopene 10"5M; 4: lycopene 10"6M; 5: lycophyll 10'5M; 6: lycophyll 10"6M; 7: lycophyll 10'7M; 8: 35,3'5 astaxanthin 10'5M; 9: 3S,3'_7 astaxantbin 10"6M; 10: 35,3'5 astaxanthin 10"7M;
FIG. 14C shows two bar graphs depicting normalized results of the data shown in FIG14A-B; FIG. 15 is a bar graph depicting the percentage of LNCaP human prostate tumor cells that undergo apoptosis following treatment with various carotenoids including, 3S,3'S-astaxanthin, lycophyll, lycopene and the 5-Lipoxygenase inhibitor MK886 at the indicated concentrations;
FIG. 16 shows a series of flow cytometric profiles indicating the DNA content and approximate cell cycle profile of LNCaP human prostate cancer cells treated with various carotenoids or MK886 for 24 hours in the presence of fetal calf serum. Apoptotic cells are indicated as the population of cells having sub Gl DNA content;
FIG. 17 shows two bar graphs depicting the percentage of LNCaP human prostate tumor cells having 4N DNA content indicating indicating G2/M stage of the cell cycle when treated with various carotenoids or MK886 in the presence of fetal calf serum for 24 hours (upper panel) and 72 hours (lower panel), respectively;
FIG. 18 shows the flow cytometric DNA profiles of LNCaP cells treated with 10 μM MK866 in the absence of fetal calf serum over a timecourse, at the indicated times after treatment from two independent experiments;
FIG. 19 is a bar graph depicting the percentage of LNCaP cells having 4N DNA content 24 hours after being treated with the indicated carotenoid or with MK866 at the indicated concentration;
FIG. 20 shows the DNA profiles of LNCaP cells treated for 24 hours in the presence of serum and the indicated carotenoid or MK866. Each experiment was performed in duplicate as indicated;
FIG. 21 is a bar graph showing the cell cycle stage of LNCaP cells treated with the indicated agents for 24 or 48 hours (upper four panels), and the same results in tabular form.
While the invention is susceptible to various modifications and alternative forms, specific embodiments thereof are shown by way of example in the drawings and will be described herein in detail. It should be understood that the drawings and detailed description attached thereto are not intended to limit the invention to the particular form disclosed, but on the contrary, the intention is to cover all modifications, equivalents and alternatives falling within the spirit and scope of the present invention as defined by the appended claims.
DETAILED DESCRIPTION DEFINITIONS
The terms used throughout this specification generally have their ordinary meanings in the art, within the context of the invention, and in the specific context where each term is used. Certain terms are discussed below, or elsewhere in the specification, to provide additional guidance to the practitioner in describing the devices and methods of the invention and how to make and use them. It will be appreciated that the same thing can be said in more than one way. Consequently, alternative language and synonyms may be used for any one or more of the terms discussed herein, nor is any special significance to be placed upon whether or not a term is elaborated or
discussed in greater detail herein. Synonyms for certain terms are provided. A recital of one or more synonyms does not exclude the use of other synonyms. The use of examples anywhere in this specification, including examples of any terms discussed herein, is illustrative only, and in no way limits the scope and meaning of the invention or of any exemplified term. As used herein, the term "xanthophyll carotenoid" generally refers to a naturally occurring or synthetic 40- carbon polyene chain with a carotenoid structure that contains at least one oxygen-containing functional group. The chain may include terminal cyclic end groups. Exemplary, though non-limiting, xanthophyll carotenoids include astaxanthin, zeaxanthin, lutein, echinenone, lycophyll, canthaxanthin, and the like. Non-limiting examples of carotenoids that are not xanthophyll carotenoids include β-carotene and lycopene. As used herein, terms such as "carotenoid analog" and "carotenoid derivative" generally refer to chemical compounds or compositions derived from a naturally occurring or synthetic carotenoid. Terms such as carotenoid analog and carotenoid derivative may also generally refer to chemical compounds or compositions that are synthetically derived from non-carotenoid based parent compounds; however, which ultimately substantially resemble a carotenoid derived analog. Non-limiting examples of carotenoid analogs and derivatives that may be used according to some of the embodiments described herein are depicted schematically in FIG. 10
The term "modulate," as used herein, generally refers to a change or an alteration in the magnitude of a be used herein to biological parameter such as, for example, foci formation, tumorigenic or neoplastic potential, apoptosis, growth kinetics, expression of one or more genes or proteins of interest, metabolism, oxidative stress, replicative status, intercellular communication, or the like. "Modulation" may refer to a net increase or a net decrease in the biological parameter.
As used herein, the term "proliferative disorder" generally refers to a disorder, a substantial component of which involves the aberrant (typically accelerated) proliferation or growth of cells. Non-limiting examples of proliferative disorders include chronic inflammatory proliferative disorders, e.g., psoriasis and rheumatoid arthritis; proliferative ocular disorders, e.g., diabetic retinopathy; benign proliferative disorders, e.g., hemangiomas; and cancer, such as neoplasia, lymphoma, sarcoma, melanoma and other malignancies and tumors.
As used herein, the term "cancer" refers to a cellular disorder characterized by uncontrolled or dysregulated cell proliferation, decreased cellular differentiation, inappropriate ability to invade surrounding tissue, and/or ability to establish new growth at ectopic sites. The term "cancer" includes, but is not limited to, solid tumors and bloodborne tumors. The term "cancer" encompasses diseases of skin, tissues, organs, bone, cartilage, blood, and vessels. The term "cancer" further encompasses primary and metastatic cancers.
As used herein, the term "cell or a group of cells" is meant to include a single cell or group of cells that are isolated in culture as well as those cells or groups of cells naturally residing in a body or as part of a body organ or body tissue. The term "organ", when used in reference to a part of the body of an animal or of a human generally refers to the collection of cells, tissues, connective tissues, fluids and structures that are part of a structure in an animal or a human that is capable of performing some specialized function. Groups of organs constitute one or more specialized body systems. The specialized function performed by an organ is typically essential to the life or the overall well-being of the animal or human. Non-limiting examples of body organs include the heart, lungs, kidney, ureter, urinary bladder, adrenal glands, pituitary gland, skin, prostate, uterus, reproductive organs (e.g., genitalia and accessory organs), liver, gall bladder, brain, spinal cord, stomach, intestine, appendix, pancreas, lymph nodes, breast, salivary glands, lacrimal glands, eyes, spleen, thymus, bone marrow. Non-limiting examples of body systems include the respiratory, circulatory, musculoskeletal, nervous, digestive, endocrine, exocrine, hepato-
biliary, reproductive, and urinary systems. In animals the organs are generally made up of several tissues, one of which usually predominates, and determines the principal function of the organ. The term "tissue", when used in reference to a part of a body or of an organ, generally refers to an aggregation or collection of morphologically similar cells and associated accessory cells and intercellular matter, including extracellular matix material and fluids, acting together to perform specific functions in the body. There are generally four basic types of tissue in animals and humans including muscle, nerve, epithelial, and connective tissues.
The terms "cells" or "groups of cells" as used herein further encompasses cultured cells that have been explanted from a body or tissue and that have been maintained in vitro in a cell culture system. Examples of such cells include "primary cell" cultures. Primary cells are those cells that are explanted directly from a donor organism or tissue. Primary cells may typically be capable of undergoing a limited number of divisions in culture, but they generally do not continue to grow and eventually senesce and die.
Further examples of isolated cells include "secondary cell" cultures. Secondary cells are those cells that are explanted directly from a donor organism or tissue and that are maintained and propagated in culture for a protracted period of time, typically exceeding that of primary cells. Often times, secondary cells may be propagated in vitro for up to as many as 100 generations or more. Secondary cells are typically not immortalized however, and eventually undergo senescence. The number of cell divisions that secondary cells may undergo is related to their degree of differentiation. More terminally differentiated cells undergo fewer cell divisions and senesce early. Less well-differentiated cells, such as embryonic fibroblasts and cells that have begun to undergo neoplastic transformation, typically have a higher generation potential and can undergo a greater number of divisions. Yet further examples of isolated cells include "immortalized cells." Immortalized cells may typically be maintained and propagated in vitro indefinitely as long as the correct culture conditions are maintained. Immortalized cell lines are commonly referred to in the art as "transformed cells." The growth properties of such cells are altered. Typically, such cells have undergone one or more genotypic changes, such as, for example point mutations, aneuploidy or other chromosomal alterations. Immortalized cells may or may not be cancerous or malignant. Non-malignant transformed cells typically exhibit one or more of several properties when grown in vitro. Non-limiting examples of the phenotypic properties exhibited by non-malignant transformed cells include anchorage-dependent growth, growth factor dependence, and growth-arrest under conditions of nutritional deficiency. Furthermore, while transformed cells are generally not as highly differentiated as their primary or secondary counterparts, they nonetheless typically retain at least a subset of the morphological and biochemical properties of the cell type from which they are derived. Finally, non-malignant cells exhibit a growth property known in the art as "contact inhibition." Typically, such cells will continue to grow and divide in vitro when plated at low density. When the density of cells is sufficient so that a "monolayer" of cells has formed (i.e., the borders of adjacent cells are substantially touching), growth inhibitory signals pass between the cells, the cells exit the cell cycle and cease dividing. Such "contact inhibited" cells are frequently coupled by gap junctions. Loss of contact inhibition is a widely regarded sign that cells have become cancerous or oncogenic. Such cells do not stop dividing when they form a monolayer in culture. Rather, they continue to divide and pile up on top of one another in "foci". It is generally well accepted by ordinary practitioners of the art that cells that form foci in culture are tumor cells. As used herein, the term "neoplastic transformation" or "oncogenic transformation," generally refers to a proliferative disorder of cells characterized by one or more of several cellular changes. Such cellular changes are manifested by cells that have become, or are on the way to becoming, cancerous or malignant. Characteristics of cells that have undergone neoplastic transformation are well known to ordinary practitioners of the art and may
include, but are not limited to, loss of contact inhibition, escape from control mechanisms, loss of GJIC, increased growth potential, increased growth rate, the ability to form colonies in soft agar, alterations in the cell surface, alterations in the expression of certain protein or gene markers, karyotypic abnormalities, aneuploidy, morphological and biochemical deviations from the norm, and other attributes that confer the ability of the cell or group of cells to invade, metastasize, and kill. Neoplastic transformation may be induced, at least in part, by exposure of a cell or group of cells to radiation, or to one or more oncogenic agents such as certain viruses or carcinogens. A "carcinogen" as used herein, generally refers to a substance that increases the likelihood that a cell or group of cells begins the process of neoplastic transformation. Carcinogens may include genotoxic agents, also known in the art as "mutagens", and non-genotoxic agents, which induce neoplasms by non-genomic mechanisms. As used herein, a "gap junction" generally refers to a specialized type of intercellular transmembrane protein channel that allows the direct exchange of small molecules (typically with a molecular mass not exceeding about 1.2 kDa) between adjacent cells. Gap junctions are comprised of two hemichannels (commonly referred to in the art as "connexons"), one of each of which spans the apposing membrane of adjacent cells, and that associate to form a unitary intercellular channel. Connexons, in turn, are formed by the oligomerization of at least six protein subunits, termed connexins (Cx). Connexons allow for the electrical coupling of adjacent cells, such as, for example, cardiomyocytes. Additionally, small molecules and ions such as, for example, water, salts, small organic or inorganic ions, mono- and oligosaccharides, amino acids, oligopeptides, nucleotides, and some second messenger molecules (e.g., calcium, cAMP, inositol triphosphate, and the like), or other small molecule signaling mediators can diffuse from the cytoplasm of one cell to that of an adjacent cell through the roughly 1.2 run wide pore traversing the channel. Macromolecules, such as polypeptides, complex lipids, and polysaccharides and polynucleotides are typically too large to pass through gap junctions and are retained in the cytosol. The exchange of molecules between substantially adjacent cells via gap junctions is generally referred to herein as "gap junctional intercellular communication" (GJIC). A major biological role of GJIC is the maintenance of tissue homeostasis and proliferation, the regulation of embryonic development and differentiation, and electric coupling of electrically excitable cells such as cardiomyocytes. Recently, it has been recognized that intracellular and intercellular signaling via and through gap junctions and their component connexins plays a major role in the regulation of cell division. GJIC may be regulated at several levels, including transcription and translation of connexin genes and mRNA, regulating the processing and stability of connexin mRNA, post-translational modification of connexins, connexon assembly, trafficking, and docking, gating of the gap junction channel, and regulation of the configuration of connexons in an "open" or "closed" configuration.
As used herein, the term "connexin" generally refers to a group of homologous proteins that form the intermembrane channels of gap junctions. Connexins are the major structural and functional proteins of the connexon and gap junctions. Connexin 43 (Cx43), a 43 kDa protein translated from the GLAl gene transcript, plays an important role in regulating gap junction function. Carboxy-terminal hyperphosphorylation of Cx43 is correlated with incorporation of the protein into functional gap junctions. Reduced cellular expression of certain connexin proteins is correlated with loss of growth inhibitory control and increased malignant potential or neoplastic cells. As used herein, the term "lipoxygenase" or "LO" generally refers to a class of enzymes that catalyze the oxidative conversion of arachidonic acid to the hydroxyeicosetrinoic acid (HETE) structure in the synthesis of leukotrienes. The term "5-lipoxygenase", or "5-LO" generally refers to one member of this class of enzymes that has lipoxygenase and dehydrase activity, and that catalyzes the conversion of arachidonic acid to 5- hydroperoxyeicatetraenoic acid (HPETE). 5-HPETE can then be converted to 5-HETE and/or various leukotrienes
(e.g., leukotriene A4 (LTA4)) that can cause inflammation and asthmatic constriction of the bronchioles in one important pathological human setting. Leukotrienes participate in numerous physiological processes, which may include host defense reactions and pathophysiological conditions such as immediate hypersensitivity and inflammation. Leukotrienes may have potent actions on many essential organs and systems, which may include the cardiovascular, pulmonary, and central nervous system as well as the gastrointestinal tract and the immune system. 5-LO requires the presence of the membrane protein 5-Lipoxygenase-activating protein (FLAP, also known as arachidonate 5-lipoxygenase-activating protein, arachidonate 5-lipoxygenase activating protein, and ALOX5AP). FLAP binds arachidonate, facilitating its interaction with the 5-LO. 5-LO, FLAP, and Phospholipase A2 (which catalyzes release of arachidonate from phospholipids) form a complex in association with the nuclear envelope during leukotriene synthesis in leukocytes. The activity of 5-LO may be reduced or inhibited in cells by contacting the cell with one or more 5-LO inhibitors. The term "5-lipoxygenase inhibitor" or "5-LO inhibitor" includes any agent or compound that inhibits, restrains, retards or otherwise interacts with the enzymatic action of 5- lipoxygenase, such as, but not limited to, zileuton, docebenone, piripost, and the like. The activity of 5-LO may also be reduced or inhibited in cells by contacting the cell with a FLAP inhibitor. The term "5-lipoxygenase activating protein inhibitor" or "FLAP inhibitor" includes any agent or compound that inhibits, restrains, retards or otherwise interacts with the action or activity of 5-lipoxygenase activating protein including but not limited to the association thereof with 5-LO. Exemplary FLAP inhibitors include the agents MK-591 and MK-886. It is within the skill level of a practioner having ordinary skill in the art to recognize FLAP inhibitors.
The term "apoptosis," as used herein, generally refers to a morphologically distinct form of programmed cell death that is important in the normal development and maintenance of multicellular organisms. Dysregulation of apoptosis can take the form of inappropriate suppression of cell death, as occurs in the development of cancers, or in a failure to control the extent of cell death, as is believed to occur in acquired immunodeficiency and certain neurodegenerative disorders. Apoptosis is an active process in which cells induce their self-destruction in response to specific cell death signals or in the absence of cell survival signals. It is distinct from necrosis, which is cell death occurring as a result of severe injurious changes in the environment. Apoptosis of a cell can be characterized at least by the rapid condensation of the cell with collapse of the nucleus but preservation of membranes; or, cleavage of nuclear DNA at the linker regions between nucleosomes to produce fragments which can be easily visualized by agarose gel electrophoresis as a characteristic ladder pattern. Cells undergoing apoptosis exhibit a characteristic series of morphological changes including mitochondrial membrane swelling and rupture, leakage of cytosolic contents into the surrounding area, and inflammation in tissues. The pattern of events occurring during apoptosis is orderly and includes; cell shrinkage; appearance of bubble-like blebs on their surface; degradation of chromatin (DNA and protein) in their nucleus; mitochondrial rupture and release of cytochrome c into the cytosol; breakage of the cell into small, membrane-wrapped, fragments (commonly referred to as "apoptotic bodies" or "corpses"); exposure of phosphatidylserine on the outer leaflet of the cell membrane; and recruitment of phagocytic cells like macrophages and dendritic cells which then engulf the cell fragments.
Various pathologies occur due to a defective or aberrant regulation of apoptosis in the affected cells of an organism. For example, defects that result in a decreased level of apoptosis in a tissue as compared to the normal level required to maintain the steady-state of the tissue can promote an abnormal increase of the amount of cells in a tissue. This has been observed in various cancers, where the formation of tumors occurs because the cells are not dying at their normal rate.
As used herein, terms such as "pharmaceutical composition," "pharmaceutical formulation," "pharmaceutical preparation," or the like, generally refer to formulations that are adapted to deliver a prescribed dosage of one or more pharmacologically active compounds to a cell, a group of cells, an organ or tissue, an animal or a human. The determination of an appropriate prescribed dosage of a pharmacologically active compound to include in a pharmaceutical composition in order to achieve a desired biological outcome is within the skill level of an ordinary practitioner of the art. Pharmaceutical preparations may be prepared as solids, semi-solids, gels, hydrogels, liquids, solutions, suspensions, emulsions, aerosols, powders, or combinations thereof. Included in a pharmaceutical preparation may be one or more carriers, preservatives, flavorings, excipients, coatings, stabilizers, binders, solvents and/or auxiliaries. Methods of incorporating pharmacologically active compounds into pharmaceutical preparations are widely known in the art.
As used herein, the term "organ", when used in reference to a part of the body of an animal or of a human generally refers to the collection of cells, tissues, connective tissues, fluids and structures that are part of a structure in an animal or a human that is capable of performing some specialized physiological function. Groups of organs constitute one or more specialized body systems. The specialized function performed by an organ is typically essential to the life or to the overall well-being of the animal or human. Non-limiting examples of body organs include the heart, lungs, kidney, ureter, urinary bladder, adrenal glands, pituitary gland, skin, prostate, uterus, reproductive organs (e.g., genitalia and accessory organs), liver, gall-bladder, brain, spinal cord, stomach, intestine, appendix, pancreas, lymph nodes, breast, salivary glands, lacrimal glands, eyes, spleen, thymus, bone marrow. Non-limiting examples of body systems include the respiratory, circulatory, cardiovascular, lymphatic, immune, musculoskeletal, nervous, digestive, endocrine, exocrine, hepato-biliary, reproductive, and urinary systems. In animals, the organs are generally made up of several tissues, one of which usually predominates, and determines the principal function of the organ.
As used herein, the term "tissue", when used in reference to a part of a body or of an organ, generally refers to an aggregation or collection of morphologically similar cells and associated accessory and support cells and intercellular matter, including extracellular matrix material, vascular supply, and fluids, acting together to perform specific functions in the body. There are generally four basic types of tissue in animals and humans including muscle, nerve, epithelial, and connective tissues.
The terms "reducing," "inhibiting" and "ameliorating," as used herein, when used in the context of modulating a pathological or disease state, generally refers to the prevention and/or reduction of at least a portion of the negative consequences of the disease state. When used in the context of an adverse side effect associated with the administration of a drug to a subject, the term(s) generally refer to a net reduction in the severity or seriousness of said adverse side effects.
As used herein, the term "systemically," when used in the context of a physiological parameter, generally refers to a parameter that affects the entire body of a subject, or to a particular body system. As used herein the terms "administration," "administering," or the like, when used in the context of providing a pharmaceutical or nutraceutical composition to a subject generally refers to providing to the subject one or more pharmaceutical, "over-the-counter" (OTC) or nutraceutical compositions in combination with an appropriate delivery vehicle by any means such that the administered compound achieves one or more of the intended biological effects for which the compound was administered. By way of non-limiting example, a composition may be administered parenteral, subcutaneous, intravenous, intracoronary, rectal, intramuscular, intraperitoneal, transdermal, or buccal routes of delivery. Alternatively, or concurrently, administration may be by the
oral route. The dosage administered will be dependent upon the age, health, weight, and/or disease state of the recipient, kind of concurrent treatment, if any, frequency of treatment, and/or the nature of the effect desired. The dosage of pharmacologically active compound that is administered will be dependent upon multiple factors, such as the age, health, weight, and/or disease state of the recipient, concurrent treatments, if any, the frequency of treatment, and/or the nature and magnitude of the biological effect that is desired.
As used herein, the term "treat" generally refers to an action taken by a caregiver that involves substantially inhibiting, slowing or reversing the progression of a disease, disorder or condition, substantially ameliorating clinical symptoms of a disease disorder or condition, or substantially preventing the appearance of clinical symptoms of a disease, disorder or condition. As used herein, terms such as "pharmaceutical composition," "pharmaceutical formulation,"
"pharmaceutical preparation," or the like, generally refer to formulations that are adapted to deliver a prescribed dosage of one or more pharmacologically active compounds to a cell, a group of cells, an organ or tissue, an animal or a human. Methods of incorporating pharmacologically active compounds into pharmaceutical preparations are widely known in the art. The determination of an appropriate prescribed dosage of a pharmacologically active compound to include in a pharmaceutical composition in order to achieve a desired biological outcome is within the skill level of an ordinary practitioner of the art. A pharmaceutical composition may be provided as sustained-release or timed-release formulations. Such formulations may release a bolus of a compound from the formulation at a desired time, or may ensure a relatively constant amount of the compound present in the dosage is released over a given period of time. Terms such as "sustained release" or "timed release" and the like are widely used in the pharmaceutical arts and are readily understood by a practitioner of ordinary skill in the art. Pharmaceutical preparations may be prepared as solids, semi-solids, gels, hydrogels, liquids, solutions, suspensions, emulsions, aerosols, powders, or combinations thereof. Included in a pharmaceutical preparation may be one or more carriers, preservatives, flavorings, excipients, coatings, stabilizers, binders, solvents and/or auxiliaries that are, typically, pharmacologically inert. It will be readily appreciated by an ordinary practitioner of the art that, pharmaceutical compositions, formulations and preparations may include pharmaceutically acceptable salts of compounds. It will further be appreciated by an ordinary practitioner of the art that the term also encompasses those pharmaceutical compositions that contain an admixture of two or more pharmacologically active compounds, such compounds being administered, for example, as a combination therapy.
The teπn "pharmaceutically acceptable salts" includes salts prepared from by reacting pharmaceutically acceptable non-toxic bases or acids, including inorganic or organic bases, with inorganic or organic acids.
Pharmaceutically acceptable salts may include salts derived from inorganic bases include aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic salts, manganous, potassium, sodium, zinc, etc. Examples include the ammonium, calcium, magnesium, potassium, and sodium salts. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins, such as argmine, betaine, caffeine, choline, N,N'-dibenzylethylenediamine, diethylamine, 2- dibenzylethylenediamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N- ethyl-morpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, etc.
As used herein the terms "subject" generally refers to a mammal, and in particular to a human.
Terms such as "in need of treatment," "in need thereof," "benefit from such treatment," and the like, when used in the context of a subject being administered a pharmacologically active composition, generally refers to a judgment made by an appropriate healthcare provider that an individual or animal requires or will benefit from a specified treatment or medical intervention. Such judgments may be made based on a variety of factors that are in the realm of expertise of healthcare providers, but include knowledge that the individual or animal is ill, will be ill, or is at risk of becoming ill, as the result of a condition that may be ameliorated or treated with the specified medical intervention.
By "therapeutically effective amount" is meant an amount of a drug or pharmaceutical composition that will elicit at least one desired biological or physiological response of a cell, a tissue, a system, animal or human that is being sought by a researcher, veterinarian, physician or other caregiver.
By "prophylactically effective amount" is meant an amount of a pharmaceutical composition that will substantially prevent, delay or reduce the risk of occurrence of the biological or physiological event in a cell, a tissue, a system, animal or human that is being sought by a researcher, veterinarian, physician or other caregiver.
The term "pharmacologically inert," as used herein, generally refers to a compound, additive, binder, vehicle, and the like, that is substantially free of any pharmacologic or "drug-like" activity.
A "pharmaceutically or nutraceutically acceptable formulation," as used herein, generally refers to a nontoxic formulation containing a predetermined dosage of a pharmaceutical and/or nutraceutical composition, wherein the dosage of the pharmaceutical and/or nutraceutical composition is adequate to achieve a desired biological outcome. The meaning of the term may generally include an appropriate delivery vehicle that is suitable for properly delivering the pharmaceutical composition in order to achieve the desired biological outcome.
As used herein the term "antioxidant" may be generally defined as any of various substances (such as beta- carotene, vitamin C, and α-tocopherol) that inhibit oxidation or reactions promoted by Reactive Oxygen Species (ROS) and other radical and non-radical species.
As used herein the term "co-antioxidant" may be generally defined as an antioxidant that is used and that acts in combination with another antioxidant (e.g., two antioxidants that are chemically and/or functionally coupled, or two antioxidants that are combined and function with each another in a pharmaceutical preparation). The effects of co-antioxidants may be additive (i.e., the anti-oxidative potential of one or more anti-oxidants acting additively is approximately the sum of the oxidative potential of each component anti-oxidant) or synergistic (i.e., the anti- oxidative potential of one or more anti-oxidants acting synergistically may be greater than the sum of the oxidative potential of each component anti-oxidant).
The terms "Rn" in a chemical formula refer to hydrogen or a functional group, each independently selected, unless stated otherwise. In some embodiments the functional group may be an organic group. In some embodiments the functional group may be an alkyl group. In some embodiments, the functional group may be a hydrophobic or hydrophilic group. Compounds described herein embrace isomers mixtures, racemic, optically active, and optically inactive stereoisomers and compounds.
Inhibition of neoplastic transformation by carotenoid analogs or derivatives
Recent studies have demonstrated the utility for modulating cell growth and inhibition of neoplastic transformation of increasing connexin protein expression and GJIC to normal or near-normal levels. In an embodiment, astaxanthin-, lycophyll-, lutein- and zeaxanthin-based supplementation may be used in the therapeutic
treatment of proliferative disorders involving dysregulated cell growth and/or neoplastic transformation of cells. The potential utility of these formulations, as well as other carotenoid-based formulations, may be extended for clinical application by providing compounds with sufficient dispersibility in aqueous delivery vehicles so that therapeutic doses of the compounds may be delivered to a subject. Adequate aqueous dispersibility may allow for parenteral administration of carotenoid analogs or derivatives. Parenteral administration may allow for better treating the significant human population of carotenoid oral non-responders as well as acute clinical application(s) requiring rapid loading of therapeutic doses.
In a first set of non-limiting embodiments, methods are provided to increase Cx43 expression in neoplastic cells. Increased expression of Cx43 may be accomplished by contacting a transformed cell or group of cells with a pharmaceutically acceptable composition containing an effective amount of one or more carotenoid analogs or derivatives. In certain embodiments, the carotenoid analog or derivative is an analog or derivative of a xanthophyll carotenoid. In certain embodiments, the carotenoid analog or derivative is an analog or derivative of lycophyll. By way of a non-limiting embodiment, lycophyll analogs or derivatives that may be suited to at least some of the therapeutic applications comtemplated herein may include an analog or derivative of a lycophyll diphosphate. In certain embodiments, the carotenoid analog or derivative is an analog or derivative of astaxanthin. In other embodiments, the carotenoid analog or derivative is an analog or derivative of astaxanthin. By way of a further non- limiting embodiment, astaxanthin analogs or derivatives that maybe suited to at least some of the therapeutic applications comtemplated herein may include an analog or derivative of an astaxanthin diphosphate. In certain embodiments, the carotenoid analog or derivative is a salt of an analog or derivative of astaxanthin. Without being bound by any particular theory of mechanism of action, it is believed that the restoration or maintenance of growth inhibitory mechanisms may result, at least in part, from a restoration of physiologically normal amounts of one or more connexin proteins, such as, for example, connexin 43. As used herein, the term "physiologically normal amounts of a reference protein, when used in the context of a transformed cell, generally refers to the level of the reference protein that is typically expressed in a non-transformed, or normal, cell of the same lineage as the transformed cell. Restoration of growth inhibitory mechanisms in neoplastic cells may further result from the reestablishment of GJIC between adjacent or substantially adjacent cells. The direct superoxide anion scavenging ability of the carotenoid analogs and derivatives described herein may provide further advantageous health benefits.
The carotenoid analogs or derivatives may be advantageously administered to increase Cx43 expression in a subject in whom a beneficial therapeutic or prophylactic effect can be achieved thereby, i.e., a subject in need of treatment for a proliferative disorder. A "subject" is a mammal, preferably a human or an animal in need of veterinary treatment, e.g., companion animals (e.g., dogs, cats, and the like), farm animals (e.g., cows, sheep, pigs, horses, and the like), and laboratory animals (e.g., rats, mice, guinea pigs, and the like).
Certain carotenoid analogs or derivatives are particularly useful in therapeutic applications relating to a disorder characterized by increased cellular proliferation resulting from reduced or inhibited GJIC. As used herein, the term "GJIC-mediated disorder" includes any disorder, disease or condition whose etiology is due, at least in part, to reduced Cx43 expression or activity, or a reduction in the number of functional gap juntions. The term "GJIC-mediated disorder" also includes any disorder, disease or condition in winch increased Cx43 expression and GJIC is beneficial. Increased Cx43 expression and GJIC resulting from the administration of carotenoid analogs or derivatives may also be used to achieve a beneficial therapeutic or prophylactic effect, for example, in subjects with a
proliferative disorder. Non-limiting examples of proliferative disorders include chronic inflammatory proliferative disorders, e.g., psoriasis and rheumatoid arthritis; proliferative ocular disorders, e.g., diabetic retinopathy; benign proliferative disorders, e.g., hemangiomas; and cancer. Non-limiting examples of solid tumors that can be treated with the disclosed carotenoid analogs or derivatives include pancreatic cancer; bladder cancer; colorectal cancer; breast cancer, including metastatic breast cancer; prostate cancer, including androgen-dependent and androgen- independent prostate cancer; renal cancer, including, e.g., metastatic renal cell carcinoma; hepatocellular cancer; lung cancer, including, e.g., non-small cell lung cancer (NSCLC), bronchioloalveolar carcinoma (BAC), and adenocarcinoma of the lung; ovarian cancer, including, e.g., progressive epithelial or primary peritoneal cancer; cervical cancer; gastric cancer; esophageal cancer; head and neck cancer, including, e.g., squamous cell carcinoma of the head and neck; melanoma; neuroendocrine cancer, including metastatic neuroendocrine tumors; brain tumors, including, e.g., glioma, anaplastic oligodendroglioma, adult glioblastoma multiforme, and adult anaplastic astrocytoma; bone cancer; and soft tissue sarcoma.
The disclosed carotenoid analogs or derivatives and treatment methods may be particularly suited to the treatment of cancers or cell types in which Cx43 expression and/or GJIC activity is downregulated, including, without limitation, rapidly proliferating cells and drug-resistant cells, as well as retinoblastomas such as Rb negative or inactivated cells. Induction of apoptosls in neoplastic cells by administration of carotenoid analogs or derivatives
It has recently been found that the subject carotenoid analogs and derivatives can function in certain cells as inhibitors of 5-Liρoxygenase. Biochemical analyses indicate that the subject carotenoid analogs and derivatives bind to 5-LO (see for example, U.S. Patent Appl. Publ. No. 2005/0261254 by Lockwood et al., incorporated herein in its entirety). It is known in the art that administering 5-LO inhibitors to certain cancer cells results in induction of apoptosis in a significant proportion of the transformed cells. For example, as discussed above, Ghosh et al. demonstrated that prostate cancer cells treated with the specific 5-LO inhibitor MK-866 underwent massive apoptosis. To determine whether the subject carotenoid analogs and derivatives can induce apoptosis in cancer cells,
LNCaP human prostate cancer cells were contacted with an effective amount of various carotenoids and xanthophyll carotenoids (over a 2 log concentration range). Induction of apoptosis was measured by flow cytometric and cell cycle analysis of DNA content in propidium iodide-stains cells. Apoptotic cells were identified as those having sub-Gl amounts of DNA (corresponding to apoptotic bodies). The results of these studies are disclosed below and presented in FIGs 15-20.
Thus, it appears that, in addition to the role of the the subject carotenoid analogs and derivatives in inhibiting the growth of neoplastic cells by enhancing gap junction formation and GJIC, an additional level of cancer treatment may be achieved in certain embodiments, by contacting neoplastic cells with an amount of a composition containing one or more of the subject carotenoid analogs or derivatives sufficient to inhibit 5-LO function and/or induce apoptosis.
Treatment of proliferative disorders with compositions containing carotenoid analogs or derivatives
In some embodiments, the disclosed carotenoid analogs or derivatives and treatment methods may be used as the sole therapeutic regimen or in conjunction with other therapeutic agents, including anticancer agents. As used herein, the term "anticancer agent" refers to any agent that is administered to a subject with cancer for purposes of treating the cancer. Use of the subject carotenoid analogs or derivatives and methods for the treatment of cancer maybe particularly advantageous and may enhance the effectiveness of the anticancer agent when combined with
radiation therapy or chemotherapeutic agents that act by causing damage to the genetic material of cells (collectively referred to herein as "DNA damaging agents"); when combined with agents which are otherwise cytotoxic to cancer cells during cell division; when combined with agents which are proteasome inhibitors; when combined with agents which inhibit NF-κB (e.g., HCK inhibitors) (Bottero et al., Cancer Res., 61:7785 (2001)); or used with combinations of cancer drags with which are not cytotoxic when administered alone, yet in combination produce a toxic effect. Anti-cancer agents having having the properties described above are collectively referred to herein as "chemotherapy agents." In some non-limiting embodiments, carotenoid analogs or derivatives may be combined with one or more DNA damaging agent and treatment methods.
Non-limiting examples of chemotherapeutic agents include topoisomerase I inhibitors (e.g., irinotecan, topotecan, camptothecin and analogs or metabolites thereof, and doxorubicin); topoisomerase II inhibitors (e.g., etoposide, teniposide, and daunorubicin); alkylating agents (e.g., melphalan, chlorambucil, busulfan, thiotepa, ifosfamide, caπnustine, lomustine, semustine, streptozocin, decarbazine, methotrexate, mitomycin C, and cyclophosphamide); DNA intercalators (e.g., cisplatin, oxaliplatin, and carboplatin); DNA intercalators and free radical generators such as bleomycin; and nucleoside mimetics (e.g., 5-fluorouracil, capecitibine, gemcitabine, fludarabine, cytarabine, mercaptopurine, thioguanine, pentostatin, and hydroxyurea).
Chemotherapy agents that disrupt cell replication include: paclitaxel, docetaxel, and related analogs; vincristine, vinblastin, and related analogs; thalidomide and related analogs (e.g., CC-5013 and CC-4047); protein tyrosine kinase inhibitors (e.g., imatinib mesylate and gefitinib); antibodies which bind to proteins overexpressed in cancers and thereby downregulate cell replication (e.g., trastuzumab, rituximab, cetuximab, and bevacizumab); and other inhibitors of proteins or enzymes known to be upregulated, over-expressed or activated in cancers, the inhibition of which downregulates cell replication.
The disclosed carotenoid analogs or derivatives and treatment methods are also effective when used in combination with chemotherapy agents and/or radiation therapy to treat subjects with multi-drug resistant cancers. A cancer is resistant to a drug when it resumes a normal rate of tumor growth while undergoing treatment with the drug after the tumor had initially responded to the drug. A tumor "responds to a drag" when it exhibits a decrease in tumor mass or a decrease in the rate of tumor growth. The term "multi-drag resistant cancer" refers to cancer that is resistant to two or more drags, often as many as five or more.
As such, an "effective amount" of the a carotenoid analog or derivative suitable for the treatment methods described herein is the quantity which increases Cx43 expression and/or induced apoptosis of neoplastic cells when administered to a subject or which, when administered to a subject with cancer, slows rumor growth, ameliorates the symptoms of the disease and/or increases longevity. When used in combination with a chemotherapy agent, an effective amount of the carotenoid analog or derivative is the quantity at which a greater response is achieved when the carotenoid analog or derivative is co-administered with the chemotherapy agents and/or radiation therapy than is achieved when the chemotherapy agent and/or radiation therapy is administered alone. When used as a combination therapy, an "effective amount" of the chemotherapy agents is administered to the subject, which is a quantity that normally produces an anti-cancer effect.
A disclosed carotenoid analog or derivative may be co-administered with another therapeutic chemotheraeutic agent (e.g., DNA-damaging agent, agent that disrupts cell replication, proteasome inhibitor, NF-IdB inhibitor, or other anticancer agent) as part of the same pharmaceutical composition or, alternatively, as separate pharmaceutical compositions. When administered separately, carotenoid analog or derivative may be administered
prior to, at the same time as, or following administration of the other agent, provided that the enhancing effect on Cx43 expression of the carotenoid analog or derivative is retained.
The amount of carotenoid analog or derivative anti-cancer drag and radiation dose administered to the subject -will depend on the type and severity of the disease or condition and on the characteristics of the subject, such as general health, age, sex, body weight and tolerance to drags. The skilled artisan will be able to determine appropriate dosages depending on these and other factors. Effective dosages for commonly used chemotherapy agents and radiation therapy are well known to the practitioner having ordinary skill in the art.
The carotenoid analog or derivative and treatment methods described herein, and the pharmaceutically acceptable salts, solvates and hydrates thereof may be used in pharmaceutical preparations in combination with a pharmaceutically acceptable carrier or diluent. Suitable pharmaceutically acceptable carriers include inert solid fillers or diluents and sterile aqueous or organic solutions. The carotenoid analog or derivative will typically be present in such pharmaceutical compositions in amounts sufficient to provide the desired dosage amount in the range described herein. Techniques for formulation and administration of the compounds of the instant invention can be found in Remington: the Science and Practice of Pharmacy, 19th edition, Mack Publishing Co., Easton, Pa. (1995).
In some embodiments, carotenoid analogs or derivatives may be employed in "self-formulating" aqueous solutions, in which the compounds spontaneously self-assemble into macromolecular complexes. These complexes may provide stable formulations in terms of shelf-life. The same formulations may be parenterally administered, upon which the spontaneous self-assembly is overcome by interactions with serum and/or tissue components in vivo.
Some specific embodiments may include phosphate derivatives, succinate derivatives, co-antioxidant derivatives (e.g., Vitamin C, Vitamin C analogs, Vitamin C derivatives, Vitamin E, Vitamin E analogs, Vitamin E derivatives, flavonoids, flavonoid analogs, or flavonoid derivatives), or combinations thereof derivatives or analogs of carotenoids. Flavonoids may include, for example, quercetin, xanthohumol, isoxanthohumol, or genistein. Derivatives or analogs may be derived from any known carotenoid (naturally or synthetically derived). Specific examples of naturally occurring carotenoids which compounds described herein may be derived from include for example zeaxanthin, lutein, lycophyll, astaxanthin, and lycopene.
In some embodiments, one or more co-antioxidants may be coupled to a carotenoid or carotenoid derivative or analog. The synthesis of water-soluble and/or water-dispersible carotenoids (e.g., C40) analogs or derivatives — as potential parenteral agents for clinical applications may improve the injectability of these compounds as therapeutic agents, a result perhaps not achievable through other formulation methods. The methodology may be extended to carotenoids with fewer than 40 carbon atoms in the molecular skeleton and differing ionic character. The methodology may be extended to carotenoids with greater than 40 carbon atoms in the molecular skeleton. The methodology may be extended to non-symmetric carotenoids. The aqueous dispersibility of these compounds allows proof-of-conceρt studies in model systems (e.g. cell culture), where the high lipophilicity of these compounds previously limited their biovailability and hence proper evaluation of efficacy. Esterification or etherification may be useful to increase oral bioavailabilty, a fortuitous side effect of the esterification process which can increase solubility in gastric mixed micelles. The net overall effect is an improvement in potential clinical utility for the lipophilic carotenoid compounds as therapeutic agents.
In some embodiments, the principles of retrometabolic drug design may be utilized to produce novel soft drugs from the asymmetric parent carotenoid scaffold (e.g., RRR-hxteia (β,ε-carotene-3,3'-diol)). For example, lutein scaffold for derivativization was obtained commercially as purified natural plant source material, and was primarily the ΛRR-stereoisomer (one of 8 potential stereoisomers). Lutein (Scheme 1) possesses key characteristics — similar to starting material astaxanthin — which make it an ideal starting platform for retrometabolic syntheses: (1) synthetic handles (hydroxyl groups) for conjugation, and (2) an excellent safety profile for the parent compound. As stated above, lutein is available commercially from multiple sources in bulk as primarily the iϊ/LR-stereoisomer, the primary isomer in the human diet and human retinal tissue.
In some embodiments, carotenoid analogs or derivatives may have increased water solubility and/or water dispersibility relative to some or all known naturally occurring carotenoids. Contradictory to previous research, improved results are obtained with derivatized carotenoids relative to the base carotenoid, wherein the base carotenoid is derivatized with substituents including hydrophilic substituents and/or co-antioxidants.
In some embodiments, the carotenoid derivatives may include compounds having a structure including a polyene chain (i.e., backbone of the molecule). The polyene chain may include between about 5 and about 15 unsaturated bonds. In certain embodiments, the polyene chain may include between about 7 and about 12 unsaturated bonds. In some embodiments a carotenoid derivative may include 7 or more conjugated double bonds to achieve acceptable antioxidant properties.
In some embodiments, decreased antioxidant properties associated with shorter polyene chains may be overcome by increasing the dosage administered to a subject or patient. In some embodiments, a chemical compound including a carotenoid derivative or analog may have the general structure (126):
Each R11 may be independently hydrogen or methyl. R9 and R10 may be independently H, an acyclic alkene with one or more substituents, or a cyclic ring including one or more substituents. y may be 5 to 12. In some embodiments, y may be 3 to 15. In certain embodiments, the maximum value of y may only be limited by the ultimate size of the chemical compound, particularly as it relates to the size of the chemical compound and the potential interference with the chemical compound's biological availability as discussed herein. In some embodiments, substituents may be at least partially hydrophilic. These carotenoid derivatives may be included in a pharmaceutical composition.
In some embodiments, the carotenoid derivatives may include compounds having the structure (128):
Each R11 may be independently hydrogen, methyl, alkyl, alkenyl, or aromatic substituents. R9 and R10 may be independently H, an acyclic alkene with at least one substituent, or a cyclic ring with at least one substituent having general structure (130):
where n may be between 4 to 10 carbon atoms. W is titte substituent.
In some embodiments, each cyclic ring may be independently two or more rings fused together to form a fused ring system (e.g., a bi-cyclic system). Each ring of the fused ring system may independently contain one or more degrees of unsaturation. Each ring of the fused ring system may be independently aromatic. Two or more of the rings forming the fused ring system may form an aromatic system.
In some embodiments, a chemical composition may include a carotenoid derivative having the structure
Each R3 may be independently hydrogen or methyl. R1 and R2 may be a cyclic ring including at least one substituent. Each cyclic ring may be independently:
W is the substituent. In some embodiments R1 and R2 may be an acyclic group including at least one substituent. Each acyclic maybe:
In some embodiments, a chemical composition may include a carotenoid derivative having the structure
R and R may be a cyclic ring including at least one substituent. Each cyclic ring may be independently:
where W is the substituent. In some embodiments R1 and R2 may be an acyclic group including at least one substituent. Each acyclic group may be:
In some embodiments, a method of treating a proliferative disorder may include administering to the subject an effective amount of a pharmaceutically acceptable formulation including a synthetic analog or derivative of a carotenoid. The synthetic analog or derivative of the carotenoid may have the structure
At least one substituent W may independently include OO
co-antioxidant. Each R' may be CH2. n may range from 1 to 9. Each R may be independently H, alkyl, aryl, benzyl, alkali metal, or a co- antioxidant. Each co-antioxidant may be independently Vitamin C, Vitamin C analogs, Vitamin C derivatives, Vitamin E, Vitamin E analogs, Vitamin E derivatives, flavonoids, fiavonoid analogs, or flavonoid derivatives. Flavonoids may include, for example, quercetin, xanthohumol, isoxanthohumol, or genistein.
Vitamin E may generally be divided into two categories including tocopherols having a general structure
is used to designate when R1 = R2 = CH3. 2?etø-tocopherol is used to designate when R1 = CH3 and R2 = H. Gαmrøα-tocopherol is used to designate when R1 = H and R2 = CH3. De/to-tocopherol is used to designate when R1 = R2 = H.
The second category of Vitamin E may include tocotrienols having a general structure
Alpha- tocotrienol is used to designate when R1 = R2 = CH3. Beta- tocotrienol is used to designate when R1 = CH3 and R2 = H. Gamma- tocotrienol is used to designate when R1 = H and R2 = CH3. Delta- tocotrienol is used to designate when R1 = R2 = H.
In some embodiments, the carotenoid analog or derivative may have the structure
Each R may be independently H, alkyl, aryl, benzyl, alkali metal, or a co-antioxidant. Each co-antioxidant may be independently Vitamin C, Vitamin C analogs, Vitamin C derivatives, Vitamin E, Vitamin E analogs, Vitamin E derivatives, flavonoids, flavonoid analogs, or flavonoid derivatives. Flavonoids may include, for example, quercetin, xanthohumol, isoxanthohumol, or genistein.
In some embodiments, the carotenoid analog or derivative may have the structure
Each R may be independently H, alkyl, aryl, benzyl, alkali metal (e.g., sodium), or a co-antioxidant. Each co- antioxidant may be independently Vitamin C, Vitamin C analogs, Vitamin C derivatives, Vitamin E, Vitamin E analogs, Vitamin E derivatives, flavonoids, flavonoid analogs, or flavonoid derivatives. Flavonoids may include, for example, quercetin, xanthohumol, isoxanthohumol, or genistein. When R includes Vitamin C, Vitamin C analogs, or Vitamin C derivatives, some embodiments may include carotenoid analogs or derivatives having the structure
Each R may be independently H, alkyl, aryl, benzyl, or alkali metal.
In some embodiments, a chemical compound including a carotenoid derivative may have the general structure (132):
Each Rπ may be independently hydrogen or methyl. Each R14 may be independently O or H2. Each R may be independently OR12 or R12. Each R12 may be independently -alkyl-NRI3 3 +, -aromatic-N R13 3 +, -alkyl-CO2 ~, - aromatic-CO2 ", -amino acid-NH3 +, -phosphorylated amino acid-NH3 +, polyethylene glycol, dextran, H, alkyl, co- antioxidant (e.g. Vitamin C, Vitamin C analogs, Vitamin C derivatives, Vitamin E, Vitamin E analogs, Vitamin E derivatives, flavonoids, flavonoid analogs, or flavonoid derivatives), or aryl. Each R13 may be independently H,
alkyl, or aryl. z may range from 5 to 12. In some embodiments, z may range from about 3 to about 15. In certain embodiments, the maximum value of z may only be limited by the ultimate size of the chemical compound, particularly as it relates to the size of the chemical compound and the potential interference with the chemical compound's biological availability as discussed herein. In some embodiments, substituents may be at least partially hydrophilic. These carotenoid derivatives may be used in a pharmaceutical composition.
In some embodiments, a chemical compound including a carotenoid derivative may have the general structure (134):
Each R11 may be independently hydrogen or methyl. Each R14 may be independently O or H2. Each X may be
CO2 ", -amino acid-NH3 +, -phosphorylated amino acid-NH3 +, polyethylene glycol, dextran, alkyl, alkali metal, co- antioxidant (e.g. Vitamin C, Vitamin C analogs, Vitamin C derivatives, Vitamin E, Vitamin E analogs, Vitamin E derivatives, flavonoids, flavonoid analogs, or flavonoid derivatives), or aryl. Each R12 is independently -alkyl-N R1V, -aromatic-N R1V, -alkyl-CO2 ", -aromatic-CO2 ", -amino acid-NH3 +, -phosphorylated amino acid-NH3 +, polyethylene glycol, dextran, H, alkyl, aryl, benzyl, alkali metal, co-antioxidant (e.g. Vitamin C, Vitamin C analogs, Vitamin C derivatives, Vitamin E, Vitamin E analogs, Vitamin E derivatives, flavonoids, flavonoid analogs, or flavonoid derivatives), or alkali salt. Each R13 may be independently H, alkyl, or aryl. z may range from 5 to 12. In some embodiments, z may range from about 3 to about 15. In certain embodiments, the maximum value of z may only be limited by the ultimate size of the chemical compound, particularly as it relates to the size of the chemical compound and the potential interference with the chemical compound's biological availability as discussed herein. In some embodiments, substituents may be at least partially hydrophilic. These carotenoid derivatives may be used in a pharmaceutical composition. In some non-limiting examples, five- and/or six-membered ring carotenoid derivatives may be more easily synthesized. Synthesis may come more easily due to, for example, the natural stability of five- and six- membered rings. Synthesis of carotenoid derivatives including five- and/or six-membered rings may be more easily synthesized due to, for example, the availability of naturally-occurring carotenoids including five- and/or six-membered rings. In some embodiments, five-membered rings may decrease steric hindrance associated with rotation of the cyclic ring around the molecular bond connecting the cyclic ring to the polyene chain. Reducing steric hindrance may allow greater overlap of any π oribitals within a cyclic ring with the polyene chain, thereby increasing the degree of conjugation and effective chromophore length of the molecule. This may have the salutatory effect of increasing antioxidant capacity of the carotenoid derivatives.
In some embodiments, a substituent (W) may be at least partially hydrophilic. A hydrophilic substituent may assist in increasing the water solubility of a carotenoid derivative. In some embodiments, a carotenoid derivative may be at least partially water-soluble. The cyclic ring may include at least one chiral center. The
acyclic alkene may include at least one chiral center. The cyclic ring may include at least one degree of unsaturation. In some cyclic ring embodiments, the cyclic ring may be aromatic. One or more degrees of unsaturation within the ring may assist in extending the conjugation of the carotenoid derivative. Extending conjugation within the carotenoid derivative may have the salutatory effect of increasing the antioxidant properties of the carotenoid derivatives. In some embodiments, the substituent W may include, for example, a carboxylic acid, an amino acid, an ester, an alkanol, an amine, a phosphate, a succinate, a glycinate, an ether, a glucoside, a sugar, or a carboxylate salt.
In some embodiments, each substituent — W may independently include -XR. Each X may independently include O, N, or S. In some embodiments, each substituent -W may independently comprises amino acids, esters, carbamates, amides, carbonates, alcohol, phosphates, or sulfonates. In some substituent embodiments, the substituent may include, for example (d) through (uu):
where each R is, for example, independently -alkyl-N R1V, -aromatic-N R1V, -allcyl-CO2 ", -aromatic-C02 ", -amino acid-NH3 +, -phosphorylated amino acid-NH3 +, polyethylene glycol, dextran, H, alkyl, alkali metal, co-antioxidant (e.g. Vitamin C, Vitamin C analogs, Vitamin C derivatives, Vitamin E, Vitamin E analogs, Vitamin E derivatives, flavonoids, flavonoid analogs, or flavonoid derivatives), or aryl. Each R' may be CH2. n may range from 1 to 9. In some embodiments, substituents may include any combination of (d) through (uu). In some embodiments, negatively charged substituents may include alkali metals, one metal or a combination of different alkali metals in an embodiment with more than one negatively charged substituent, as counter ions. Alkali metals may include, but are not limited to, sodium, potassium, and/or lithium.
Water-soluble carotenoid analogs or derivatives may have a water solubility of greater than about 1 mg/mL in some embodiments. In certain embodiments, water-soluble carotenoid analogs or derivatives may have a water solubility of greater than about 5 mg/mL. In certain embodiments, water-soluble carotenoid analogs or derivatives may have a water solubility of greater than about 10 mg/mL. In some embodiments, water-soluble carotenoid analogs or derivatives may have a water solubility of greater than about 50 mg/mL.
Naturally occurring carotenoids such as xanthophyll carotenoids of the C40 series, which includes commercially important compounds such as lutein, zeaxanthin, and astaxantfain, have poor aqueous solubility in the native state. The aqueous solubility and/or dispersibility of derivatized carotenoids may be vastly increased by varying the chemical structure(s) of the esterified moieties.
In some embodiments, highly water-dispersible C40 carotenoid derivatives may 'include natural source RRR-hxteia (β,ε-carotene-3,3'-diol) derivatives. Derivatives may be synthesized by esterification with inorganic phosphate and succinic acid, respectively, and subsequently converted to the sodium salts. Deep orange, evenly- colored aqueous suspensions were obtained after addition of these derivatives to USP-purified water. Aqueous dispersibility of the disuccinate sodium salt of natural lutein was 2.85 mg/mL; the dipshosphate salt demonstrated a > 10-fold increase in dispersibility at 29.27 mg/mL. Aqueous suspensions may be obtained without the addition of heat, detergents, co-solvents, or other additives.
The direct aqueous superoxide scavenging abilities of these derivatives were subsequently evaluated by electron paramagnetic resonance (EPR) spectroscopy in a well-characterized in vitro isolated human neutrophil assay. The derivatives may be potent (millimolar concentration) and nearly identical aqueous-phase scavengers, demonstrating dose-dependent suppression of the superoxide anion signal (as detected by spin-trap adducts of DEPMPO) in the millimolar range. Evidence of card-pack aggregation was obtained for the disphosphate derivative with UV-Vis spectroscopy (discussed herein), whereas limited card-pack and/or head-to-tail aggregation was noted for the disuccinate derivative. These lutein-based soft drugs may find utility in those commercial and clinical applications for which aqueous-phase singlet oxygen quenching and direct radical scavenging may be required. The absolute size of a carotenoid derivative (in 3 dimensions) is important when considering its use in biological and/or medicinal applications. Some of the largest naturally-occurring carotenoids are no greater than about C50. This is probably due to size limits imposed on molecules requiring incorporation into and/or interaction with cellular membranes. Cellular membranes may be particularly co-evolved with molecules of a length of approximately 30 nm. In some embodiments, carotenoid derivatives may be greater than or less than about 30 nm in size. In certain embodiments, carotenoid derivatives may be able to change conformation and/or otherwise assume an appropriate shape which effectively enables the carotenoid derivative to efficiently interact with a cellular membrane.
Although the above structure, and subsequent structures, depict alkenes in the E configuration this should not be seen as limiting. Compounds discussed herein may include embodiments where alkenes are in the Z configuration or include alkenes in a combination of Z and E configurations within the same molecule. The compounds depicted herein may naturally convert between the Z and E configuration and/or exist in equilibrium between the two configurations.
In an embodiment, a chemical compound may include a carotenoid derivative having the structure (136)
Each R14 may be independently O or H2. Each R may be independently OR12 or R12. Each R12 may be independently -alkyl-NR13 3 +, -aromatic-NR13 3 +, -alkyl-CO2 ~, -aromatic-CO2 ", -amino acid-NH3 +, -phosphorylated amino acid-NH3 +, polyethylene glycol, dextran, H, alkyl, peptides, poly-lysine, co-antioxidant (e.g. Vitamin C, Vitamin C analogs, Vitamin C derivatives, Vitamin E, Vitamin E analogs, Vitamin E derivatives, flavonoids, flavonoid analogs, or flavonoid derivatives), or aryl. In addition, each R13 may be independently H, alkyl, or aryl. The carotenoid derivative may include at least one chiral center.
In a specific embodiment where R14 is O, the carotenoid derivative may have the structure (140)
(140).
In an embodiment, a chemical compound may include a carotenoid derivative having the structure (142)
Each R14 may be independently O or H2. Each R may be independently H, alkyl, benzyl, alkali metal, co- antioxidant, or aryl. The carotenoid derivative may include at least one chiral center. In a specific embodiment R14 may be H2, the carotenoid derivative having the structure (144)
In a specific embodiment where R14 is O, the carotenoid derivative may have the structure (146)
In an embodiment, a chemical compound may include a carotenoid derivative having the structure (148)
Each R14 may be independently O or H2. Each R' may be CH2. n may range from 1 to 9. Each X may be independently
analogs, Vitamin C derivatives, Vitamin E, Vitamin E analogs, Vitamin E derivatives, flavonoids, flavonoid analogs, or flavonoid derivatives). Each R may be independently -alkyl-NR12 3 +, -aromatic-NRI2 3 +, -alkyl-CO2\ - aromatic-CO2 ", -amino acid-NH3 +, -phosphorylated amino acid-NH3 +, polyethylene glycol, dextran, H, alkyl, alkali metal, benzyl, co-antioxidant (e.g. Vitamin C, Vitamin C analogs, Vitamin C derivatives, Vitamin E, Vitamin E analogs, Vitamin E derivatives, flavonoids, flavonoid analogs, or flavonoid derivatives), or aryl. Each R12 may be independently H, alkyl, or aryl. The carotenoid derivative may include at least one chiral center.
In a specific embodiment where R14 is H2, the carotenoid derivative may have the structure (150)
In an embodiment, a chemical compound may include a carotenoid derivative having the structure (148)
Each R14 may be independently O or H2. Each R' may be CH2. n may range from 1 to 9. Each X may be independently
Vitamin C analogs, Vitamin C derivatives, Vitamin E, Vitamin E analogs, Vitamin E derivatives, flavonoids, flavonoid analogs, or flavonoid derivatives). Each R may be independently -alkyl-N R12 3 +, -aromatic-N R12 3 + > -alkyl-CO2 ~, - aromatic-CO2 ", -amino acid-NH3 +, -phosphorylated amino acid-NH3 +, polyethylene glycol, dextran, H, alkyl, alkali
metal, co-antioxidant (e.g. Vitamin C, Vitamin C analogs, Vitamin C derivatives, Vitamin E, Vitamin E analogs, Vitamin E derivatives, flavonoids, flavonoid analogs, or flavonoid derivatives), or aryl. Each R12 may be independently H, alkyl, or aryl. The carotenoid derivative may include at least one chiral center.
In a specific embodiment where R14 is H2, the carotenoid derivative may have the structure (150)
In an embodiment, a chemical compound may include a carotenoid derivative having the structure (154)
Each R14 may be independently O or H2. The carotenoid derivative may include at least one chiral center. In a specific embodiment R14 may be H2, the carotenoid derivative having the structure (156)
In a specific embodiment where R14 is O, the carotenoid derivative may have the structure (158)
In some embodiments, a chemical compound may include a disuccinic acid ester carotenoid derivative having the structure (160)
In some embodiments, a chemical compound may include a disodium salt disuccinic acid ester carotenoid derivative having the structure (162)
In some embodiments, a chemical compound may include a carotenoid derivative with a co-antioxidant, in particular one or more analogs or derivatives of vitamin C (i.e., L ascorbic acid) coupled to a carotenoid. Some embodiments may include carboxylic acid and/or carboxylate derivatives of vitamin C coupled to a carotenoid (e.g., structure (164))
(164).
Carbohydr. Res. 1978, 60, 251-258 ,herein incorporated by reference, discloses oxidation at C-6 of ascorbic acid as depicted in EQN. 5.
Some embodiments may include vitamin C and/or vitamin C analogs or derivatives coupled to a carotenoid. Vitamin C may be coupled to the carotenoid via an ether linkage (e.g., structure (166))
(166).
Some embodiments may include vitamin C disuccinate analogs or derivatives coupled to a carotenoid (e.g., structure (168))
(168).
Some embodiments may include solutions or pharmaceutical preparations of carotenoids and/or carotenoid derivatives combined with co-antioxidants, in particular vitamin C and/or vitamin C analogs or derivatives. Pharmaceutical preparations may include about a 2:1 ratio of vitamin C to carotenoid respectively.
In some embodiments, co-antioxidants (e.g., vitamin C) may increase solubility of the chemical compound. In certain embodiments, co-antioxidants (e.g., vitamin C) may decrease toxicity associated with at least some carotenoid analogs or derivatives. In certain embodiments, co-antioxidants (e.g., vitamin C) may increase the potency of the chemical compound synergistically. Co-antioxidants may be coupled (e.g., a covalent bond) to the carotenoid derivative. Co-antioxidants may be included as a part of a pharmaceutically acceptable formulation.
In some embodiments, a carotenoid (e.g., astaxanthin) may be coupled to vitamin C forming an ether linkage. The ether linkage may be formed using the Mitsunobu reaction as in EQN. 1.
In some embodiments, vitamin C may be selectively esterified. Vitamin C may be selectively esterified at the C-3 position (e.g., EQN. 2). J. Org. Chem. 2000, 65, 911-913, herein incorporated by reference, discloses selective esterification at C-3 of unprotected ascorbic acid with primary alcohols.
R = Me, 77% Propyl, 63% Octyl, 72% ally], 72%
(2) benzyl, 64%
In some embodiments, a carotenoid may be coupled to vitamin C. Vitamin C may be coupled to the carotenoid at the C-6, C-5 diol position as depicted in EQNS. 3 and 4 forming an acetal.
In some embodiments, a carotenoid may be coupled to a water-soluble moiety (e.g., vitamin C) with a glyoxylate linker as depicted in EQN. 6. Tetrahedron 1989, 22, 6987-6998, herein incorporated by reference, discloses similar acetal formations.
HO. HθV OEtEt HΛTV? 5° a) AcCI Cl °'v IQ
HO OH HO OH b) SOCI2 AcO OAc
In some embodiments, a carotenoid may be coupled to a water-soluble moiety (e.g., vitamin C) with a glyoxylate linker as depicted in EQN. 7. J. Med. Chem. 1988, 31, 1363-1368, herein incorporated by reference, discloses the glyoxylic acid chloride.
In some embodiments, a carotenoid may be coupled to a water-soluble moiety (e.g., vitamin C) with a phosphate linker as depicted in EQN. 8. Carbohydr. Res. 1988, 176, 73-78, herein incorporated by reference, discloses the L-ascorbate 6-phosphate.
In some embodiments, a carotenoid may be coupled to a water-soluble moiety (e.g., vitamin C) with a phosphate linker as depicted in EQN. 9. Carbohydr. Res. 1979, 68, 313-319, herein incorporated by reference, discloses the 6-bromo derivative of vitamin C. Carbohydr. Res. 1988, 176, 73-78, herein incorporated by reference, discloses the 6-bromo derivative of vitamin Cs reaction with phosphates.
In some embodiments, a carotenoid may be coupled to a water-soluble moiety (e.g., vitamin C) with a phosphate linker as depicted in EQN. 10. J. Med Chem. 2001, 44, 1749-1757 and J. Med Chem. 2001, 44, 3710- 3720, herein incorporated by reference, disclose the allyl chloride derivative and its reaction with nucleophiles, including phosphates, under mild basic conditions.
In some embodiments, a carotenoid may be coupled to a water-soluble moiety (e.g., vitamin C) with a phosphate linker as depicted in EQN. 11. Vitamin C may be coupled to the carotenoid using selective esterification at C-3 of unprotected ascorbic acid with primary alcohols.
In some embodiments, a carotenoid may be coupled to a water-soluble moiety (e.g., vitamin C) with a phosphate linker as in 242. Structure 242 may include one or more counterions (e.g., alkali metals).
242
EQN. 12 depicts an example of a synthesis of a protected form of 242.
In some embodiments, a chemical compound may include a carotenoid derivative including one or more amino acids (e.g., lysine) and/or amino acid analogs or derivatives (e.g., lysine hydrochloric acid salt) coupled to a carotenoid (e.g., structure (170)).
(170).
In some embodiments, a carotenoid analog or derivative may include:
In some embodiments, a chemical compound may include a disuccinic acid ester carotenoid derivative having the structure (160)
In some embodiments, a chemical compound may include a disodium salt disuccinic acid ester carotenoid derivative having the structure (162)
In an embodiment, the carotenoid derivatives may be synthesized from naturally-occurring carotenoids. The carotenoids may include structures 2A-2E depicted in FIG. 1. In some embodiments, the carotenoid derivatives may be synthesized from any naturally-occurring carotenoid including one or more alcohol substituents. In other embodiments, the carotenoid derivatives may be synthesized from a derivative of a naturally-occurring carotenoid including one or more alcohol substituents. The synthesis may result in a single stereoisomer. The synthesis may result in a single geometric isomer of the carotenoid derivative. The synthesis/synthetic sequence may include any prior purification or isolation steps carried out on the parent carotenoid.
In some embodiments, a synthesis may be a total synthesis using methods described herein to synthesize carotenoid derivatives and/or analogs. An example may include, but is not limited to, a 3S,3'S all-E carotenoid
derivative, where the parent carotenoid is astaxanthin. The synthetic sequence may include protecting and subsequently deprotecting various functionalities of the carotenoid and/or substituent precursor. The alcohols may be deprotonated with a base. The deprotonated alcohol may be reacted with a substituent precursor with a good leaving group. The base may include any non-nucleophilic base known to one skilled in the art such as, for example, dimethylaminopyridine (DMAP). The deprotonated alcohol may act as a nucleophile reacting with the substituent precursor, displacing the leaving group. Leaving goups may include, but are not limited to, I, Cl, Br, tosyl, brosyl, mesyl, or trifyl. These are only a few examples of leaving groups that may be used, many more are known and would be apparent to one skilled in the art. In some embodiments, it may not even be necessary to deprotonate the alcohol, depending on the leaving group employed. In other examples the leaving group may be internal and may subsequently be included in the final structure of the carotenoid derivative, a non-limiting example may include anhydrides or strained cyclic ethers. For example, the deprotonated alcohol may be reacted with succinic anhydride. In an embodiment, the disuccinic acid ester of astaxanthin may be further converted to the disodium salt. Examples of synthetic sequences for the preparation of some of the specific embodiments depicted are described in the Examples section. The example depicted below is a generic non-limiting example of a synthetic sequence for the preparation of carotenoid derivatives.
In some embodiments, the total synthesis of naturally-occurring as well as synthetic carotenoids as starting scaffolds for carotenoid analogs or derivatives may be a method of generation of said carotenoid analogs or derivatives.
In some embodiments, one or more of the conversions and/or reactions discussed herein may be carried out ■within one reaction vessel increasing the overall efficiency of the synthesis of the final product. In some embodiments, a product of one reaction during a total synthesis may not be fully worked up before continuing on with the following reaction. In general fully working up a reaction implies completely isolating and purify the product from a reaction. A reaction may instead only partially be worked up. For example, solid impurities which fall out of solution during the course of a reaction may be filtered off and the filtrate washed with solvent to ensure all of the resulting product is washed through and collected. In such a case the resulting collected product still in solution may not be isolated, but may then be combined with another reagent and further transformed. In some cases multiple transformations may be carried out in a single reaction flask simply by adding reagents one at a time without working up intermediate products. These types of "shortcuts" will improve the overall efficiency of a synthesis, especially when dealing with large scale reactions (e.g., along the lines of pilot plant scale and/or plant scale).
The synthetic preparation of carotenoid derivatives or analogs such as disodium disuccinate astaxanthin 162 at multigram scale (e.g., 200 g to 1 kg) is necessary if one wishes to produce these molecules commercially. Synthetic modifications of carotenoids, with the goal of increasing aqueous solubility and/or dispersibility, have been sparingly reported in the literature. At the time process development began, surveys of the peer-reviewed and patent literature indicated that neither a synthetic sequence nor an efficient process for the synthesis of 160 or 162 had been reported. Therefore, the bench-scale synthetic sequence and later the scale-up to multigram scale were optimized to improve both the yield and purity of the desired compound. Examples of synthetic preparation of carotenoids and carotenoid derivatives or analogs are illustrated in U.S. Patent Application Serial No. 60/615,032 filed on October 1, 2004, entitled "METHODS FOR SYNTHESIS OF CAROTENOIDS, INCLUDING ANALOGS, DERIVATIVES, AND SYNTHETIC AND BIOLOGICAL INTERMEDIATES" to Lockwood et al. which is incorporated by reference as if fully set forth herein.
The disodium disuccinate derivatives of synthetic astaxanthin were successfully synthesized in gram amounts and at high purity (>90%) area under the curve (AUC) by HPLC. The compound in "racemic" form demonstrated water "dispersibility" of 8.64 mg/mL, a significant improvement over the parent compound astaxanthin, which is insoluble in water. Initial biophysical characterization demonstrated that Cardax™ derivatives (as both the statistical mixture of stereoisomers and as individual stereoisomers) were potent direct scavengers of superoxide anion in the aqueous phase, the first such description in this model system for a C40 carotenoid. Plasma-protein binding studies in vitro revealed that the røesø-(3i?,3'>S)-disodium disuccinate astaxanthin derivative bound immediately and preferentially to human serum albumin (HSA) at a binding site, suggesting that beneficial ligand-binding associations might take place in vivo after parenteral administration of the compound. The single- and multiple-dose pharmacokinetics of an oral preparation of the racemic compound (in lipophilic emulsion) were then investigated in a murine model, and significant plasma and tissue levels of nonesterified astaxanthin were achieved. Proof-of-concept studies in ischemia-reperfusion injury performed in rodents subsequently revealed that intravenous pretreatment with Cardax™ was significantly cardioprotective and achieved myocardial salvage in this experimental infarction model (e.g., up to 56% at the highest dose tested). The test material for three of the studies described above was obtained from a single pilot batch of compound (>200 g single batch at >97% purity by HPLC).
In some embodiments, it may be advantageous to be able to efficiently separate out individual stereoisomers of a racemic mixture of a chemical compound. Efficiently separating out individual stereoisomers on a relatively large scale may advantageously increase availability of starting materials.
In some embodiments, chromatographic separation techniques may be used to separate stereoisomers of a racemic mixture. In some embodiments pure optically active stereoisomers may be reacted with a mixture of stereoisomers of a chemical compound to form a mixture of diastereomers. Diastereomers may have different physical properties as opposed to stereoisomers, thus making it easier to separate diastereomers.
For example it maybe advantageous to separate out stereoisomers from a racemic mixture of astaxanthin. In some embodiments, astaxanthin may be coupled to an optically active compound (e.g., dicamphanic acid). Coupling astaxanthin to optically active compounds produces diastereomers with different physical properties. The diastereomers produced may be separated using chromatographic separation techniques as described herein.
Bulk chromatographic separation of the diastereomeric dicamphanic acid ester(s) of synthetic astaxanthin at preparative chromatography scale was performed to subsequently make gram-scale quantities of each stereoisomer of disodium disuccinate ester astaxanthin. As used herein the terms "structural carotenoid analogs or derivatives" may be generally defined as carotenoids and the biologically active structural analogs or derivatives thereof. "Derivative" in the context of this application is generally defined as a chemical substance derived from another substance either directly or by modification or partial substitution. "Analog" in the context of this application is generally defined as a compound that resembles another in structure but is not necessarily an isomer. Typical analogs or derivatives include molecules which demonstrate equivalent or improved biologically useful and relevant function, but which differ structurally from the parent compounds. Parent carotenoids are selected from the more than 700 naturally- occurring carotenoids described in the literature, and their stereo- and geometric isomers. Such analogs or derivatives may include, but are not limited to, esters, ethers, carbonates, amides, carbamates, phosphate esters and ethers, sulfates, glycoside ethers, with or without spacers (linkers). As used herein the terms "the synergistic combination of more than one structural analog or derivative or synthetic intermediate of carotenoids" may be generally defined as any composition including one structural carotenoid analog or derivative or synthetic intermediate combined with one or more other structural carotenoid analogs or derivatives or synthetic intermediate or co-antioxidants, either as derivatives or in solutions and/or formulations. In some embodiments, techniques described herein may be applied to the inhibition and/or amelioration of proiferative disorder, including but not limted to neoplastic transformation of one or more cells..
An embodiment may include the administration of structural carotenoid analogs or derivatives or synthetic intermediates alone or in combination to a subject such that the occurrence of a proliferative disorder is thereby inhibited and/or ameliorated. The structural carotenoid analogs or derivatives or synthetic intermediates may be water-soluble and/or water dispersible derivatives. The carotenoid derivatives may include any substituent that substantially increases the water solubility of the naturally-occurring carotenoid. The carotenoid derivatives may retain and/or improve the antioxidant properties of the parent carotenoid. The carotenoid derivatives may retain the non-toxic properties of the parent carotenoid. The carotenoid derivatives may have increased bioavailability, relative to the parent carotenoid, upon administration to a subject. The parent carotenoid may be naturally occurring.
Another embodiments may include the administration of a composition comprised of the synergistic combination of more than one structural analog or derivative or synthetic intermediate of carotenoids to a subject such that the occurrence of a proliferative disorder is thereby reduced. The composition may be a "racemic" (i.e. mixture of the potential stereoisomeric forms) mixture of carotenoid derivatives. Included as well are pharmaceutical compositions comprised of structural analogs or derivatives or synthetic intermediates of carotenoids in combination with a pharmaceutically acceptable carrier. In one embodiment, a pharmaceutically acceptable carrier may be serum albumin. In one embodiment, structural analogs or derivatives or synthetic intermediates of carotenoids may be complexed with human serum albumin (i.e., HSA) in a solvent. HSA may act as a pharmaceutically acceptable carrier. In some embodiments, a single stereoisomer of a structural analog or derivative or synthetic intermediate of carotenoids may be administered to a human subject in order to ameliorate a pathological condition. Administering a single stereoisomer of a particular compound (e.g., as part of a pharmaceutical composition) to a human subject may be advantageous (e.g., increasing the potency of the pharmaceutical composition). Administering a single stereoisomer may be advantageous due to the fact that only one isomer of potentially many may be biologically active enough to have the desired effect.
In some embodiments, compounds described herein may be administered in the form of nutraceuticals. "Nutraceuticals" as used herein, generally refers to dietary supplements, foods, or medical foods that: 1. possess health benefits generally defined as reducing the risk of a disease or health condition, including the management of a disease or health condition or the improvement of health; and 2. are safe for human consumption in such quantity, and with such frequency, as required to realize such properties. Generally a nutraceutical is any substance that is a food or a part of a food and provides medical or health benefits, including the prevention and treatment of disease. Such products may range from isolated nutrients, dietary supplements and specific diets to genetically engineered designer foods, herbal products, and processed foods such as cereals, soups and beverages. It is important to note that this definition applies to all categories of food and parts of food, ranging from dietary supplements such as folic acid, used for the prevention of spina bifida, to chicken soup, taken to lessen the discomfort of the common cold. This definition also includes a bio-engineered designer vegetable food, rich in antioxidant ingredients, and a stimulant functional food or pharmafood. Within the context of the description herein where the composition, use and/or delivery of pharmaceuticals are described nutraceuticals may also be composed, used, and/or delivered in a similar manner where appropriate. DOSAGE AMD ADMINISTRATION
The xanthophyll carotenoid, carotenoid derivative or analog may be administered at a dosage level up to conventional dosage levels for xanthophyll carotenoids, carotenoid derivatives or analogs, but will typically be less than about 2 gm per day. Suitable dosage levels may depend upon the overall systemic effect of the chosen xanthophyll carotenoids, carotenoid derivatives or analogs, but typically suitable levels will be about 0.001 to 50 mg/kg body weight of the patient per day, from about 0.005 to 30 mg/kg per day, or from about 0.05 to 10 mg/kg per day. The compound may be administered on a regimen of up to 6 times per day, between about 1 to 4 times per day, or once per day.
In the case where an oral composition is employed, a suitable dosage range is, e.g. from about 0.01 mg to about 100 mg of a xanthophyll carotenoid, carotenoid derivative or analog per kg of body weight per day, preferably from about 0.1 mg to about 10 mg per kg and for cytoprotective use from 0.1 mg to about 100 mg of a xanthophyll carotenoid, carotenoid derivative or analog per kg of body weight per day.
It will be understood that the dosage of the therapeutic agents will vary with the nature and the severity of the condition to be treated, and with the particular therapeutic agents chosen. The dosage will also vary according to the age, weight, physical condition and response of the individual patient. The selection of the appropriate dosage for the individual patient is within the skills of a clinician. In some embodiments, compositions may include all compositions of 1.0 gram or less of a particular structural carotenoid analog, in combination with 1.0 gram or less of one or more other structural carotenoid analogs or derivatives or synthetic intermediates and/or co-antioxidants, in an amount which is effective to achieve its intended purpose. While individual subject needs vary, determination of optimal ranges of effective amounts of each component is with the skill of the art. Typically, a structural carotenoid analog or derivative or synthetic intermediates may be administered to mammals, in particular humans, orally at a dose of 5 to 100 mg per day referenced to the body weight of the mammal or human being treated for a particular disease. Typically, a structural carotenoid analog or derivative or synthetic intermediate may be administered to mammals, in particular humans, parenterally at a dose of between 5 to 1000 mg per day referenced to the body weight of the mammal or human being treated for a particular disease. In other embodiments, about 100 mg of a structural carotenoid analog or derivative or synthetic intermediate is either orally or parenterally administered to treat or prevent disease.
The unit oral dose may comprise from about 0.25 mg to about 1.0 gram, or about 5 to 25 mg, of a structural carotenoid analog. The unit parenteral dose may include from about 25 mg to 1.0 gram, or between 25 mg and 500 mg, of a structural carotenoid analog. The unit intracoronary dose may include from about 25 mg to 1.0 gram, or between 25 mg and 100 mg, of a structural carotenoid analog. The unit doses may be administered one or more times daily, on alternate days, in loading dose or bolus form, or titrated in a parenteral solution to commonly accepted or novel biochemical surrogate marker(s) or clinical endpoints as is with the skill of the art.
In addition to administering a structural carotenoid analog or derivative or synthetic intermediate as a raw chemical, the compounds may be administered as part of a pharmaceutical preparation containing suitable pharmaceutically acceptable carriers, preservatives, excipients and auxiliaries which facilitate processing of the structural carotenoid analog or derivative or synthetic intermediates which may be used pharmaceutically. The preparations, particularly those preparations which may be administered orally and which may be used for the preferred type of administration, such as tablets, softgels, lozenges, dragees, and capsules, and also preparations which may be administered rectally, such as suppositories, as well as suitable solutions for administration by injection or orally or by inhalation of aerosolized preparations, may be prepared in dose ranges that provide similar bioavailability as described above, together with the excipient. While individual needs may vary, determination of the optimal ranges of effectrve amounts of each component is within the skill of, the art.
General guidance in determining effective dose ranges for pharmacologically active compounds and compositions for use in the presently described embodiments may be found, for example, in the publications of the International Conference on Harmonisation and in REMINGTONS PHARMACEUTICAL SCIENCES, 8Λ Edition Ed. Bertram G. Katzung, chapters 27 and 28, pp. 484-528 (Mack Publishing Company 1990) and yet further in BASIC & CLINICAL PHARMACOLOGY, chapters 5 and 66, (Lange Medical Books/McGraw-Hill, New York, 2001). PHARMACEUTICAL COMPOSITIONS
Any suitable route of administration may be employed for providing a patient with an effective dosage of drugs of the present invention. For example, oral, rectal, topical, parenteral, ocular, pulmonary, nasal, and the like may be employed. Dosage forms include tablets, troches, dispersions, suspensions, solutions, capsules, creams,
ointments, aerosols, and the like. In certain embodiments, it may be advantageous that the compositions described herein be administered orally.
The compositions may include those compositions suitable for oral, rectal, topical, parenteral (including subcutaneous, intramuscular, and intravenous), ocular (ophthalmic), pulmonary (aerosol inhalation), or nasal administration, although the most suitable route in any given case will depend on the nature and severity of the conditions being treated and on the nature of the active ingredient. They may be conveniently presented in unit dosage form and prepared by any of the methods well-known in the art of pharmacy.
For administration by inhalation, the drags used in the present invention are conveniently delivered in the form of an aerosol spray presentation from pressurized packs or nebulisers. The compounds may also be delivered as powders which may be formulated and the powder composition may be inhaled with the aid of an insufflation powder inhaler device.
Suitable topical formulations for use in the present embodiments may include transdermal devices, aerosols, creams, ointments, lotions, dusting powders, and the like.
In practical use, drugs used can be combined as the active ingredient in intimate admixture with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques. The carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g., oral or parenteral (including intravenous). In preparing the compositions for oral dosage form, any of the usual pharmaceutical media may be employed, such as, for example, water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents and the like in the case of oral liquid preparations, such as, for example, suspensions, elixirs and solutions; or carriers such as starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents and the like in the case of oral solid preparations such as, for example, powders, capsules and tablets, with the solid oral preparations being preferred over the liquid preparations. Because of their ease of administration, tablets and capsules represent the most advantageous oral dosage unit form in which case solid pharmaceutical carriers are obviously employed. If desired, tablets may be coated by standard aqueous or nonaqueous techniques.
The pharmaceutical preparations may be manufactured in a manner which is itself known to one skilled in the art, for example, by means of conventional mixing, granulating, dragee-making, softgel encapsulation, dissolving, extracting, or lyophilizing processes. Thus, pharmaceutical preparations for oral use may be obtained by combining the active compounds with solid and semi-solid excipients and suitable preservatives, and/or co- antioxidants. Optionally, the resulting mixture may be ground and processed. The resulting mixture of granules may be used, after adding suitable auxiliaries, if desired or necessary, to obtain tablets, softgels, lozenges, capsules, or dragee cores.
Suitable excipients may be fillers such as saccharides (e.g., lactose, sucrose, or mannose), sugar alcohols (e.g., mannitol or sorbitol), cellulose preparations and/or calcium phosphates (e.g., tricalcium phosphate or calcium hydrogen phosphate). In addition binders may be used such as starch paste (e.g., maize or corn starch, wheat starch, rice starch, potato starch, gelatin, tragacanth, methyl cellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose, and/or polyvinyl pyrrolidone). Disintegrating agents may be added (e.g., the above- mentioned starches) as well as carboxymethyl-starch, cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof (e.g., sodium alginate). Auxiliaries are, above all, flow-regulating agents and lubricants (e.g., silica, talc, stearic acid or salts thereof, such as magnesium stearate or calcium stearate, and/or polyethylene glycol, or PEG). Dragee cores are provided with suitable coatings, which, if desired, are resistant to gastric juices.
Softgelatin capsules ("softgels") are provided with suitable coatings, which, typically, contain gelatin and/or suitable edible dye(s). Animal component-free and kosher gelatin capsules may be particularly suitable for the embodiments described herein for wide availability of usage and consumption. For this purpose, concentrated saccharide solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, polyethylene glycol (PEG) and/or titanium dioxide, lacquer solutions and suitable organic solvents or solvent mixtures, including dimethylsulfoxide (DMSO), tetrahydrofuran (TE-F), acetone, ethanol, or other suitable solvents and co-solvents. In order to produce coatings resistant to gastric juices, solutions of suitable cellulose preparations such as acetylcellulose phthalate or hydroxypropylmethyl-cellulose phthalate, may be used. Dye stuffs or pigments may be added to the tablets or dragee coatings or softgelatin capsules, for example, for identification or in order to characterize combinations of active compound doses, or to disguise the capsule contents for usage in clinical or other studies.
Other pharmaceutical preparations that may be used orally include push-fit capsules made of gelatin, as well as soft, thermally sealed capsules made of gelatin and a plasticizer such as glycerol or sorbitol. The push-fit capsules may contain the active compounds in the form of granules that may be mixed with fillers such as, for example, lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers and/or preservatives. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils such as rice bran oil or peanut oil or palm oil, or liquid paraffin. In some embodiments, stabilizers and preservatives may be added.
In some embodiments, pulmonary administration of a pharmaceutical preparation may be desirable. Pulmonary administration may include, for example, inhalation of aerosolized or nebulized liquid or solid particles of the pharmaceutically active component dispersed in and surrounded by a gas.
Possible pharmaceutical preparations, which may be used rectally, include, for example, suppositories, which consist of a combination of the active compounds with a suppository base. Suitable suppository bases are, for example, natural or synthetic triglycerides, or paraffin hydrocarbons. In addition, it is also possible to use gelatin rectal capsules that consist of a combination of the active compounds with a base. Possible base materials include, for example, liquid triglycerides, polyethylene glycols, or paraffin hydrocarbons.
Suitable formulations for parenteral administration include, but are not limited to, aqueous solutions of the active compounds in water-soluble and/or water dispersible form, for example, water-soluble salts, esters, carbonates, phosphate esters or ethers, sulfates, glycoside ethers, together with spacers and/or linkers. Suspensions of the active compounds as appropriate oily injection suspensions may be administered, particularly suitable for intramuscular injection. Suitable lipophilic solvents, co-solvents (such as DMSO or ethanol), and/or vehicles including fatty oils, for example, rice bran oil or peanut oil and/or palm oil, or synthetic fatty acid esters, for example, ethyl oleate or triglycerides, may be used. Aqueous injection suspensions may contain substances that increase the viscosity of the suspension including, for example, sodium carboxymethyl cellulose, sorbitol, dextran, and/or cyclodextrins. Cyclodextrins (e.g., β-cyclodextrin) may be used specifically to increase the water solubility for parenteral injection of the structural carotenoid analog. Liposomal formulations, in which mixtures of the structural carotenoid analog or derivative with, for example, egg yolk phosphotidylcholine (E-PC), may be made for injection. Optionally, the suspension may contain stabilizers, for example, antioxidants such as BHT, and/or preservatives, such as benzyl alcohol. The compounds of this invention can be administered in such oral dosage forms as tablets, capsules (each of which includes sustained release or timed release formulations), pills, powders, granules, elixirs, tinctures,
suspensions, syrups, and emulsions. They may also be administered in intravenous (bolus or infusion), intraperitoneal, subcutaneous, or intramuscular form, all using dosage forms well known to those of ordinary skill in the pharmaceutical arts. They can be administered alone, but generally will be administered with a pharmaceutical carrier selected on the basis of the chosen route of administration and standard pharmaceutical practice. The dosage regimen for the compounds of the present invention will, of course, vary depending upon known factors, such as the pharmacodynamic characteristics of the particular agent and its mode and route of administration; the species, age, sex, health, medical condition, and weight of the recipient; the nature and extent of the symptoms; the kind of concurrent treatment; the frequency of treatment; the route of administration, the renal and hepatic function of the patient, and the effect desired. By way of general guidance, the daily oral dosage of each active ingredient, when used for the indicated effects, will range between about 0.001 to 1000 mg/kg of body weight, between about 0.01 to 100 mg/kg of body weight per day, or between about 1.0 to 20 mg/kg/day. Intravenously administered doses may range from about 1 to about 10 mg/kg/minute during a constant rate infusion. Compounds of this invention maybe administered in a single daily dose, or the total daily dosage maybe administered in divided doses of two, three, or four or more times daily.
The pharmaceutical compositions described herein may further be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal routes, using transdermal skin patches. When administered in the form of a transdermal delivery system, the dosage administration will, of course, be continuous rather than intermittent throughout the dosage regimen. The compounds are typically administered in admixture with suitable pharmaceutical diluents, excipients, or carriers (collectively referred to herein as "pharmacologically inert carriers") suitably selected with respect to the intended form of administration, that is, oral tablets, capsules, elixirs, syrups and the like, and consistent with conventional pharmaceutical practices.
For instance, for oral administration in the form of a tablet or capsule, the pharmacologically active component may be combined with an oral, non-toxic, pharmaceutically acceptable, inert carrier such as lactose, starch, sucrose, glucose, methyl cellulose, magnesium stearate, dicalcium phosphate, calcium sulfate, mannitol, sorbitol and the like; for oral administration in liquid form, the oral drug components can be combined with any oral, non-toxic, pharmaceutically acceptable inert carrier such as ethanol, glycerol, water, and the like. Moreover, when desired or necessary, suitable binders, lubricants, disintegrating agents, and coloring agents can also be incorporated into the mixture. Suitable binders include starch, gelatin, natural sugars such as glucose or beta- lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth, or sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes, and the like. Lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride, and the like. Disintegrators include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan gum, and the like. The compounds of the present invention may also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles, and multilamellar vesicles. Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine, or phosphatidylcholines.
Compounds of the present invention may also be coupled with soluble polymers as targetable drug carriers. Such polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxypropylmethacrylamide- phenol, polyhydroxyethylaspartamidephenol, or polyethyleneoxide-polylysine substituted with pahnitoyl residues. Furthermore, the compounds of the present invention may be coupled to a class of biodegradable polymers useful in
achieving controlled release of a drug, for example, polylactic acid, polyglycolic acid, copolymers of polylactic and polyglycolic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacylates, and crosslinked or amphipathic block copolymers of hydrogels.
Dosage forms (pharmaceutical compositions) suitable for administration may contain from about 1 milligram to about 100 milligrams or more of active ingredient per dosage unit. In these pharmaceutical compositions the active ingredient will ordinarily be present in an amount of about 0.5-95% by weight based on the total weight of the composition.
Gelatin capsules may contain the active ingredient and powdered carriers, such as lactose, starch, cellulose derivatives, magnesium stearate, stearic acid, and the like. Similar diluents can be used to make compressed tablets. Both tablets and capsules can be manufactured as sustained release products to provide for continuous release of medication over a period of hours. Compressed tablets can be sugar coated or film coated to mask any unpleasant taste and protect the tablet from the atmosphere, or enteric coated for selective disintegration in the gastrointestinal tract.
Liquid dosage forms for oral administration can contain coloring and flavoring to increase patient acceptance. In general, water, a suitable oil, saline, aqueous dextrose (glucose), and related sugar solutions and glycols such as propylene glycol or polyethylene glycols are suitable carriers for parenteral solutions. Solutions for parenteral administration preferably contain a water soluble salt of the active ingredient, suitable stabilizing agents, and if necessary, buffer substances. Antioxidizing agents such as sodium bisulfite, sodium sulfite, or ascorbic acid, either alone or combined, are suitable stabilizing agents. Also used are citric acid and its salts and sodium EDTA. In addition, parenteral solutions can contain preservatives, such as benzalkonium chloride, methyl- or propyl-paraben, and chlorobutanol.
Suitable pharmaceutical carriers are described in Remington's Pharmaceutical Sciences, Mack Publishing Company, a standard reference text in this field.
In some embodiments, compositions may include all compositions of 1.0 gram or less of a particular structural carotenoid analog, in combination with 1.0 gram or less of one or more other structural carotenoid analogs or derivatives or synthetic intermediates and/or co-antioxidants, in an amount which is effective to achieve its intended purpose. While individual subject needs vary, determination of optimal ranges of effective amounts of each component is with the skill of the art. Typically, a structural carotenoid analog or derivative or synthetic intermediates may be administered to mammals, in particular humans, orally at a dose of 5 to 100 mg per day referenced to the body weight of the mammal or human being treated for a particular disease. Typically, a structural carotenoid analog or derivative or synthetic intermediate may be administered to mammals, in particular humans, parenterally at a dose of between 5 to 1000 mg per day referenced to the body weight of the mammal or human being treated for a particular disease. In other embodiments, about 100 mg of a structural carotenoid analog or derivative or synthetic intermediate is either orally or parenterally administered to treat or prevent disease. The unit oral dose may comprise from about 0.25 mg to about 1.0 gram, or about 5 to 25 mg, of a structural carotenoid analog. The unit parenteral dose may include from about 25 mg to 1.0 gram, or between 25 mg and 500 mg, of a structural carotenoid analog. The unit intracoronary dose may include from about 25 mg to 1.0 gram, or between 25 mg and 100 mg, of a structural carotenoid analog. The unit doses may be administered one or more times daily, on alternate days, in loading dose or bolus form, or titrated in a parenteral solution to commonly accepted or novel biochemical surrogate marker(s) or clinical endpoints as is with the skill of the art.
In addition to administering a structural carotenoid analog or derivative or synthetic intermediate as a raw chemical, the compounds may be administered as part of a pharmaceutical preparation containing suitable pharmaceutically acceptable carriers, preservatives, excipients and auxiliaries which facilitate processing of the structural carotenoid analog or derivative or synthetic intermediates which may be used pharmaceutically. The preparations, particularly those preparations which may be administered orally and which may be used for the preferred type of administration, such as tablets, softgels, lozenges, dragees, and capsules, and also preparations which may be administered rectally, such as suppositories, as well as suitable solutions for administration by injection or orally or by inhalation of aerosolized preparations, may be prepared in dose ranges that provide similar bioavailability as described above, together with the excipient. While individual needs may vary, determination of the optimal ranges of effective amounts of each component is within the skill of the art. EXAMPLES
Having now described the invention, the same will be more readily understood through reference to the following example(s), which are provided by way of illustration, and are not intended to be limiting of the present invention. General. Natural source lutein (90%) was obtained from ChemPacific, Inc. (Baltimore, MD) as a red-orange solid and was used without further purification. All other reagents and solvents used were purchased from Acros (New Jersey, USA) and were used without further purification. All reactions were performed under N2 atmosphere. All flash chromatographic purifications were performed on Natland International Corporation 230-400 mesh silica gel using the indicated solvents. LC/MS (APCI) and LC/MS (ESI) were recorded on an Agilent 1100 LCMSD VL system; column: Zorbax Eclipse XDB-C18 Rapid Resolution (4.6 x 75 mm, 3.5 μm, USUT002736); temperature: 25 0C; starting pressure: 105 bar; flow rate: 1.0 mL/ min; mobile phase (%A= 0.025% trifluoroacetic acid in H2O, %B= 0.025% trifluoroacetic acid in acetonitrile) Gradient program: 70% A/ 30% B (start), step gradient to 50% B over 5 min, step gradient to 98% B over 8.30 min, hold at 98% B over 25.20 min, step gradient to 30% B over 25.40 min; PDA Detector: 470 nm. The presence of trifluoroacetic acid in the LC eluents acts to protonate synthesized lutein disuccinate and diphosphate salts to give the free di-acid forms, yielding M+= 768 for the disuccinate salt sample and M+ = 728 for the diphosphate salt sample in MS analyses. LRMS: + mode; ESI: electrospray chemical ionization, ion collection using quadrapole; APCI: atmospheric pressure chemical ionization, ion collection using quadrapole. MS (ESI-IT) was recorded on a HCT plus Bruker Daltonics Mass Spectrometer system, LRMS: + mode; ESI-IT: electrospray chemical ionization, ion collection using ion trap. 1H NMR analyses were attempted on Varian spectrometers (300 and 500 MHz). NMR analyses of natural source lutein as well as synthesized lutein derivatives yielded only partially discernable spectra, perhaps due to the presence of interfering impurities (natural source lutein), or due to aggregation (natural source lutein and derivatives). In attempts to circumvent the problems associated with NMR analyses, samples were prepared using mixtures of deuterated solvents including methanol/ chloroform, methanol/ water, methyl sulfoxide/ water, and chloroform/ methanol/ water. However, such attempts failed to give useful data.
Natural source lutein (β,ε-carotene-3,3'-diol), 1. LC/MS (ESI): 9.95 min (2.78%), X1^ 226 nm (17%), 425 nm (100%); 10.58 min (3.03%), λ,nax 225 nm (21%), 400 nm (100%); 11.10 min (4.17%), λ,nax 225 nm (16%), 447 nm (100%); 12.41 min (90.02%), λ,nax 269 nm (14%), 447 nm (100%), m/z 568 M+ (69%), 551 [M - H2O + H]+ (100%), 533 [M - 2H2O + H]+ (8%). β,ε-carotenyl 3, 3 '-disuccinate, 2. To a solution of natural source lutein (1) (0.50 g, 0.879 mmol) in CH2Cl2
(8 mL) was added ΛζiV-diisopropylethylainine (3.1 mL, 17.58 mmol) and succinic anhydride (0.88 g, 8.79 mmol).
The solution was stirred at RT overnight and then diluted with CH2Cl2 and quenched with water/ 1 MHCl (5/ 1). The aqueous layer was extracted two times with CH2Cl2 and the combined organic layer was washed three times with cold water/ 1 MHCl (5/ 1), dried over Na2SO4, and concentrated. The resulting red-orange oil was washed (slurried) three times with hexanes to yield disuccinate 2 (0.433 g, 64%) as a red-orange solid; LCfNlS (APCI): 10.37 min (4.42%), X1113x 227 nm (56%), 448 nm (100%), m/z 769 [M + H]+ (8%), 668 [M - C4O3H4]4" (9%), 637 (36%), 138 (100%); 1 1.50 min (92.40%), X1113x 269 nm (18%), 447 nm (100%), m/z 769 [M + H]+ (7%), 668 [M - C4O3Ht]+ (9%), 651 (100%); 12.03 min (3.18%) X1113x 227 nm (55%), 446 nm (100%), m/z 668 [M - C4O3HJ+ (15%), 550 (10%), 138 (100%) β,ε-carotenyl 3,3 '-disuccinate sodium salt, 3. To a solution of disuccinate 2 (0.32 g, 0.416 mmol) in CH2Cl2/ methanol (5 mL/ 1 mL ) at 0 0C was added drop-wise sodium methoxide (25% wt in methanol; 0.170 mL, 0.748 mmol). The solution was stirred at RT overnight and then quenched with water and stirred for 5 min. The solution was then concentrated and the aqueous layer was washed four times with Et2O. Lyophilization of the clear, red-orange aqueous solution yielded 3 (0.278 g, 91%) as an orange, hygroscopic solid; LC/MS (APCI): 11.71 min (94.29%), X1113x 269 nm (18%), 446 nm (100%), m/z 769 [M - 2Na + 3H]+ (8%), 668 [M - 2Na + 2H - C4O3Ht]+ (6%), 651 (100%); 12.74 min (5.71%), X1113x 227 nm (30%), 269 nm (18%), 332 nm (39%), 444 nm (100%), m/z 768 [M - 2Na + 2H]+ (2%), 668 [M - 2Na + 2H - C4O3H4J+ (3%), 651 (12%), 138 (100%)
Tribenzyl phosphite, 4. To a well-stirred solution of phosphorus trichloride (1.7 mL, 19.4 mmol) in Et2O (430 mL) at 0 0C was added dropwise a solution of triethylamine (8.4 mL, 60.3 mmol) in Et2O (20 mL), followed by a solution of benzyl alcohol (8.1 mL, 77.8 mmol) in Et2O (20 mL). The mixture was stirred at 0 0C for 30 min and then at RT overnight. The mixture was filtered and the filtrate concentrated to give a colorless oil. Silica chromatography (hexanes/ Et2O/ triethylamine, 4/ 1/ 1%) of the crude product yielded 4 (5.68 g, 83%) as a clear, colorless oil that was stored under N2 at -20 0C; 1H NMR: δ 7.38 (15H, m), 4.90 (6H, d)
Dibenzyl phosphoroiodidate, 5. To a solution of tribenzyl phosphite (5.43 g, 15.4 mmol) in CH2Cl2 (8 mL) at 0 0C was added I2 (3.76 g, 14.8 mmol). The mixture was stirred at 0 0C for 10 min or until the solution became clear and colorless. The solution was then stirred at RT for 10 min and used directly in the next step.
3-(Bis benzyl-phosphoryloxy)-3'-(phosphoryloxy)-β,ε-carotene, 6. To a solution of natural source lutein (1) (0.842 g, 1.48 mmol) in CH2Cl2 (8 mL) was added pyridine (4.8 mL, 59.2 mmol). The solution was stirred at 0 0C for 5 min and then freshly prepared 5 (14.8 mmol) in CH2Cl2 (8 mL) was added drop-wise to the mixture at 0 0C. The solution was stirred at 0 0C for 1 h and then diluted with CH2Cl2 and quenched with brine. The aqueous layer was extracted twice with CH2Cl2 and the combined organic layer was washed once with brine, then dried over Na2SO4 and concentrated. Pyridine was removed from the crude red oil by azeotropic distillation using toluene. The crude product was alternately washed (slurried) twice with hexanes and Et2O to yield 6 as a red oil, used in the next step without further purification; LC/MS (ESI): 9.93 min (44.78%), X1113x 267 nm (33%), 444 nm (100%), m/z 890 [M - H2O]+ (8%), 811 [M - PO3H - H2O + H]+ (73%), 533 (100%); 9.99 min (29.0%), λm3X 268 nm (24%), 446 nm (100%), m/z 890 [M - H2O]+ (6%), 811 [M - PO3H - H2O + H]+ (72%), 533 (100%); 10.06 min (26.23%), X1113x 266 nm (15%), 332 nm (22%), 444 nm (100%), m/z 890 [M - H2O]+ (5%), 811 [M - PO3H - H2O + H]+ (90%), 533 (100%)
3-(Bis benzyl-phosρhoryloxy)-3'-hydroxy-β,ε-carotene, 7. To a solution of 6 (0.033 mmol) in tetrahydrofuran/ water (1 mL/ 0.5 mL) at 0 0C was added LiOH-H2O (0.003 g, 0.073 mmol). The solution was stirred at RT for 1 h and then quenched with methanol. The crude reaction mixture was analyzed by LC/MS; LC/MS (ESI): 10.02 min (40.60%), X1113x 266 nm (12%), 333 nm (25%), 445 nm (100%), m/z 890 [M - H2O]+
(33%), 811 [M - PO3H - H2O + H]+ (50%), 533 (100%); 16.37 min (49.56%) X1113x 267 nm (16%), 332 nm (27%), 446 nm (100%), m/z 828 M+ (55%), 550 (44%)
3,3'-Diphosphoryloxy-β,ε-carotene, 8. To a solution of 6 (1.48 mmol) in CH2Cl2 (10 niL) at 0 0C was added drop-wise Af,0-bis(trimethylsilyl)acetamide (3.7 mL, 14.8 mmol) and then bromotrimethylsilane (1.56 mL, 11.8 mmol). The solution was stirred at 0 0C for 1 h, quenched with methanol, diluted with CH2Cl2, and then concentrated. The resulting red oil was alternately washed (slurried) three times with ethyl acetate and CH2Cl2 to yield crude phosphate 8 (2.23 g) as a dark orange oil, used in the next step without further purification; LCYMS (ESI): 8.55 min (45.67%), X1113x 214 nm (25%), 268 nm (28%), 447 nm (100%), m/z 631 [M - PO3H - H2O + H]+ (30%), 533 (18%), 279 (13%), 138 (87%); 8.95 min (35.0%), X1113x 217 nm (14%), 268 nm (23%), 448 nm (100%), m/z 631 [M - PO3H - H2O + H]+ (26%), 533 (32%), 279 (18%), 138 (100%); 9.41 min (9.70%), X11111x 225 nm (37%), 269 nm (23%), 335 nm (19%), 447 nm (100%), m/z 631 [M - PO3H - H2O + H]+ (6%), 533 (18%), 279 (13%), 138 (100%)
3,3'-Diphosphoryloxy-β,ε-carotene sodium salt, 9. To a solution of crude 8 (ca 50%; 2.23 g, 3.06 mmol) in methanol (20 mL) at 0 0C was added drop-wise sodium methoxide (25%; 3.5 mL, 15.3 mmol). The solution was stirred at RT for 2h and the resulting orange solid was washed (slurried) three times with methanol. Water was added to the moist solid and the resulting aqueous layer was extracted with CH2Cl2, ethyl acetate, and again with CH2Cl2. Lyophilization of the clear, red-orange aqueous solution yielded 9 (0.956 g, 80% over 3 steps) as an orange, hygroscopic solid; LC/MS (ESI): 7.81 min (22.34%), X1113x 215 nm (34%), 268 nm (30%), 448 nm (100%), m/z 711 [M - 4Na - H2O + 5H]+ (9%), 533 (13%), 306 (100%); 8.33 min (39.56%), X1113x 217 nm (14%), 268 nm (20%), 448 nm (100%), m/z 711 [M - 4Na - H2O + 5H]+ (10%), 533 (11%), 306 (100%); 8.90 min (38.09%), X1113x
223 nm (45%), 269 nm (30%), 336 nm (26%), 448 nm (100%), m/z 711 [M - 4Na - H2O + 5H]+ (8%), 631 [M - 4Na - PO3H - H2O + 5H]+ (18%), 533 (20%), 306 (100%); MS (ESI-IT): m/z 816 M+ (55%), 772 [M - 2Na + 2H]+ (37%), 728 [M - 4Na + 4H]+ (74%) UV/Visible spectroscopy. For spectroscopic sample preparations, 3 and 9 were dissolved in the appropriate solvent to yield final concentrations of approximately 0.01 mM and 0.2 niM, respectively. The solutions were then added to a rectangular cuvette with 1 cm path length fitted with a glass stopper. The absorption spectrum was subsequently registered between 250 and 750 nm. All spectra were accumulated one time with a bandwidth of 1.0 nm at a scan speed of 370 nm/min. For the aggregation time-series measurements, spectra were obtained at baseline (immediately after solvation; time zero) and then at the same intervals up to and including 24 hours post- solvation (see FIG. 2-FIG. 7). Concentration was held constant in the ethanolic titration of the diphosphate lutein sodium salt, for which evidence of card-pack aggregation was obtained (FIG. 5 - FIG. 7). Determination of aqueous solubility/dispersibility. 30.13 mg of 3 was added to 1 mL of USP-purifϊed water. The sample was rotated for 2 hours, then centrifuged for 5 minutes. After centrifuging, solid was visible in the bottom of the tube. A 125-μL aliquot of the solution was then diluted to 25 mL. The sample was analyzed by UV/Vis spectroscopy at 436 nm, and the absorbance was compared to a standard curve compiled from 4 standards of known concentration. The concentration of the original supernatant was calculated to be 2.85 mg/mL and the absorptivity was 36.94 AU*mL/cm*mg. Slight error may have been introduced by the small size of the original aliquot.
Next, 30.80 mg of 9 was added to 1 mL of USP-purified water. The sample was rotated for 2 hours, then centrifuged for 5 minutes. After centrifuging, solid was visible in the bottom of the tube. A 125-μL aliquot of the solution was then diluted to 25 mL. The sample was analyzed by UV/Vis spectroscopy at 411 nm, and the
absorbance was compared to a standard curve compiled from 4 standards of known concentration. The concentration of the original supernatant was calculated to be 29.27 mg/mL and the absorptivity was 2.90 AU*mL/cm*mg. Slight error may have been introduced by the small size of the original aliquot. Leukocyte Isolation and Preparation. Human polymorphonuclear leukocytes (PMNs) were isolated from freshly sampled venous blood of a single volunteer (S.F.L.) by Percoll density gradient centrifugation as described previously. Briefly, each 10 mL of whole blood was mixed with 0.8 mL of 0.1 M EDTA and 25 mL of saline. The diluted blood was then layered over 9 mL of Percoll at a specific density of 1.080 g/mL. After centrifugation at 400 x g for 20 min at 20 °C, the plasma, mononuclear cell, and Percoll layers were removed. Erythrocytes were subsequently lysed by addition of 18 mL of ice-cold water for 30 s, followed by 2 mL of 10x PIPES buffer (25 mM PIPES, 110 mM NaCl, and 5 mM KCl, titrated to pH 7.4 with NaOH). Cells were then pelleted at 4 0C, the supernatant was decanted, and the procedure was repeated. After the second hypotonic cell lysis, cells were washed twice with PAG buffer [PIPES buffer containing 0.003% human serum albumin (HSA) and 0.1% glucose]. Afterward, PMNs were counted by light microscopy on a hemocytometer. The isolation yielded PMNs with a purity of > 95%. The final pellet was then suspended in PAG-CM buffer (PAG buffer with 1 mM CaCl2 and 1 mM MgCl2). EPR Measurements. All EPR measurements were performed using a Bruker ER 300 EPR spectrometer operating at X-band with a TMn0 cavity as previously described. The microwave frequency was measured with a Model 575 microwave counter (EIP Microwave, Inc., San Jose, CA). To measure superoxide anion (O* 2) generation from phorbol-ester (PMA)-stimulated PMNs, EPR spin-trapping studies were performed using the spin trap DEPMPO (Oxis, Portland, OR) at 10 mM. 1 X 106 PMNs were stimulated with PMA (1 ng/niL) and loaded into capillary tubes for EPR measurements. To determine the radical scavenging ability of 3 and 9 in aqueous and ethanolic formulations, PMNs were pre-incubated for 5 minutes with test compound, followed by PMA stimulation. Instrument settings used in the spin-trapping experiments were as follows: modulation amplitude, 0.32 G; time constant, 0.16 s; scan time, 60 s; modulation frequency, 100 IcHz; microwave power, 20 milliwatts; and microwave frequency, 9.76 GHz. The samples were placed in a quartz EPR flat cell, and spectra were recorded. The component signals in the spectra were identified and quantified as reported previously. UV/Vis spectral properties in organic and aqueous solvents.
UV- Vis spectral evaluation of the disuccinate lutein sodium salt is depicted in FIG. 2 -FIG. 4. FIG. 2 depicts a time series of the UV/Vis absorption spectra of the disodium disuccinate derivative of natural source lutein in water. The λmax (443 nm) obtained at time zero did not appreciably blue-shift over the course of 24 hours, vibrational fine structure was maintained (%III/II = 35%), and the spectra became only slightly hypochromic (i.e. decreased in absorbance intensity) over time, indicating minimal time-dependent supramolecular assembly (aggregation) of the card-pack type during this time period. Existence of head-to-tail (J-type) aggregation in solution cannot be ruled out.
FIG. 3 depicts a UV/Vis absorption spectra of the disodium disuccinate derivative of natural source lutein in water (λmax = 443 nm), ethanol (λmax = 446 nm), and DMSO (λmax = 461 nm). Spectra were obtained at time zero. A prominent cis peak is seen with a maximum at 282 nm in water. The expected bathochromic shift of the spectrum in the more polarizable solvent (DMSO) is seen (461 nm). Only a slight hypsochromic shift is seen between the spectrum in water and that in ethanol, reflecting minimal card-pack aggregation in aqueous solution. Replacement of the main visible absorption band observed in EtOH by an intense peak in the near UV region — narrow and displaying no vibrational fine structure — is not observed in the aqueous solution of this highly water- dispersible derivative, in comparison to the spectrum of pure lutein in an organic/ water mixture.
FIG. 4 depicts a UV/Vis absorption spectra of the disodium disuccinate derivative of natural source lutein in water (λmax = 442 nm) with increasing concentrations of ethanol. The λmax increases to 446 nm at an EtOH concentration of 44%, at which point no further shift of the absorption maximum occurs (i.e. a molecular solution has been achieved), identical to that obtained in 100% EtOH (See FIG. 3). UV-Vis spectral evaluation of the diphosphate lutein sodium salt is depicted in FIG. 5-FIG. 7. FIG. 5 depicts a time series of the UV/Vis absorption spectra of the disodium diphosphate derivative of natural source lutein in water. Loss of vibrational fine structure (spectral distribution beginning to approach unimodality) and the blue-shifted lambda max relative to the lutein chromophore in EtOH suggested that card-pack aggregation was present immediately upon solvation. The λmax (428 nm) obtained at time zero did not appreciably blue-shift over the course of 24 hours, and the spectra became slightly more hypochromic over time (i.e. decreased in absorbance intensity), indicating additional time-dependent supramolecular assembly (aggregation) of the card-pack type during this time period. This spectrum was essentially maintained over the course of 24 hours (compare with FIG. 2, disuccinate lutein sodium salt).
FIG. 6 depicts a UV/Vis absorption spectra of the disodium diphosphate derivative of natural source lutein in 95% ethanol (λmax = 446 nm), 95% DMSO (λmax = 459 nm), and water (λmax = 428 nm). A red-shift was observed (^3x to 446 nm), as was observed with the disuccinate derivate. Wetting of the diphosphate lutein derivative with a small amount of water was required to obtain appreciable solubility in organic solvent (e.g. EtOH and DMSO). Spectra were obtained at time zero. The expected bathochromic shift (in this case to 459 nm) of the spectrum in the more polarizable solvent (95% DMSO) is seen. Increased vibrational fine structure and red-shifting of the spectra were observed in the organic solvents.
FIG. 7 depicts a UV/Vis absorption spectra of the disodium diphosphate derivative of natural source lutein in water (λmax = 428 nm) with increasing concentrations of ethanol. Concentration of the derivative was held • constant for each increased concentration of EtOH in solution. The λ,nax increases to 448 nm at an EtOH concentration of 40%, at which no further shift of the absorption maximum occurs (i.e. a molecular solution is reached).
Direct superoxide anion scavenging by EPR spectroscopy
The mean percent inhibition of superoxide anion signal (± SEM) as detected by DEPMPO spin-trap by the disodium disuccinate derivative of natural source lutein (tested in water) is shown in FIG. 8. A 100 μM formulation (0.1 niM) was also tested in 40% EtOH, a concentration shown to produce a molecular (i.e. non-aggregated) solution. As the concentration of the derivative increased, inhibition of superoxide anion signal increased in a dose- dependent manner. At 5 mM, approximately % (75%) of the superoxide anion signal was inhibited. No significant scavenging (0% inhibition) was observed at 0.1 mM in water. Addition of 40% EtOH to the derivative solution at 0.1 mM did not significantly increase scavenging over that provided by the EtOH vehicle alone (5% inhibition). The millimolar concentration scavenging by the derivative was accomplished in water alone, without the addition of organic co-solvent (e.g., acetone, EtOH), heat, detergents, or other additives. This data suggested that card-pack aggregation for this derivative was not occurring in aqueous solution (and thus limiting the interaction of the aggregated carotenoid derivative with aqueous superoxide anion).
The mean percent inhibition of superoxide anion signal (± SEM) as detected by DEPMPO spin-trap by the disodium diphosphate derivative of natural source lutein (tested in water) is shown in FIG. 9. A 100 μM formulation (0.1 mM) was also tested in 40% EtOH, a concentration also shown to produce a molecular (i.e. non- aggregated) solution of this derivative. As the concentration of the derivative increased, inhibition of the
superoxide anion signal increased in a dose-dependent manner. At 5 mM, slightly more than 90% of the superoxide anion signal was inhibited (versus 75% for the disuccinate lutein sodium salt). As for the disuccinate lutein sodium salt, no apparent scavenging (0% inhibition) was observed at 0.1 mM in water. However, a significant increase over background scavenging by the EtOH vehicle (5%) was observed after the addition of 40% EtOH , resulting in a mean 18% inhibition of superoxide anion signal. This suggested that disaggregation of the compound lead to an increase in scavenging ability by this derivative, pointing to slightly increased scavenging ability of molecular solutions of the more water-dispersible diphosphate derivative relative to the disuccinate derivative. Again, the millimolar concentration scavenging by the derivative was accomplished in water alone, without the addition of organic co-solvent (e.g., acetone, EtOH), heat, detergents, or other additives.
Mean (%
Sample Solvent Concentration N S.D. SEM Min Max Range inhibition)
Lutein Disuccinate 40%
0.1 mM 5.0 4.4 2.5 Sodium Salt EtOH
Lutein Disuccinate
Water 0.1 mM 0.0 ND ND Sodium Salt
Lutein Disuccinate Water 1.O mM 13.0 5.6 3.2 19 11 Sodium Salt
Lutein Disuccinate Water 3.O mM 3 61.7 4.0 2.3 58 66 Sodium Salt
Lutein Disuccinate Water 5.O mM 74.7 4.5 2.6 70 79 Sodium Salt
Table I. Descriptive statistics of mean % inhibition of superoxide anion signal for aqueous and ethanolic (40%) formulations of disodium disuccinate derivatives of natural source lutein tested in the current study. Sample sizes of 3 were evaluated for each formulation, with the exception of natural source lutein in 40% EtOH stock solution (N = 1). Mean % inhibition did not increase over background levels until sample concentration reached 1 mM in water; likewise, addition of 40% EtOH at the 0.1 mM concentration did not increase scavenging over background levels attributable to the EtOH vehicle (mean = 5% inhibition).
Mean (%
Sample Solvent Concentration N S.D. SEM Min Max Range inhibition)
Lutein Diphosphate 40%
0.1 mM 18.0 7.0 4.0 11 25 14
Sodium Salt EtOH
Lutein Diphosphate Water 0.1 mM 0.0 ND ND 0 0
Sodium Salt
Lutein Diphosphate
Water 1.O mM 3 9.3 3.5 2.0 6 13 7
Sodium Salt
Lutein Diphosphate
Water 3.O mM 3 72.3 3.1 1.8 69 75 6
Sodium Salt
Lutein Diphosphate
Water 5.O mM 3 91.0 2.6 1.5 88 93 5
Sodium Salt
Table π. Descriptive statistics of mean % inhibition of superoxide anion signal for aqueous and ethanolic (40%) formulations of disodium diphosphate derivatives of natural source lutein tested in the current study. Sample sizes of 3 were evaluated for each formulation, with the exception of lutein diphosphate in water at 100 μM (0.1 mM) where N = I. Mean % inhibition of superoxide anion signal increased in a dose-dependent manner as the concentration of lutein diphosphate was increased in the test assay. At 100 μM in water, no inhibition of scavenging was seen. The molecular solution in 40% EtOH (mean % inhibition = 18%) was increased above background scavenging (5%) by the ethanolic vehicle, suggesting that disaggregation increased scavenging at that concentration. Slightly increased scavenging (on a molar basis) may have been obtained with the diphosphate derivative in comparison to disuccinate derivative (see Table 1 and FIG. 8).
In the current study, facile preparations of the disodium disuccinate and tetrasodium phosphate esters of natural source (RRR) lutein are described. These asymmetric C40 carotenoid derivatives exhibited aqueous dispersibility of 2.85 and 29.27 mg/mL, respectively. Evidence for both card-pack (H-type) and head-to-tail (J- type) supramolecular assembly was obtained with UV- Vis spectroscopy for the aqueous solutions of these compounds. Electronic paramagnetic spectroscopy of direct aqueous superoxide scavenging by these derivatives demonstrated nearly identical dose-dependent scavenging profiles, with slightly increased scavenging noted for the diphosphate derivative. In each case, scavenging in the millimolar range was observed. These results show that as parenteral soft drugs with aqueous radical scavenging activity, both compounds are useful in those clinical applications in which rapid and/or intravenous delivery is desired for the desired therapeutic effect(s). Tetrasodium diphosphate astaxanthin derivatives
General. The racemic tetrasodium diphosphate derivative of astaxanthin (pAST; > 97% purity by HPLC) was synthesized from commercial astaxanthin and its structure verified (see below for synthetic methodology). The chemical structures of the three stereoisomers, (3R,3'R)-, (3S,3'S)-, and (3R,3'S; meso)-tetrasodium diphosphate astaxanthin are shown in FIG.10. The racemic pAST used in this study is comprised of the statistical mixture of the above stereoisomers in a 1 : 1 :2 ratio. Non-esterified, ήl-E synthetic astaxanthin utilized for biological tests
(AST; > 96% purity by HPLC) was obtained from Sigma (St. Louis, MO). Canthaxanthin (CTX) and the synthetic retinoid tetraliydrotetramethylnaphalenylpropenyl benzoic acid (TTNPB) were gifts from Hoffman-LaRoche (Nutley, NJ). TTNPB, canthaxanthin and astaxanthin concentrations were confirmed by comparing their UV absorption and their published extinction coefficients. Due to the sensitivity of carotenoids to light, heat and oxygen, special precautions were taken throughout the study. All compounds were stored under nitrogen at -70 °C and care was taken to ensure minimal exposure to direct sunlight or UV light.
Synthesis of tetrasodium diphosphate astaxanthin (pAST). Unless otherwise noted, all reagents and solvents were
purchased from commercial suppliers and used as received without further purification. Proton and carbon nuclear magnetic resonance (NMR) spectra were obtained on a Bruker AMX 500 spectrometer at 500 MHz for proton NMR (1H NMR) and 202 MHz for phosphorous NMR (31P NMR). Chemical shifts are given in ppm (δ) and coupling constants, J, are reported in Hertz (Hz). Tetramethylsilane (TMS) was used as an internal standard for proton spectra. High performance liquid chromatography (HPLC) analysis for in-process control (IPC) was performed on a Varian Prostar Series 210 liquid chromatograph with a PDA detector using methods A and B. Method A: Waters Symmetry C18, 3.5 μm, 4.6 x 150 mm column; 25 °C; Mobile phase: [A = water (pH 4.5, 20 mM ammonium acetate), B = acetonitrile], 95% A/5% B (start); hold for 5 min; linear gradient to 100% B over 25 min; hold for 8 min; linear gradient to 5% B over 2 min; flow rate: 1.0 ml/min; detector wavelength: 474 nm (astaxanthin 30.5 min). Method B: Agilent Zorbax SB CN 5 μm, 4.6 x 150 mm column; 25 0C; Mobile phase: [A = water (pH 6.8, 20 mM ammonium acetate), B = acetonitrile], 80% A/20% B (start); hold for 5 min; linear gradient to 100% B over 20 min; hold for 10 min; linear gradient to 20% B over 5 min; flow rate: 1.0 ml/min; detector wavelength: 474 nm (astaxanthin, 30.5 min).
The intermediate ;-αc-3,3'-dihydroxy-β,β-carotene-4,4'-dione diphosphoric acid bis-(2-cyano-ethyl) ester was synthesized as follows: a 100 ml round bottom flask wrapped with aluminum foil was equipped with a stir bar under nitrogen at room temperature. Racemic astaxanthin (Buckton Scott, India) (0.440 g, 0.74 mmol) was dissolved in methylene chloride (13.2 ml) then reacted with bis (2-cyanoethyl)-N,N-diisopropyl phosphoramidite (0.80 g, 2.95 mmol), and tetrazole (0.21 g, 2.95 mmol). After 14 h, the reaction was complete by HPLC and 7.4 ml 0.4 M iodine in a solution of pyridine-dichloromethane (DCM)- water (3:1:1) was added dropwise over 15 min. The reaction was diluted with DCM (10 ml) and washed with aqueous sodium thiosulfate (1 M, 2 x 10 ml) and brine (10 ml). The solution was concentrated to dryness to afford 590 mg of dried red solid (83% yield). 1H NMR (CDCl3) δ 6.42-6.17 (14 H, m), 5.12-5.06 (2 H, m), 4.59-4.31 (m, 8 H), 2.93-2.83 (8 H, m), 2.07-1.98 (16 H, m), 1.89 (6 H, s), 1.35 (6 H, s), 1.24 (6 H, s); 31P NMR (CDCl3) δ -2.62; Anal. Calculated for [C32H66OI0P2]: 969.05, ESI MS m/z 969.29 [C52H66OioP2]+; HPLC (Method B) 94.0% area under the curve (AUC), tκ = 26.0 min. rac-3,3'-dihydroxy-β,β-carotene-4,4'-dione diphosphoric acid bis-(2-cyano-ethyl) (500 mg, 0.52 mmol) and 10 ml of 50% dimethylamine in water was added to a 250 ml flask under nitrogen (N2) with a stir bar and heated to 40 0C. The reaction was complete by HPLC after 4d and the reaction mixture was concentrated to dryness. The red solid was re-dissolved in 50 ml of water and then eluted through a sodium ion exchange resin (50 g, Amberlite IR-120 Na+). The solution was concentrated using acetonitrile to form an azeotrope with water. The red solid was then re-dissolved in a minimum amount of water (~20 ml) and precipitated with the addition of ethanol (20 ml). The precipitate was filtered through a 2 μm filter and dried under vacuum to afford 66 mg of red solid. The solid was again re-dissolved in 2 ml of water and lyophilized to afford 42 mg of red solid (28% yield). 1H NMR (CD3OD) δ 6.81-6.35 (14 H, m), 4.87-4.83 (2 H, m), 2.07-1.98 (16 H, m), 1.90 (6 H, s), 1.30 (6 H, s), 1.14 (6 H, s); 31P NMR (CDCl3) δ 3.28; Anal. Calculated for [C40H54OI0P2]: 756.80, ESI MS m/z 755.2 [C4OH53OiOP2]-; HPLC (Method B) 97.7% AUC, tR = 14.05 min.
Determination of aqueous solubility/dipsersibility ofpAST. 23.70 mg of tetrasodium diphosphate astaxanthin was added to 1 ml of USP purified water. The mixture was stirred for 2 hours, and centrifuged for 5 minutes. The solution was diluted in water and analyzed by UV/vis spectroscopy at 480 nm and absorbance was compared to a standard curve compiled from 4 standards of known concentration. The solubility was calculated to be 25.21 mg/ml with an extinction coefficient of 0.0187 AU*ml/cm*mg.
Cell lines and culture conditions. Mouse embryonic fibroblast 10T1/2 cells were cultured in Eagle's basal medium with Earle's salts supplemented with 4% fetal calf serum (Atlanta Biologicals, Norcross, GA), 25 μg/ml gentamicin sulfate (Sigma, St. Louis, MO), and passaged by trypsin/EDTA (Gibco Invitrogen, Carlsbad, CA) and maintained at 37 °C in a 5% CO2 atmosphere. The cells were allowed to grow until a monolayer was formed. The confluent cells were treated 7 days after seeding, unless otherwise indicated. dAST was prepared in a formulation of 20% EtOH and sterile water (0.2% final EtOH ) to minimize supramolecular aggregation, and the final concentration of EtOH in culture medium was 0.2%. CTX was dissolved in THF and added to media. TTNPB was dissolved in acetone (Sigma, St. Louis, MO) and cultures received a final acetone concentration of 0.1%. Treatments/Compounds. _TTNPB (Biomol, Plymouth Meeting, PA); stock 5 x 10"6M in acetone, diluted 1:500 in culture media (final 10'8 M in 0.2% acetone). Lycophyll (All-trans, 95% pure, Hawaii Biotech, Inc., Aiea, HI); stocks 10"2M and 10"3 M in tetrahydrofuran (THF; Sigma, St. Louis, MO) diluted 1:1000 and stirred into culture media immediately before treatment (final 10"5M and 10"6M in 0.1% THF). Lycopene (92.7% pure, Chromadex, Inc., Santa Ana, CA); stocks 10"2M and 10"3M in tetrahydrofuran (Sigma, St. Louis, MO) diluted 1:1000 and stirred into culture media immediately before treatment (final 10"5M and 10"6M in 0.1% THF). Homochiral 35,3 'S- astaxanthin (95% pure, Hawaii Biotech, Inc., Aiea, HI); stocks 10"2 M and lO"3 M in THF (Sigma, St. Louis, MO) diluted 1:1000 and stirred into culture media immediately before treatment (final 10"5M and 10"6M in 0.1% THF). SDS-PAGE Electrophoresis, Transfer and Immunodetection. Cell were trypsinized and pelleted briefly. Pellets were lysed in phosphate buffered saline (PBS) containing protease inhibitor cocktail (Roche, Nutley, NJ; 1 tablet/lOmL), 10 mM sodium fluoride, 0.5 mM sodium vanadate, 4 niM para-methyl-sulfonyl fluoride and 0.5% sodium dodecylsulfate. Lysates were sonicated and protein concentrations quantified using the BCA protein determination assay (Pierce, Rockford, IL). Equal amounts of total protein were boiled in sample buffer (Fisher, Fairlawn, NJ) containing 10% β-mercaptoethanol, loaded onto 10% Tris-Glycine gels (Cambrex, East Rutherford, NJ) and run at 115 V for 1.5 hours using Tris (25 mM)/Glycine (192 mM)/SDS (0.1%) running buffer. Protein standards were utilized to confirm molecular weight of detected protein (SeeBlue, Invitrogen, Carlsbad, CA). Protein was transferred from SDS-PAGE gels to PVDF membranes (Invitrogen, Carlsbad, CA) using Tris (19 mM)/Glycine (144 mM)/10% Methanol/0.1% SDS buffer at 33 volts for 2 hours. Cx43 protein was detected according to the manufacturer's instructions using the WesternBreeze Immunodetection Kit (Invitrogen, Carlsbad, CA) and a rabbit primary antibody reactive against the cytoplasmic tail of Cx43 (1 :2000, Sigma, St. Louis, MO). Quantification of Relative Western Blot Cx43 Protein Levels. Digital scans of immunodetected membranes were analyzed for relative intensity of Cx43 protein bands using the public domain densitometry program NIH Image J and presented as relative fold inductions standardized to THF only control levels.
EXAMPLE 1
Analysis of CX43 protein expression. Expression of CX43 protein in 10T1/2 cells was assessed by Western blotting. 10T1/2 cell monolayers were treated with the indicated carotenoid derivatives or with retinoids (as a positive control for the modulation of CX43 expression) 7 days after seeding in 100 mm dishes (Fisher Scientific, Pittsburgh, PA). Fours days after the drug was added to the cells, the cells were harvested, total cellular protein was isolated and the total protein concentration thereof was determined using a commercially available Protein Assay Reagent kit (Pierce Chemical Co., Rockford, IL). 40 μg of total cellular protein was resolved on an SDS-PAGE gel, transferred to a nitrocellulose membrane, and analyzed by Western blotting using the NuPage Western blotting kit (Invitrogen, Carlsbad, CA). CX43 was detected using a rabbit polyclonal antibody (Zymed, San Francisco, CA)
raised against a synthetic polypeptide corresponding to the C-teπninal domain common to mouse, human and rat CX43. Equal protein loafing was verified by immunoblotting for GAPDH, the expression of which is unaffected by treatment with retinoids or carotenoids, using a rabbit polyclonal GAPDH antibody was also used (Zymed, San Francisco, CA). CX43 and GAPDH immunoreactive bands were visualized by chemiluminescence using an anti- rabbit HRP-conjugated secondary antibody (Pierce Chemical Co., Rockford, IL). Images were obtained by exposure to X-ray film as previously described [26] and scanned for digital analysis on the Fluoro-S Imager (Bio- Rad, Richmond, CA).
Results. Turning to FIG. 11 , racemic pAST increased the level of detectable CX43 protein in cells in comparison with solvent-treated controls at concentrations of 10"6 and 10'7 M, and was equipotent to CTX at these concentrations (about 5- and 2-fold induction, respectively). CTX, included as a positive carotenoid control, was active at 10"5 M as had been previously observed (~7-fold induction). No change in CX43 protein levels were detectable in cells treated with identical concentrations of AST. Surprisingly, no change in protein levels was observed in cells treated with 10"5 M of either compound, suggesting potential toxicity of the compounds at high concentrations. As expected, CX43 expression was increased about 13-fold by the synthetic retinoid TTNPB at 10"8 M included as positive control. These results demonstrate that the novel water-soluble carotenoids delivered in an aqueous ethanol formulation are superior to AST itself, delivered in THF, in modulating CX43 protein levels. EXAMPLE 2
Analysis of CX43 protein by indirect immunofluorescence. Expression and assembly of CX43 into plaques was assessed by immunofluorescence staining essentially as described in Rogers et al, 1990, which is incorporated herein by reference. Briefly, confluent cultures of 10T1/2 cells were grown on Permanox plastic 4-chamber slides (Nalge Nunc International, Naperville, IL) and treated for 4 days as described above. Cells were fixed with ~ 20 0C methanol overnight, washed in buffer, blocked in 1% bovine serum albumin (Sigma, St. Louis, MO) in PBS, incubated with the rabbit anti-CX43 antibody, and visualized with Alexa568 conjugated anti-rabbit secondary antibody (Molecular Probes, Eugene, OR). Images were acquired with a Zeiss Axioplan microscope and a Roper Scientific cooled CCD camera.
Results. It has previously been demonstrated that monolayer cultures of 10T1/2 cells have relatively low levels of CX43 protein. Consequently, CX43 immunoreactive plaques, corresponding to assembled gap junctions, are infrequent. Turning to FIG. 12, treatment 10T1/2 cell monolayers with racemic pAST at 10"6 M (panel B) increased the prevalence of CX43 immunoreactive plaques in regions of cell/cell apposition when compared to cells in untreated control cultures (panel A). In contrast, few immunoreactive plaques were observed in cultures treated with AST at 10"6 M (panel C); the frequency of which is lower than in untreated monolayers. At the lowest concentration of AST (10"8 M; not shown) tested, gap junction assembly was comparable to untreated cultures. Cells treated with TTNPB at 10"8 M (panel E), as expected, exhibited extensive CX43 immunoreactive plaques, while treatment with CTX at 10'5 M (panel D) resulted in a prevalence of CX43 immunoreactive plaques that was roughly equivalent to that achieved in cells treated with pAST at 10'6M, indicating that pAST is more efficient than CTX or AST at modulating the number of gap junctions in a cell.
Gap junctional communication assay. Junctional permeability was assayed by the scrape-loading dye transfer assay essentially as described in El-Fouly et al., 1987, which is incorporated herein by reference. Briefly, confluent cultures of 10T1/2 cells grown in 60 mm dishes were treated with the indicated compounds for 7 days. The treated cells were washed with Ca+2 -free phosphate-buffered saline (PBS). 1.5 ml of Lucifer Yellow CH (Sigma, St.
Louis, MO) 0.2% in PBS was then added, and linear cuts were made on the monolayer using a surgical scalpel. The
cultures were incubated for 2 minutes at 37 0C then rinsed thoroughly with PBS. The cultures were then fixed with 2 ml of 5% formaldehyde in PBS. Images were digitally quantitated by intensity thresholding using the SigmaScan software program (Jandel Scientific, San Rafael, CA).
Results. Turning to FIG. 13, racemic pAST (•-•) or AST (■-■) was added to monolayer cultures at concentrations ranging from 1040 to 10"6M as indicated. At a concentration of 10'9 M, pAST increased the level of GJIC approximately 4-fold over that seen in untreated controls cultures, or cultures treated with AST. The relative amount of GJIC in pAST-treated cells remained constant over a 4-log concentration range, indicating that maximal GJIC induction by pAST can be achieved at low concentration. At a concentration of 10"δ M AST, dye-transfer in monolayer cultures is below that observed in untreated control cultures. At a concentration of 10"7 M AST, dye transfer roughly equivalent to that achieved in cultures treated with pAST. Therafter, communication decreased in a dose-responsive manner. The positive controls CTX 10"5 M and TTNPB 10"8 M increased dye transfer 4-fold and 6-fold respectively (not shown).
Inhibition ofMCA-induced neoplastic transformation in 10T1/2 cells. Cells were initiated with methylcholanthrene (MCA) 5 μg/ml (Sigma, St. Louis, MO) in acetone for 24 hours. Potential inhibitors of neoplastic transformation were added 7 days after removal of carcinogen as indicated and were renewed weekly by adding fresh medium supplemented with the appropriate drug for four weeks after removal of the carcinogen. The cultures were fixed and stained as described above. A total of 24 dishes of cells were used per treatment group. Type II and III foci were identified and then quantitated as described in Bertram et al., 1990, which is incorporated herein by reference. Results. In each case, AST or pAST was added to monolayer cultures 7 days after the removal of the carcinogen
MCA so as not to potentially interfere with the production of carcinogen-initiated cells. Results are presented as the mean number of foci per dish (Table 3). In control cultures treated with acetone only, about 1 focus/6 dishes was observed (mean 0.17 foci/dish); this was increased to 1.67 foci/dish in cultures exposed to MCA (P > 0.0002). No foci were observed in MCA-induced cells treated with 10"6 M pAST. Cell treated with 10'7 M and 10'8 M pAST showed substantially lowered levels of neoplastic transformation compared to untreated cells (P < 0.04). AST at all concentrations tested inhibited transformation to about 40% of control (0.98 foci/dish) in a dose-independent manner. Transformation was strongly inhibited in cells treated with either pAST or AST at 10"5 M for 4 weeks, however these cultures failed to form complete monolayers, potentially indicating cumulative toxicity at this concentration. Selective cytotoxicity. Determination of plating efficiencies and growth rates were performed as described in Pung et al., 1988, which is incorporated herein by reference. Briefly, normal 10T1/2 cells and MCA-transformed 10T1/2 cells were plated onto 100 mm plates at a density of 104/dish and treated 24 h later with either pAST, AST or EtOH- only as controls. Cells from duplicate cultures were trypsinized after 1, 2, 6 and 8 days, and the density of cells in the cultures was determined using a Coulter counter (Coulter Electronics, Inc., Hialeah, FL). Cellular uptake ofcarotenoid derivatives. Cellular levels of astaxanthin in pAST- and AST-treated cells were determined in confluent 10T1/2 cells treated with pAST or AST at 10"δ M or cells treated with media-alone as a control. Duplicate cultures of cells were treated as described above. After 1, 4 and 7 days after treatment with the indicated compounds, the cells were harvested by trypsinization, pelleted by centrifugation and snap frozen in liquid nitrogen. The frozen cell pellets subjected to HPLC analysis to determine the cytosolic concentration of the compound. Astaxanthin was extracted from the samples as essentially as described in Showalter et al., 2004, with slight modifications. Methanol (1.0 ml) and water (1.0 ml) were added to each sample weighed in advance, and
then mixed with an Ultraturax® mixer for 20 seconds. Chloroform (3 ml) was added to the samples, and the samples were mixed for 20 seconds. Finally, a saturated sodium chloride (NaCl) solution (1 ml) was added to each sample, after which the samples were mixed for an additional 20 seconds. The samples were allowed to sit for 5 min to allow particulate matter to settle to the bottom of the tube. The samples were then centrifuged (1700 x g, 10 rnin). The chloroform phase containing astaxanthin (2 ml was transferred to a clean test tube and the chloroform was evaporated on a heating block (40 °C) with a gentle flow of N2 gas. The residue was then dissolved in n- hexane:acetone (86:14; 75 μl) and transferred directly into sample vials. Total astaxanthin, including all-i?-, 9Z- and 13Z- astaxanthin, was quantified by HPLC using a phosphoric acid-modified silica gel column, with all-ϋ1- astaxanthin as an external standard. The flow was 1 ml/min and the detection wavelength was set at 470 nm. The employed extinction coefficients (Eicmji%) at 472 nm in hexane containing 4% chloroform were 2100 for aΑ-E- astaxantbin, and 1350 and 1750 for 13Z- and 9Z-astaxanthin, respectively.
Compound Concentration Foci/disha % Inhibition"
MCA
5μg/ml 1.63 N/A
+THF 0.1% 1.92 N/A
10"8 M 0.96 41*
+pASTK 10"6 M 0 100** 10"7 M 0.91 44*
10"s M 1.04 36*
Table 3. Inhibitory effects of carotenoids on MCA-induced transformation 10T1/2 cells were exposed to MCA as carcinogen, then 7 days after removal, received the indicated carotenoids for a 4 week period. aMean number of Type II + Type III foci in a total of 24 dishes. 0.17 foci/dish were observed in dishes not receiving MCA. bCalculated with respect to THF controls. Statistical Significance: "**" denotes highly significant (P-value < 0.000006); "*" (P < 0.04). There was no significant difference between MCA-alone and MCA then THF-treated controls. Statistical analysis. Transformation data was analyzed by one-tailed, two-sample t-tests that incorporated unequal variances. The scrape-loading data was analyzed by paired t-tests. EXAMPLE 3
Previous studies have demonstrated that treatment of C3H10T1/2 immortalized embryonic mouse fibroblast cells and normal human fibroblasts with several carotenoids including lycopene and 'racemic' (i.e. the statistical mixture of stereoisomers) astaxanthin results in elevated protein levels of the gap junction protein,
Connexin43 (Cx43) (Bertram 1999). Here, we show that treatment of the same mouse fibroblast cell line with 10"5 M, 10'6 M and 10'7 M lycophyll for seven days also resulted in increased Cx43 protein levels. Lycophyll at 10"5 M appeared to induce Cx43 protein increases equivalently to 10"5M homochiral (3S,3'S) astaxanthin and 10"5M, 10"6 M lycopene. This is the second such study utilizing these compounds in the mouse fibroblast system for which upregulation of Cx43 has been reported, with slight methods modifications as summarized below. Lycophyll from total synthesis in this case was tested as a mixture of geometric isomers (cis and trans), and the utility here for
upregulation of Cx43 supports the previous demonstration of activity for all-trans lycophyll prepared by semi- preparative chromatrography (Jackson et al. 2005).
Immortalized mouse fibroblast cells (C3H10T1/2) were cultured in Dulbecco's Modification of Eagle's Medium (DMEM) containing 5% calf serum (Mediatech Inc.) and Penicillin (200 i.u.)/Streptomycin (200 μg/ml, Mediatech, Inc.) and incubated at 37 degrees C (0C) in 5% CO2/air atmosphere. Cell dissociation was performed utilizing trypsin:EDTA (0.25%: 2.21 mM, Mediatech Inc.).
TTNPB (Biomol, Plymouth Meeting, PA); stock 5 x 10"6M in acetone, diluted 1:500 in culture media (final 10"8M in 0.2% acetone). Lycophyll (Ml-trans, 95% pure, Hawaii Biotech, Inc., Aiea, HI); stocks 10"2M and 10"3M in tetrahydrofuran (THF; Sigma, St. Louis, MO) diluted 1 : 1000 and stirred into culture media immediately before treatment (final 10"5M and 10"6M in 0.1% THF). Lycopene (92.7% pure, Chromadex, Inc., Santa Ana, CA); stocks 10"2M and 10"3 M in tetrahydrofuran (Sigma, St. Louis, MO) diluted 1:1000 and stirred into culture media immediately before treatment (final 10"5 M and 10"6M in 0.1% THF). Homochiral SS^'S-asϊaxanthin (95% pure, Hawaii Biotech, Inc., Aiea, HI); stocks 10"2M and 10"3M in THF (Sigma, St. Louis, MO) diluted 1:1000 and stirred into culture media immediately before treatment (final 10"5M and 10"6M in 0.1% THF). Cell were trypsinized and pelleted briefly. Pellets were lysed in phosphate buffered saline (PBS) containing protease inhibitor cocktail (Roche, Nutley, NJ; 1 tablet/lOmL), 10 mM sodium fluoride, 0.5 mM sodium vanadate, 4 mM para-methyl-sulfonyl fluoride and 0.5% sodium dodecylsulfate. Lysates were sonicated and protein concentrations quantified using the BCA protein determination assay (Pierce, Rockford, IL). Equal amounts of total protein were boiled in sample buffer (Fisher, Fairlawn, NJ) containing 10% β-mercaptoethanol, loaded onto 10% Tris-Glycine gels (Cambrex, East Rutherford, NJ) and run at 115 V for 1.5 hours using Tris (25 mM)/Glycine (192 mM)/SDS (0.1%) running buffer. Protein standards were utilized to confirm molecular weight of detected protein (SeeBlue, Invitrogen, Carlsbad, CA). Protein was transferred from SDS-PAGE gels to PVDF membranes (Invitrogen, Carlsbad, CA) using Tris (19 mM)/Glycine (144 mM)/10% Methanol/0.1% SDS buffer at 33 volts for 2 hours. Cx43 protein was detected according to the manufacturer's instructions using the WesternBreeze Immunodetection Kit (Invitrogen, Carlsbad, CA) and a rabbit primary antibody reactive against the cytoplasmic tail of Cx43 (1:2000, Sigma, St. Louis, MO).
Digital scans of immunodetected membranes were analyzed for relative intensity of Cx43 protein bands using the public domain densitometry program NIH Image J and presented as relative fold inductions standardized to THF only control levels. The results of individual experiments are shown in FIG. 14A and FIG. 14B. The results were normalized to the expression of Cx43 in 10T1/2 cells treated with vehicle alone and are summarized graphically in FIG. 14C.
Results: The results presented in FIGs 14A-14C demonstrate once again that lycophyll (in this case a mixture of geometric isomers) is capable of upregulating Cx43 expression in mouse embryonic fibroblast cells. The relative inductions (in duplicate) are consistent with induction by the comparable carotenoids lycopene (positive control) and homochiral (3S,3'S) astaxanthin. The synthetic retinoid TTNPB demonstrates characteristic strong induction of Cx43 in this system. Cx43 is a tumor suppressor gene that has utility in cancer chemoprevention, and its modulation by the naturally-occurring lycophyll compound is novel and suggests potential clinical utility in the setting of cancer chemoprevention and treatment. Results are also summarized in Table 4.
Compound Concentration Fold induction11
THF 0.1 % 1.0
+TTNPB 10"8 M 2.03
+Lycopene 10"6 M 1.55
10"5 M 1.51
+Lycophyll \ 10"7 M 1.28
LA 10"6 M 1.30
10"5 M 1.54
+Astaxanthin
Table 4. Increased expression of Cx43 in transformed cells after treatment with the indicated synthetic carotenoid analog or derivative. aTaken from an average of two independent experiments and normalized using Cx43 expresssion in the presence of THF as baseline. EXAMPLE 4
In order to evaluate the efficacy of certain carotenoid analogs and derivatives for induction of apoptosis in cancer cells, the compounds were applied in various concentrations to a transformed human cell line derived from a malignant prostate tumor that had metastasized to the lymph nodes of a prostate cancer patient (LNCaP cells). The cells were cultured in vitro using standart art-recognized methods. The cells were treated with doses of lycophyll, lycopene or astaxanthin at concentrations ranging from 10"5 - 10"7 M for 1 - 72 hours. As a negative control, cells were left untreated, or were treated with the the pharmacologic vehicle THF. As a positive control to detect apoptosis, cells were administered 10"8 M of the 5-LO/FLAP inhibitor MK-866. Cells were harvested and the DNA was stained with propidium iodide according to methods widely known in the art. The stained cells were subjected to flow cytometry and the percentage of cells having sub Gl amounts levels of DNA (corresponding to apoptotic bodies) as well as those cells that were growth arrested in G2/M were determined. The results obtained from these experiments are shown in FIGs 15-21. All carotenoids tested were able to induce apoptosis in at least a portion of the cells that were administered the compound.
These data therefore demonstrate that the subject carotenoid analogs or derivatives are are effective agents for use in the treatment of proliferative disorders. These data further demonstrate that the subject carotenoid analogs or derivatives affect the growth and survival of neoplastic cells through at least two two distinct mechanisms, namely, through upregulation of Cx43 and GJIC, and by inducing apoptosis, likely through inhibition of the 5-LO pathway. As such, they may be considered as both "chemopreventive" (i.e. used for the prevention of neoplastic disease) and "chemotherapeutic" (Le. used for the amelioration of disease once established) agents. In this patent, certain U.S. patents, U.S. patent applications, and other materials (e.g., non-U.S. patents and journal articles) have been incorporated by reference. The text of such U.S. patents, U.S. patent applications, and other materials is, however, only incorporated by reference to the extent that no conflict exists between such text and the other statements and drawings set forth herein. In the event of such conflict, then any such conflicting text in such incorporated by reference U.S. patents, U.S. patent applications, and other materials is specifically not incorporated by reference in this patent.
Further modifications and alternative embodiments of various aspects of the invention may be apparent to those skilled in the art in view of this description. Accordingly, this description is to be construed as illustrative only and is for the purpose of teaching those skilled in the art the general manner of carrying out the invention. It is to be understood that the forms of the invention shown and described herein are to be taken as the presently preferred embodiments. Elements and materials may be substituted for those illustrated and described herein, parts and processes may be reversed, and certain features of the invention may be utilized independently, all as would be apparent to one skilled in the art after having the benefit of this description to the invention. Changes may be made in the elements described herein without departing from the spirit and scope of the invention as described in the following claims. In addition, it is to be understood that features described herein independently may, in certain embodiments, be combined.
Claims
1. A method of treating a proliferative disorder in a subject comprising administering to a subject who would benefit from such treatment a therapeutically effective amount of a pharmaceutical composition that facilitates gap junctional intercellular communication, wherein the pharmaceutical composition comprises a carotenoid analog or derivative having the structure;
where each R3 is independently hydrogen or methyl, and where each R1 and R2 are independently:
where R4 is hydrogen or methyl; where each R5 is independently hydrogen, -OH, or -OR6 wherein at least one R5 group is -OR6; wherein each R6 is independently: alkyl; aryl; -alkyl-N(R7)2; -aryl-N(R7)2; -alkyl- N4 (R7)3; -aryl-N^R7^ -alkyl-CO2R7; -aryl-CO2R7; -alkyl-CO2 "; -aryl-CO2 "; -0-C(O)-R8; -P(O)(OR8)2; - S(O)(ORS)2; an amino acid; a peptide, a carbohydrate; -C(O)-(CH2)n-CO2R9; a nucleoside reside, or a co- antioxidant; where R7 is hydrogen, alkyl, or aryl; wherein R8 is hydrogen, alkyl, aryl, benzyl or a co- antioxidant; where R9 is hydrogen; alkyl; aryl; -P(O)(OR8)2; -S(O)(OR8)2; an amino acid; a peptide, a carbohydrate; a nucleoside, or a co-antioxidant; and where n is 1 to 9.
2. The method of claim 1 , wherein the proliferative disorder is a cancer.
3. The method of claim 1 , wherein the proliferative disorder is a solid tumor.
4. The method of claim 1, wherein the proliferative disorder is selected from this consisting of pancreatic cancer; bladder cancer; colorectal cancer; breast cancer; metastatic breast cancer; prostate cancer; androgen-dependent prostate cancer; androgen-independent prostate cancer; renal cancer; metastatic renal cell carcinoma; hepatocellular cancer; lung cancer, non-small cell lung cancer (NSCLC); bronchioloalveolar carcinoma (BAC); adenocarcinoma of the lung; ovarian cancer; progressive epithelial cancer; primary peritoneal cancer; cervical cancer; gastric cancer; esophageal cancer; head and neck cancer; squamous cell carcinoma of the head and neck; melanoma; neuroendocrine cancer; metastatic neuroendocrine tumor; brain cancer; glioma, anaplastic oligodendroglioma: adult glioblastoma multiforme; adult anaplastic astrocytoma; bone cancer; and soft tissue sarcoma
5. The method of claim 1 , wherein the proliferative disorder is prostate cancer.
6. The method of claim 1 , further comprising administering to the subject an additional anti-cancer agent.
7. The method of claim 6, wherein the additional anticancer agent is a DNA-damaging agent, an agent that disrupts cell replication, a proteasome inhibitor, an NF-icB inhibitor, an IKK inhibitor, a topoisomerase I inhibitor, irinotecan, topotecan, camptothecin, doxorubicin, topoisomerase II inhibitor, etoposide, teniposide, daunorubicin, an alkylating agent, melphalan, chlorambucil, busulfan, thiotepa, ifosfamide, caπnustine, lomustine, semustine, streptozocin, decarbazine, methotrexate, mitomycin C, and cyclophosphamide, a DNA intercalator, cisplatin, oxaliplatin, carboplatin, a free-radical generator, bleomycin, a nucleoside mimetics, 5-fluorouracil, capecitibine, gemcitabine, fludarabine, cytarabine, mercaptopurine, thioguanine, pentostatin, and hydroxyurea, paclitaxel, docetaxel, vincristine, vinblastin, thalidomide, CC-5013, CC-4047, a protein tyrosine kinase inhibitor, imatinib mesylate and gefitinib, an antibody that binds specifically to antigens expressed on the surface of cancer cells, trastuzumab, rituximab, cetuximab, bevacizumab, or analogs, derivatives or metabolite thereof.
8. The method of claim 1, wherein the carotenoid analog or derivative is an analog or derivative of a naturally occurring carotenoid.
9. The method of claim 1, wherein the carotenoid analog or derivative is an analog or derivative of a naturally occurring carotenoid, and wherein the naturally occurring carotenoid is lycophyll.
10. The method of claim 1, wherein the carotenoid analog or derivative is an analog or derivative of a naturally occurring carotenoid, and wherein the naturally occurring carotenoid is astaxanthin.
11. The method of claim 1 , wherein the composition comprises one or more carotenoid derivatives or analogs having the structure:
where each R5 is independently hydrogen, -OH, or -OR6 wherein at least one R5 group is -OR6; wherein each R6 is independently: alkyl; aryl; -alkyl-N(R7)2; -aryl-N(R7)2; -alkyl-N+(R7)3; -aryl-N+(R7)3; -alkyl- CO2R7; -aryl-CO2R7; -alkyl-CO2 '; -aryl-CO2 "; -0-C(O)-R8; -P(O)(OR8)2; -S(O)(OR8),; an amino acid; a peptide, a carbohydrate; -C(O)-(CH2)B-CO2R9; a nucleoside reside, or a co-antioxidant; where R7 is hydrogen, alkyl, or aryl; wherein R8 is hydrogen, alkyl, aryl, benzyl, or a co-antioxidant; and where R9 is hydrogen; alkyl; aryl; -P(O)(OR8)2; -S(O)(OR8)2; an amino acid; a peptide, a carbohydrate; a nucleoside, or a co-antioxidant; and where n is 1 to 9.
12. The method of claim 1 , wherein the composition comprises one or more carotenoid derivatives or analogs having the structure:
where each R1 and R2 are independently:
13. The method of claim 1, wherein the composition comprises one or more carotenoid derivatives or analogs having the structure:
wherein each -OR6 is independently:
14. The method of claim 1, wherein the composition comprises one or more carotenoid derivatives or analogs having the structure:
wherein each -OR is independently:
15. The method of claim 1, wherein the composition comprises two or more carotenoid derivatives or analogs having the structures:
wherein each -OR is independently:
16. The method of claim 1, wherein each -OR6 independently comprises:
17. The method of claim 1 , wherein each -OR6 independently comprises:
18. The method of claim 1, wherein the substituent R6 in at least a portion of the carotenoid analogs or derivatives administered to the subject is cleaved during use, and wherein the cleavage product is biologically active.
19. The method of claim 1, wherein cleavage of the carotenoid analog or derivative is carried out by one or more enzymes.
20. The method of claim 1, wherein the distance between R1 and R2 is between about 25 A to about 55 A.
21. The method of claim 1 , wherein the distance between R1 and R2 is between about 40 A to about 45 A.
22. The method of claim 1, wherein the composition comprises one or more carotenoid derivatives or analogs having the structures:
where each R is independently H, alkyl, aryl, benzyl, Group IA metal, or a co-antioxidant.
23. The method of claim 1, wherein the composition comprises one or more carotenoid derivatives or analogs having the structures:
where each R is independently H, alkyl, aryl, benzyl, Group IA metal, or a co-antioxidant.
24. The method of claim 1, wherein the co-antioxidant comprises Vitamin C, Vitamin C analogs, Vitamin C derivatives, Vitamin E, Vitamin E analogs, Vitamin E derivatives, flavonoids, flavonoid derivatives, or flavonoid analogs.
25. The method of claim 1, wherein the flavonoids comprise quercetin, xanthohumol, isoxanthohumol, or genistein.
26. The method of claim 1, wherein the composition comprises one or more carotenoid derivatives or analogs having the structures:
where each R is independently H, alkyl, aryl, benzyl, or a Group IA metal.
27. The method of claim 1, wherein the composition comprises a carotenoid analog or derivative that at least partially dissolves hi water.
28. The method of claim 1, wherein one or more carotenoid derivatives or analogs is synthetically derived.
29. The method of claim 1, wherein the subject is a mammal.
30. The method of claim 1, wherein the subject is human.
31. The method of claim 1, further comprising administering the composition orally.
32. The method of claim 1, further comprising administering the composition parenterally.
33. The method of claim 1, further comprising administering the composition as an aqueous solution.
34. The method of claim 1, further comprising administering the composition as an aqueous dispersion.
35. The method of claim 1, further comprising administering the composition intravenously.
36. The method of claim 1, further comprising administering the composition intravascularly.
37. The method of claim 1, further comprising administering the composition by intramuscular injection.
38. The method of claim 1, further comprising administering the composition subcutaneously.
39. The method of claim 1, further comprising administering the composition transdermally.
40. A method of treating a proliferative disorder in a subject comprising administering to a subject who would benefit from such treatment a therapeutically effective amount of a pharmaceutical composition that facilitates induction of apoptosis in cancer cells, wherein the pharmaceutical composition comprises a carotenoid analog or derivative having the structure;
where each R3 is independently hydrogen or methyl, and where each R1 and R2 are independently:
where R4 is hydrogen or methyl; where each R5 is independently hydrogen, -OH, or -OR6 wherein at least one R5 group is -OR6; wherein each R6 is independently: alkyl; aryl; -alkyl-N(R7)2; -aryl-N(R7)?; -alkyl- N+(R^3; -aryl-r^(R7)3; -alkyl-CO2R7; -aryl-CO2R7; -alkyl-CO2 "; -aryl-CO2-; -0-C(O)-R8; -P(O)(OR8)2; - S(O)(OR8)2; an amino acid; a peptide, a carbohydrate; -C(O)-(CH2)n-CO2R9; a nucleoside reside, or a co- antioxidant; where R7 is hydrogen, alkyl, or aryl; wherein R is hydrogen, alkyl, aryl, benzyl or a co- antioxidant; where R9 is hydrogen; alkyl; aryl; -P(O)(OR8)2; -S(O)(OR8)2; an amino acid; a peptide, a carbohydrate; a nucleoside, or a co-antioxidant; and where n is 1 to 9.
41. The method of claim 40, wherein the proliferative disorder is a cancer.
42. The method of claim 40, wherein the proliferative disorder is selected from this consisting of pancreatic cancer; bladder cancer; colorectal cancer; breast cancer; metastatic breast cancer; prostate cancer; androgen-dependent prostate cancer; androgen-independent prostate cancer; renal cancer; metastatic renal cell carcinoma; hepatocellular cancer; lung cancer, non-small cell lung cancer (NSCLC); bronchioloalveolar carcinoma (BAC); adenocarcinoma of the lung; ovarian cancer; progressive epithelial cancer; primary peritoneal cancer; cervical cancer; gastric cancer; esophageal cancer; head and neck cancer; squamous cell carcinoma of the head and neck; melanoma; neuroendocrine cancer; metastatic neuroendocrine tumor; brain cancer; glioma, anaplastic oligodendroglioma; adult glioblastoma multiforme; adult anaplastic astrocytoma; bone cancer; and soft tissue sarcoma.
43. The method of claim 40, wherein the proliferative disorder is prostate cancer.
44. The method of claim 40, further comprising administering to the subject an additional anti-cancer agent.
45. The method of claim 44, wherein the additional anticancer agent is a DNA-damaging agent, an agent that disrupts cell replication, a proteasome inhibitor, an NF-κB inhibitor, an IKK inhibitor, a topoisomerase I inhibitor, irinotecan, topotecan, camptothecin, doxorubicin, topoisomerase II inhibitor, etoposide, teniposide, daunorabicin, an alkylating agent, melphalan, chlorambucil, busulfan, thiotepa, ifosfamide, caπnustine, lomustine, semustine, streptozocin, decarbazine, methotrexate, mitomycin C, and cyclophosphamide, a DNA intercalator, cisplatin, oxaliplatin, carboplatin, a free-radical generator, bleomycin, a nucleoside mimetics, 5-fluorouracil, capecitibine, gemcitabine, fludarabine, cytarabine, mercaptopurine, thioguanine, pentostatin, and hydroxyurea, paclitaxel, docetaxel, vincristine, vinblastin, thalidomide, CC-5013, CC-4047, a protein tyrosine kinase inhibitor, imatinib mesylate and gefitinib, an antibody that binds specifically to antigens expressed on the surface of cancer cells, trastuzumab, rituximab, cetuximab, bevacizumab, or analogs, derivatives or metabolite thereof.
46. The method of claim 44, wherein the carotenoid analog or derivative and the additional anticancer agent are administered concurrently.
47. The method of claim 44, wherein the carotenoid analog or derivative and the additional anticancer agent are administered separately.
48. The method of claim 40, wherein the carotenoid analog or derivative is an analog or derivative of a naturally occurring carotenoid.
49. The method of claim 40, wherein the carotenoid analog or derivative is an analog or derivative of a naturally occurring carotenoid, and wherein the naturally occurring carotenoid is lycophyll.
50. The method of claim 40, wherein the carotenoid analog or derivative is an analog or derivative of a naturally occurring carotenoid, and wherein the naturally occurring carotenoid is astaxanthin.
51. The method of claim 40, wherein the composition comprises one or more carotenoid derivatives or analogs having the structure:
where each R1 and R2 are independently:
where each R5 is independently hydrogen, -OH, or -OR6 wherein at least one R5 group is -OR6; wherein each R6 is independently: alkyl; aryl; -alkyl-N(R7)2; -aryl-N(R7)2; -alkyl-N^R7^; -aryl-lsTCR^; -alkyl- CO2R7; -aryl-CO2R7; -alkyl-CO2 ~; -aryl-CO2 "; -0-C(O)-R8; ~P(O)(OR8)2; -S(O)(OR8)2; an amino acid; a peptide, a carbohydrate; -C(O)-(CH2)n-CO2R9; a nucleoside reside, or a co-antioxidant; where R7 is hydrogen, alkyl, or aryl; wherein R8 is hydrogen, alkyl, aryl, benzyl, or a co-antioxidant; and where R9 is hydrogen; alkyl; aryl; -P(O)(OR8)2; -S(O)(OR8)2; an amino acid; a peptide, a carbohydrate; a nucleoside, or a co-antioxidant; and where n is 1 to 9.
52. The method of claim 40, wherein the composition comprises one or more carotenoid derivatives or analogs having the structure:
where each R1 and R2 are independently:
where each R5is independently hydrogen, -OH, or -OR6 wherein at least one R5 group is -OR6; wherein each R6 is independently:
53. The method of claim 40, wherein the composition comprises one or more carotenoid derivatives or analogs having the structure:
wherein each -OR is independently:
54. The method of claim 40, wherein the composition comprises one or more carotenoid derivatives or analogs having the structure:
wherein each -OR6 is independently:
55. The method of claim 40, wherein the composition comprises two or more carotenoid derivatives or analogs having the structures:
56. The method of claim 40, wherein each -OR6 independently comprises:
57. The method of claim 40, wherein each -OR independently comprises:
58. The method of claim 40, wherein the substituent R6 in at least a portion of the carotenoid analogs or derivatives administered to the subject is cleaved during use, and wherein the cleavage product is biologically active.
59. The method of claim 40, wherein cleavage of the carotenoid analog or derivative is carried out by one or more enzymes.
60. The method of claim 40, wherein the distance between R1 and R2 is between about 25 A to about 55 A.
61. The method of claim 40, wherein the distance between R1 and R2 is between about 40 A to about 45 A.
62. The method of claim 40, wherein the composition comprises one or more carotenoid derivatives or analogs having the structures:
where each R is independently H, alkyl, aryl, benzyl, Group IA metal, or a co-antioxidant.
63. The method of claim 40, wherein the composition comprises one or more carotenoid derivatives or analogs having the structures:
where each R is independently H, alkyl, aryl, benzyl, Group IA metal, or a co-antioxidant.
64. The method of claim 40, wherein the co-antioxidant comprises Vitamin C, Vitamin C analogs, Vitamin C derivatives, Vitamin E, Vitamin E analogs, Vitamin E derivatives, flavonoids, flavonoid derivatives, or flavonoid analogs.
65. The method of claim 40, wherein the flavonoids comprise quercetin, xanthohumol, isoxanthohumol, or genistein.
66. The method of claim 40, wherein the composition comprises one or more carotenoid derivatives or analogs having the structures:
where each R is independently H, alkyl, aryl, benzyl, or a Group IA metal.
67. The method of claim 40, wherein the composition comprises a carotenoid analog or derivative that at least partially dissolves in water.
68. The method of claim 40, wherein one or more carotenoid derivatives or analogs is synthetically derived.
69. The method of claim 40, wherein the subject is a mammal.
70. The method of claim 40, wherein the subject is human.
71. The method of claim 40, further comprising administering the composition orally.
72. The method of claim 40, further comprising administering the composition parenterally.
73. The method of claim 40, further comprising administering the composition as an aqueous solution.
74. The method of claim 40, further comprising administering the composition as an aqueous dispersion.
75. The method of claim 40, further comprising administering the composition intravenously.
76. The method of claim 40, further comprising administering the composition intravascularly.
77. The method of claim 40, further comprising administering the composition by intramuscular injection.
78. The method of claim 40, further comprising administering the composition subcutaneously.
79. The method of claim 40, further comprising administering the composition transdermally.
80. A method treating cancer in a subject comprising:
administering to a subject who would benefit from such treatment a therapeutically effective amount of a pharmaceutical composition comprising a carotenoid analog or derivative; and
a pharmaceutical composition comprising at least one additional anti-cancer agent;
wherein the carotenoid analog or derivative has the structure;
where each R3 is independently hydrogen or methyl, and where each R1 and R2 are independently:
where R4 is hydrogen or methyl; where each R5 is independently hydrogen, -OH, or -OR6 wherein at least one R5 group is -OR6; wherein each R6 is independently: alkyl; aryl; -alkyl-N(R7)2; -aryl-N(R7)2; -alkyl- ISf(RT)3; -aryl-N^R^; -alkyl-CO2R7; -aryl-CO2R7; -alkyl-CO^; -aryl-CO/; -0-C(O)-R8; -P(O)(OR8)2; - S(O)(OR8)2; an amino acid; a peptide, a carbohydrate; -C(O)-(CH2)n-CO2R9; a nucleoside reside, or a co- antioxidant; where R7 is hydrogen, alkyl, or aryl; wherein R8 is hydrogen, alkyl, aryl, benzyl or a co- antioxidant; where R9 is hydrogen; alkyl; aryl; -P(O)(OR8)2; -S(O)(OR8)2; an amino acid; a peptide, a carbohydrate; a nucleoside, or a co-antioxidant; and where n is 1 to 9.
81. The method of claim 81 , wherein the additional anticancer agent is a DNA-damaging agent, an agent that disrupts cell replication, a proteasome inhibitor, an NF-κB inhibitor, an IKK inhibitor, a topoisomerase I inhibitor, irinotecan, topotecan, camptothecin, doxorubicin, topoisomerase II inhibitor, etoposide, teniposide, daunorubicin, an alkylating agent, melphalan, chlorambucil, busulfan, thiotepa, ifosfamide, carmustine, lomustine, semustine, streptozocin, decarbazine, methotrexate, mitomycin C, and cyclophosphamide, a DNA intercalator, cisplatin, oxaliplatin, carboplatin, a free-radical generator, bleomycin, a nucleoside mimetics, 5-fluorouracil, capecitibine, gemcitabine, fludarabine, cytarabine, mercaptopurine, thioguanine, pentostatin, and hydroxyurea, paclitaxel, docetaxel, vincristine, vinblastin, thalidomide, CC-5013, CC-4047, a protein tyrosine kinase inhibitor, imatinib mesylate and gefϊtinib, an antibody that binds specifically to antigens expressed on the surface of cancer cells, trastuzumab, rituximab, cetuximab, bevacizumab, or analogs, derivatives or metabolite thereof.
82. The method of claim 81, wherein the carotenoid analog or derivative and the anti-cancer agent are administered in the same pharmaceutical composition.
83. The method of claim 81 , wherein the carotenoid analog or derivative and the anti-cancer agent are administered in different pharmaceutical compositions.
84. The method of claim 81, wherein the pharmaceutical compositions are administered to the subject concurrently.
85. The method of claim 81, wherein the pharmaceutical compositions are administered to the subject at different times.
86. A method of reducing the risk of occurrence of a proliferative disorder in a subject comprising administering to a subject who would benefit from chemopreventive therapy a prophylactically effective amount of pharmaceutical composition comprising a of a carotenoid analog or derivative having the structure;
where R4 is hydrogen or methyl; where each R5 is independently hydrogen, -OH, or -OR6 wherein at least one R5 group is -OR6; wherein each R6 is independently: alkyl; aryl; -alkyl-N(R7)2; -aryl-N(R7)2; -alkyl- N+(R^3; -aryl-N÷CR7^; -alkyl-COaR7; -aryl-CO2R7; -alkyl-CO2 "; -aryl-CO2 "; -0-C(O)-R8; -P(O)(OR8)2; - S(O)(OR8)2; an amino acid; a peptide, a carbohydrate; -C(O)-(CH2)n-CO2R9; a nucleoside reside, or a co- antioxidant; where R7 is hydrogen, alkyl, or aryl; wherein R8 is hydrogen, alkyl, aryl, benzyl or a co- antioxidant; where R9 is hydrogen; alkyl; aryl; -P(O)(OR8)2; -S(O)(OR8)2; an amino acid; a peptide, a carbohydrate; a nucleoside, or a co-antioxidant; and where n is 1 to 9.
87. The method of claim 86, wherein pharmaceutical composition is adapted to be administered orally.
88. A pharmaceutical composition suitable for cancer chemotherapy comprising:
an amount of a carotenoid analog or derivative effective for cancer chemotherapy; a delivery vehicle; and one or more pharmacologically inert carriers,
wherein the carotenoid analog or derivative has the structure
where R4 is hydrogen or methyl; where each R5 is independently hydrogen, -OH, or -OR6 wherein at least one R5 group is -OR6; wherein each R6 is independently: alkyl; aryl; -alkyl-N(R7)2; -aryl-N(R7)2; -alkyl- ^(R7)3; -aryl-tf-(R7)3; -alkyl-CO2R7; -aryl-CO2R7; -alkyl-CQf; -aryl-CQf; -0-C(O)-R8; -P(O)(OR8)2; - S(O)(OR8)2; an amino acid; a peptide, a carbohydrate; -C(O)-(CH2)n-CO2R9; a nucleoside reside, or a co- antioxidant; where R7 is hydrogen, alkyl, or aryl; wherein R8 is hydrogen, alkyl, aryl, benzyl or a co- antioxidant; where R9 is hydrogen; alkyl; aryl; -P(O)(OR8)2; -S(O)(OR8)2; an amino acid; a peptide, a carbohydrate; a nucleoside, or a co-antioxidant; and where n is 1 to 9.
89. The pharmaceutical composition of claim 88, further comprising an effective amount of at least one additional anticancer or chemotherapy agent.
90. The pharmaceutical composition of claim 89, wherein the additional anticancer agent is a DNA-damaging agent, an agent that disrupts cell replication, a proteasome inhibitor, an NF-κB inhibitor, an IKK inhibitor, a topoisomerase I inhibitor, irinotecan, topotecan, camptothecin, doxorubicin, topoisomerase II inhibitor, etoposide, teniposide, daunorubicin, an alkylating agent, melphalan, chlorambucil, busulfan, thiotepa, ifosfamide, carmustine, lomustine, semustine, streptozocin, decarbazine, methotrexate, mitomycin C, and cyclophosphamide, a DNA intercalator, cisplatin, oxaliplatin, carboplatin, a free-radical generator, bleomycin, a nucleoside mimetics, 5-fluorouracil, capecitibine, gemcitabine, fludarabine, cytarabine, mercaptopurine, thioguanine, pentostatin, and hydroxyurea, paclitaxel, docetaxel, vincristine, vinblastin, thalidomide, CC-5013, CC-4047, a protein tyrosine kinase inhibitor, imatinib mesylate and gefitinib, an antibody that binds specifically to antigens expressed on the surface of cancer cells, trastuzumab, rituximab, cetuximab, bevacizumab, or analogs, derivatives or metabolite thereof.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06737528A EP1861109A2 (en) | 2005-03-09 | 2006-03-09 | Carotenoids, carotenoid analogs, or carotenoid derivatives for the treatment of proliferative disorders |
CA002606329A CA2606329A1 (en) | 2005-03-09 | 2006-03-09 | Carotenoids, carotenoid analogs, or carotenoid derivatives for the treatment of proliferative disorders |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US65998305P | 2005-03-09 | 2005-03-09 | |
US60/659,983 | 2005-03-09 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2006099015A2 true WO2006099015A2 (en) | 2006-09-21 |
WO2006099015A3 WO2006099015A3 (en) | 2006-12-21 |
Family
ID=36650839
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2006/008363 WO2006099015A2 (en) | 2005-03-09 | 2006-03-09 | Carotenoids, carotenoid analogs, or carotenoid derivatives for the treatment of proliferative disorders |
Country Status (4)
Country | Link |
---|---|
US (1) | US20060276372A1 (en) |
EP (1) | EP1861109A2 (en) |
CA (1) | CA2606329A1 (en) |
WO (1) | WO2006099015A2 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1867327A1 (en) | 2006-06-16 | 2007-12-19 | Yamaha Hatsudoki Kabushiki Kaisha | Astaxanthin and esters thereof for protecting neurocytes and treating Parkinson's disease |
WO2007147163A2 (en) * | 2006-06-16 | 2007-12-21 | Cardax Pharmaceuticals, Inc. | Compositions comprising carotenoid analogs or derivatives and methods for synthesis |
WO2008106606A2 (en) * | 2007-02-28 | 2008-09-04 | Cardax Pharmaceuticals, Inc. | Carotenoid analogs and derivatives in the treatment of prostate cancer |
WO2008106614A2 (en) * | 2007-02-28 | 2008-09-04 | Microsoft Corporation | Radical set determination for hmm based eastern asian character recognition |
US9572783B1 (en) | 2015-10-08 | 2017-02-21 | Chuen Wei Lu | Use of xanthophylls for the treatment of cancers |
CN106458881A (en) * | 2014-05-20 | 2017-02-22 | 富士化学工业株式会社 | Carotenoid derivative, pharmaceutically acceptable salt thereof, and pharmaceutically acceptable ester or amide thereof |
EP3153160A1 (en) * | 2015-10-08 | 2017-04-12 | Chuen Wei Lu | Use of xanthophylls for the treatment of cancers |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003215396B2 (en) * | 2002-02-25 | 2010-04-08 | Diffusion Pharmaceuticals Llc | Bipolar trans carotenoid salts and their uses |
US7759506B2 (en) | 2002-02-25 | 2010-07-20 | Diffusion Pharmaceuticals Llc | Bipolar trans carotenoid salts and their uses |
EA017982B1 (en) | 2005-02-24 | 2013-04-30 | ДИФФЬЮЖН ФАРМАСЬЮТИКАЛЗ ЭлЭлСи | Trans carotenoids-based pharmaceutical composition and methods for treating tumour |
DE102006062264A1 (en) * | 2006-12-22 | 2008-06-26 | Joh. Barth & Sohn Gmbh & Co. Kg | Use of xanthohumol for the prevention and / or control of liver diseases |
WO2008136900A1 (en) | 2007-04-13 | 2008-11-13 | Diffusion Pharmaceuticals Llc | Use of bipolar trans carotenoids as a pretreatment and in the treatment of peripheral vascular disease |
US8221803B1 (en) | 2007-06-25 | 2012-07-17 | OncoNatural Solutions, Inc. | Composition for prostate health |
AR069079A1 (en) * | 2007-10-29 | 2009-12-30 | Takeda Pharmaceutical | PHARMACO FOR THE PREVENTION OR TREATMENT OF CANCER |
US8206751B2 (en) * | 2007-10-31 | 2012-06-26 | Diffusion Pharmaceuticals Llc | Class of therapeutics that enhance small molecule diffusion |
KR101782023B1 (en) * | 2009-06-22 | 2017-10-23 | 디퓨젼 파마슈티컬즈 엘엘씨 | Diffusion enhancing compounds and their use alone or with thrombolytics |
CN103124498A (en) | 2010-06-02 | 2013-05-29 | 扩散药品有限公司 | Oral formulations of bipolar trans carotenoids |
US10155715B2 (en) | 2010-11-02 | 2018-12-18 | The United States Of America As Represented By The Department Of Veterans Affairs | Purified crocetin compound and method for treating, inhibiting, and/or prophylaxis of cancer, such as pancreatic cancer |
US9889105B2 (en) | 2010-11-02 | 2018-02-13 | U.S. Department Of Veterans Affairs | In vivo method for treating, inhibiting, and/or prophylaxis of cancer, such as pancreatic cancer |
CA3018550A1 (en) * | 2016-03-24 | 2017-09-28 | Diffusion Pharmaceuticals Llc | Use of bipolar trans carotenoids with chemotherapy and radiotherapy for treatment of cancer |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004011423A2 (en) * | 2002-07-29 | 2004-02-05 | Hawaii Biotech, Inc. | Structural carotenoid analogs for the inhibition and amelioration of disease |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7351739B2 (en) * | 2004-04-30 | 2008-04-01 | Wellgen, Inc. | Bioactive compounds and methods of uses thereof |
-
2006
- 2006-03-09 EP EP06737528A patent/EP1861109A2/en not_active Withdrawn
- 2006-03-09 WO PCT/US2006/008363 patent/WO2006099015A2/en active Application Filing
- 2006-03-09 US US11/372,353 patent/US20060276372A1/en not_active Abandoned
- 2006-03-09 CA CA002606329A patent/CA2606329A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004011423A2 (en) * | 2002-07-29 | 2004-02-05 | Hawaii Biotech, Inc. | Structural carotenoid analogs for the inhibition and amelioration of disease |
Non-Patent Citations (1)
Title |
---|
MOLNAR, JOSEPH ET AL: "Modulation of multidrug resistance and apoptosis of cancer cells by selected carotenoids" IN VIVO, vol. 18, no. 2, 2004, pages 237-244, XP008066870 * |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1867327A1 (en) | 2006-06-16 | 2007-12-19 | Yamaha Hatsudoki Kabushiki Kaisha | Astaxanthin and esters thereof for protecting neurocytes and treating Parkinson's disease |
WO2007147163A2 (en) * | 2006-06-16 | 2007-12-21 | Cardax Pharmaceuticals, Inc. | Compositions comprising carotenoid analogs or derivatives and methods for synthesis |
WO2007147163A3 (en) * | 2006-06-16 | 2008-03-20 | Cardax Pharmaceuticals Inc | Compositions comprising carotenoid analogs or derivatives and methods for synthesis |
WO2008106614A3 (en) * | 2007-02-28 | 2011-07-14 | Microsoft Corporation | Radical set determination for hmm based eastern asian character recognition |
WO2008106614A2 (en) * | 2007-02-28 | 2008-09-04 | Microsoft Corporation | Radical set determination for hmm based eastern asian character recognition |
WO2008106606A3 (en) * | 2007-02-28 | 2009-07-02 | Cardax Pharmaceuticals Inc | Carotenoid analogs and derivatives in the treatment of prostate cancer |
WO2008106606A2 (en) * | 2007-02-28 | 2008-09-04 | Cardax Pharmaceuticals, Inc. | Carotenoid analogs and derivatives in the treatment of prostate cancer |
CN106458881A (en) * | 2014-05-20 | 2017-02-22 | 富士化学工业株式会社 | Carotenoid derivative, pharmaceutically acceptable salt thereof, and pharmaceutically acceptable ester or amide thereof |
JPWO2015178404A1 (en) * | 2014-05-20 | 2017-04-20 | 富士化学工業株式会社 | Carotenoid derivative, pharmaceutically acceptable salt thereof, or pharmaceutically acceptable ester or amide thereof |
EP3147279A4 (en) * | 2014-05-20 | 2018-01-10 | Fuji Chemical Industry Co., Ltd. | Carotenoid derivative, pharmaceutically acceptable salt thereof, and pharmaceutically acceptable ester or amide thereof |
US10125104B2 (en) | 2014-05-20 | 2018-11-13 | Asta Pharmaceuticals Co., Ltd. | Carotenoid derivative, pharmaceutically acceptable salt thereof, or pharmaceutically acceptable ester or amide thereof |
AU2015262405B2 (en) * | 2014-05-20 | 2019-01-03 | Asta Pharmaceuticals Co., Ltd. | Carotenoid derivative, pharmaceutically acceptable salt thereof, and pharmaceutically acceptable ester or amide thereof |
US9572783B1 (en) | 2015-10-08 | 2017-02-21 | Chuen Wei Lu | Use of xanthophylls for the treatment of cancers |
EP3153160A1 (en) * | 2015-10-08 | 2017-04-12 | Chuen Wei Lu | Use of xanthophylls for the treatment of cancers |
Also Published As
Publication number | Publication date |
---|---|
US20060276372A1 (en) | 2006-12-07 |
CA2606329A1 (en) | 2006-09-21 |
WO2006099015A3 (en) | 2006-12-21 |
EP1861109A2 (en) | 2007-12-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20060276372A1 (en) | Carotenoids, carotenoid analogs, or carotenoid derivatives for the treatment of proliferative disorders | |
US9180111B2 (en) | Reduction in complement activation and inflammation during tissue injury by carotenoids, carotenoid analogs, or derivatives thereof | |
US7691901B2 (en) | Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation | |
Pashkow et al. | Astaxanthin: a novel potential treatment for oxidative stress and inflammation in cardiovascular disease | |
Gross et al. | Cardioprotection and myocardial salvage by a disodium disuccinate astaxanthin derivative (Cardax™) | |
Hix et al. | Bioactive carotenoids: potent antioxidants and regulators of gene expression | |
US20070238793A1 (en) | Structural carotenoid analogs or derivatives for the modulation of systemic and/or target organ redox status | |
Liu et al. | Recent advances in health benefits and bioavailability of dietary astaxanthin and its isomers | |
KR19990014941A (en) | Use of flavano league eggs in the manufacture of pharmaceuticals with anti-proliferative effects of uterine, ovarian and breast cancer | |
WO2007027834A1 (en) | Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation | |
RU2492862C2 (en) | Anti-cancer agents with benzophenanthridine structure and preparations containing them | |
KR102575312B1 (en) | Norbixin-containing composition for protecting retinal pigment epithelial cells | |
US8063101B2 (en) | Carotenoid analogs and derivatives for the prevention of platelet aggregation | |
AU2019217990A1 (en) | Methods for treating mitochondrial disorders | |
WO2006119168A2 (en) | Use of carotenoids and/or carotenoid derivatives/analogs for reduction/inhibition of certain negative effects of cox inhibitors | |
US20070015735A1 (en) | Water-dispersible carotenoids, including analogs and derivatives | |
Huang et al. | Bioactivity and mechanism of action of sanguinarine and its derivatives in the past 10 years | |
WO2008106606A2 (en) | Carotenoid analogs and derivatives in the treatment of prostate cancer | |
US20060270589A1 (en) | Carotenoids, carotenoid analogs, or carotenoid derivatives for the treatment of visual disabilities | |
KR101990054B1 (en) | Anti-cancer Composition Comprising Lawsone | |
WO2022164901A1 (en) | Enhanced anti-proliferative and antitumor immune effects of mitochondria-targeted hydroxyurea | |
JP2006273751A (en) | Antitumor agent | |
BRPI0902039A2 (en) | pharmaceutical composition and use of pharmaceutical composition for the treatment, prophylaxis or prevention of neoplastic diseases in humans and animals | |
US20080293679A1 (en) | Use of carotenoids and/or carotenoid derivatives/analogs for reduction/inhibition of certain negative effects of COX inhibitors | |
ITMI951210A1 (en) | NEW ALPHA-TOCOPHEROL DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AS ACTIVE INGREDIENTS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
NENP | Non-entry into the national phase |
Ref country code: RU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006737528 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2606329 Country of ref document: CA |